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Abstract 
Rationale & Hypothesis. 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause 
of end stage renal disease (ESRD). Cyst formation in ADPKD requires epithelial cell 
proliferation and fluid secretion into closed cyst cavities. These effects are mediated mainly by 
elevated intracellular cAMP levels which induce both cell proliferation and increased fluid 
secretion. Prostaglandin E2 (PGE2) has been shown to increase intracellular cAMP levels and 
we and others have shown that its receptor (PTGER2) is increased in renal cyst epithelia 
possibly leading to increases in cAMP levels in these cells. This study was designed to test the 
hypothesis that blocking PGE2 activation might have a therapeutic role in reducing cyst growth 
in ADPKD. 
Methodology. 
Taqman qPCR, Western blotting, immunohistochemistry and ELISA for cAMP level were 
used to determine the expression of PTGER2 and PTGER4 in normal and ADPKD samples. 
Kidney epithelial cells derived from patients with ADPKD, non-ADPKD controls and MDCK 
cells were tested for their ability to form cysts or tubules in 3D cultures using a variety of 
extracellular matrices. The effect of selective PTGER2 and PTGER4 antagonists on 
cystogenesis was determined in 3D cultures. Furthermore, I tested the effect of PGE2, PTGER2 
and PTGER4 antagonist on cell proliferation and apoptosis. Levels of intracellular cAMP in 
cystic human cells, and control cells were measured by commercial ELISA assays. 
Results: 
PTGER2 mRNA and protein levels were significantly increased in cells and tissue sections 
derived from patients with ADPKD compared to normal controls and also in inducible kidney 
iv 
 
specific PKD1 knock-out mouse models compared to wild-type littermates. In human 3D cyst 
assays, PTGER2 and PTGER4 antagonists inhibited cytogenesis in a dose dependent manner. 
Furthermore, PTGER2 and PTGER4 antagonists inhibited cystic cell proliferation and 
increased apoptosis compared to the control cells. 
Conclusions:  
These results suggest that the use of specific PTGER2 and PTGER4 receptor antagonists could 
be effective in slowing cyst growth in human ADPKD. 
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General Introduction 
 
  
- 2 - 
 
1.1. The definition of ADPKD.  
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited 
disorder affecting the kidney. Its cardinal feature is 
the formation of fluid filled cysts (Figure 1.1) in 
both kidneys (Gabow 1993). It is a common cause 
of end stage renal disease (ESRD) in both adults 
and children worldwide and accounts for 10% of all 
ESRD cases (Grantham 1997). Polycystic kidney 
disease has two traits: an Autosomal dominant trait 
with 100% penetration which affects mainly adults 
and second, the recessive pattern which typically 
affects neonates (Feehally 2007). The autosomal 
dominant form occurs worldwide and affects all races with a prevalence between 1:400 to 
1:1000 and with a 1.2-1.3 male to female ratio; it is a more progressive disease in men than in 
women (Torres, Harris et al. 2007). 
 Furthermore it is a multi-systemic disorder with bilateral renal cysts as well as the occurrence 
of cysts in other organs like the liver (75% of patients).  Cysts can also be found in the pancreas, 
seminal vesicle, ovaries and arachnoid membranes. Other extra renal symptoms include: mitral 
valve prolapse, mitral and tricuspid regurgitation, intracranial and aortic aneurysms, colonic 
diverticulae and abdominal or inguinal hernias (Torres 1999, Rossetti, Consugar et al. 2007). 
Hypertension is the most prevalent clinical presentation of polycystic kidney disease affecting 
75% of patients. Other common presentations include: abdominal masses, chronic abdominal 
pain and backache, renal stones, urinary tract infections and hematuria (Boulter, Mulroy et al. 
2001). The affected individual usually presents in the 3rd or 4th decade and develops ESRD in 
the 6th decade of life (Paterson, Magistroni et al. 2005). 
Figure 1.1:  A polycystic kidney from a patient 
with ADPKD.  
The accumulation of fluid filled cysts leads to 
enlargement of both kidneys as comparing with 
normal kidney, and lead to kidney failure (Koptides 
and Deltas 2000, Wu and Somlo 2000). 
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 The pathophysiological process of the disease involves renal cysts that develop from any 
segment of the nephron initially as a tubular dilation with increased cellular proliferation, 
apoptosis, and fluid secretion into cyst lumen, changes in cell polarity and an abnormal 
extracellular matrix ultra-structure.  Eventually when only a few millimeters in diameter, the 
cyst detaches from the tubule (Grantham, Geiser et al. 1987). The diagnosis of pre-symptomatic 
ADPKD is usually made by imaging tests such as ultrasound. The diagnostic criteria using 
ultrasound for an individual’s risk (50% risk by positive family history) include the following: 
two cysts, unilateral or bilateral is diagnostic in a patient younger than 30 years; two cysts in 
each kidney between 30-59 years; 4 cysts in each kidney for 60 years of age (Nicolau, Torra et 
al. 1999) (Ravine, Gibson et al. 1994). Other imaging studies such as CT and MRI may also be 
used as part of donor evaluation. In addition genetic diagnosis by mutation or linkage analysis 
allows prenatal diagnosis, and can be used for young, living related donors with an inconclusive 
diagnosis by other imaging studies (Torra, Badenas et al. 1996).   
Polycystic kidney disease has a wide differential diagnoses which includes other less common 
cystic diseases like ARPKD, Von Hipple-Lindau disease, Tuberous Sclerosis, Orofacial 
Syndrome, Medullary sponge kidney, acquired and simple renal cysts (Fick and Gabow 1994).  
One of the most important recent clinical studies in polycystic kidney disease has been the 
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease or CRISP study 
(Chapman, Guay-Woodford et al. 2003). This prospective study has followed a cohort of 240 
ADPKD patients with early stage disease over 12 years, monitoring disease progression and 
renal complications. The investigators found that hypertension and micro-albuminuria are 
directly related to total kidney volume (TKV) with an average increase of kidney volume by 
5.3% a year. Most importantly, a greater baseline TKV was associated with a more rapid decline 
in renal function (to CKD Stage 3) at 8 years follow-up (Chapman, Guay-Woodford et al. 2003).  
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1.2. The PKD genes encode the Polycystin proteins. 
ADPKD can result in mutations in one of two genes identified. The PKD1 gene is located on 
the short arm of chromosome 16p13.3 and accounts for 85% of cases (Hughes, Ward et al. 
1995). It is characterized clinically by earlier onset of ESRD (Hateboer, v Dijk et al. 1999). The 
second gene identified is PKD2 (4q21-23) which accounts for 15% of cases; patients with 
usually present later in life. The median age at diagnosis is 65 years for PKD2 versus 42 years 
for PKD1 (Peters and Sandkuijl 1992, Pei, He et al. 1998). The single gene responsible for 
ARPKD is PKHD1 (Bergmann, Senderek et al. 2004).  
The PKD1 gene (45 exons distributed over 52 kb of genomic DNA) can be altered by many 
different types of mutation in ADPKD. The most common mutation (70%) is a truncating 
mutation which are strongly associated with early and severe disease with an estimated time to 
ESRD of 52.5 years. The second most common type of mutation is (NT) non truncating (in 
frame deletion or insertion (IF) with an estimated time to ESRD of 58.6 years. Finally mis-
sense or atypical splice site variants are associated with less severe disease with an estimated 
time to ESRD of 70.8 years according to Toronto Genetic Epidemiology Study of PKD 
(TGESP) study (Harris and Torres 2014, Hwang, Conklin et al. 2015). The mutation type and 
TKV provide valuable prognostic factors for defining disease severity and potentially 
identifying patients who are candidate for experimental drugs or novel treatment (Hwang, 
Conklin et al. 2015). In addition, mutations at the 5′ end of the gene have been associated with 
an earlier onset of ESRD and a higher risk of intracranial aneurysm compared to mutations 
found in the 3′ end of the gene (Rossetti, Burton et al. 2002).   
The PKD2 gene consists of 15 exons distributed over 68 kb of genomic DNA. PKD2 mutation 
is associated with mild disease and may not need to treatment until later age. It encodes the 
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protein PC2 that acts as calcium channel (Pei, He et al. 1998). These two genes have been 
shown to encode two proteins termed Polycystin 1 and Polycystin 2 respectively (Figure 1.2) 
 
 
(Ong and Harris 2005) with permission 
Figure 1.2: The structure of polycystin-1 and 2 
The structure of the Polycystin-1and polycystin 2. Polycystin-1, it contains an extracellular N-
terminal domain, 11 transmembrane domains,  and a short cytoplasmic C-terminal domain.  
PC-1 plays an important role in cell-cell and cell-matrix interactions (Sandford, Sgotto et al. 
1997).  PC-2 is a membrane protein with 6 transmembrane domains, and the intracellular amino 
and carboxy-terminals.  PC-2 is a member of the transient receptor potential channel family of 
proteins (TRP), acting as a Ca2+  channel.  Polycystin-1 and-2 interact through domains that are 
present in their  cytoplasmic C-terminal region, known as coiled-coil domains (Tsiokas, Kim 
et al. 1997). 
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1.3. Polycystin 1. 
The polycystin-1 protein, the product of the PKD1 gene, is a large integral glycoprotein of 4302 
amino acid with a molecular mass of 460 KDa (Hughes, Ward et al. 1995).  It has a large N-
extracellular domain of 3000 amino acids, 11 trans-membrane domains, and a short C-
cytoplasmic domain terminal of 200 amino acids, it site for coil-coil protein, and it contains a 
number of phosphorylation sites and G-protein binding site (Figure 1.2). There are a number 
of short motifs that have been recognized on the N-extracellular terminal domain. Two leucine-
rich repeats are flanked by two cysteine–rich domains. The immunoglobulin-like motifs consist 
of 80-90 amino acids, which are believed to be involved in mediating protein-protein or 
protein–carbohydrate interactions (Hughes, Ward et al. 1995) (Moy, Mendoza et al. 1996).  The 
C-terminal is the site of the coiled-coil structure through which polycystin-1 interacts with 
polycystin-2 to form a Polycystin complex that is believed to regulate a number of intracellular 
signaling pathways (Koptides and Deltas 2000). The C-terminal is also a site of phosphorylation 
by protein kinase A and a src-like tyrosine kinase (Li, Geng et al. 1999).  Polycystin-1 acts as 
a cell surface receptor protein which undergoes proteolytic cleavage at a proteolytic cleavage 
site (GPS) which is important for its function (Mengerink, Moy et al. 2002).  Polycystin-1 acts 
as a G- protein coupled receptor which activates the Gα subunit signaling that regulates 
proliferation, cell polarity and fluid secretion (Grantham 2001, Delmas, Nomura et al. 2002). It 
is also involved in the activation of other signals like Wnt, STAT/JAK signaling through a 
carboxyl-terminal domain of polycystin-1(Bhunia, Piontek et al. 2002). PC1 is expressed in 
many tissues including the kidneys (Yoder, Hou et al. 2002), and other organs like the heart, 
brain, muscles and bones. Within the cell, it has multiple locations such as in cilia, cytoplasmic 
vesicle, desmosome, focal adhesion and adherens junctions (Newby, Streets et al. 2002, Yoder, 
Hou et al. 2002).  
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1.4. Polycystin 2. 
Polycystin-2 is the protein product of the PKD2 gene. It is composed of 968 amino acids, and 
six trans-membrane domains (Hanaoka, Qian et al. 2000) with a molecular mass of 110 kDa.  
Polycystin-2 contains an N-terminal cytoplasmic domain, and a C-terminal cytoplasmic 
domain. The C-terminal domain contains a calcium binding motif (EF-hand) that has been 
shown to undergo calcium–induced conformational changes.  The C-terminal is also the site of 
coiled-coil interaction with polycystin-1 (Qian, Germino et al. 1997). Polycystin-2 is localised 
mainly in the endoplasmic reticulum although it has also been found localised to the basolateral 
plasma membrane, mitotic spindles and primary cilia (Rundle, Gorbsky et al. 2004) (Newby, 
Streets et al. 2002, Yoder, Hou et al. 2002).  Polycystin-2 shares structural features of voltage 
activated sodium channels, and calcium channels as well as transient receptor potential (TRP) 
channels (Tsiokas, Arnould et al. 1999). The structure of polycystin-2 suggests that it may play 
a role as an ion channel.  Polycystin-2 is expressed in the kidneys with the highest levels found 
in the distal convoluted tubule as well as in other organs including the heart, ovaries, testis and 
small intestine (Newby, Streets et al. 2002, Yoder, Hou et al. 2002).   Polycystin-2 has been 
shown to act as a Ca2+ permeable channel protein regulating calcium releases from intracellular 
ER stores (Hanaoka, Qian et al. 2000). Both PC-1 and PC-2 interact through the coil-coil 
domain localized in the C-terminal to form a complex that acts to regulate intracellular calcium 
levels (Qian, Germino et al. 1997). Extracellular signals are sensed by polycystin-1 passed into 
polycystin-2 leading to activation of calcium channels and other downstream signaling 
pathways leading to regulation of cellular function and gene transcription (Tsiokas, Kim et al. 
1997) (Hanaoka, Qian et al. 2000). These include G protein, mTOR, STAT and Wnt signaling 
pathways (Figure 1.3)(Chapin and Caplan 2010).  
PC1, through inhibition of a mTOR pathway via a TSC1-TSC2 complex, controls the 
proliferation and growth rate of the cells (Inoki, Li et al. 2002). PC1 also increases the level of 
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p21 that activates the STAT1-STAT-3 pathways and decreases cell proliferation (Bhunia, 
Piontek et al. 2002). In addition, PC1 acts as G-protein coupled receptors through C-terminal 
domains that control the transcriptional factor AP-1 that is important in cell apoptosis, 
proliferation and differentiation (Le, van der Wal et al. 2005). On other hand, PC2 via NFAT, 
stimulate the calcineurin and increases the Ca2+ level (Puri, Magenheimer et al. 2004). 
Furthermore, PC1 inhibits the -catenin pathway and decreases the activity of TCF dependent 
transcription (Lal, Song et al. 2008). Moreover, PC1 plays a critical role in maintaining planar 
cell polarity through the non-canonical pathway (Chapin and Caplan 2010) (Figure 1.3).  The 
increase in cell proliferation, disturbance of cellular polarity and increase in secretory function 
results in a transformation of epithelial cells in the kidney from tubular into a cystic phenotype 
(Torres and Harris 2009).  
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Figure 1.3.  The role of Polycystin 1 and 2 in the pathogenesis of ADPKD. 
A summary of the key roles of Polycystin 1 and 2 in the regulation of signalling pathways are 
involved in cell proliferation and differentiation (Chapin and Caplan 2010). 
 
 
 
 
 
 
 
 
©YEAR AUTHOR et al. Journal of Cell Biology. VOL:PP-PP. doi:10.1083/jcb.######## (Chapin and Caplan 2010) with 
permission 
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1.5. The role of primary cilia in ADPKD. 
The primary cilium is a single hair-like organelle which arises from the mother centrosome in 
non-dividing cells. It is also a major microtubule organizing centre (MTOC) of the cell (Figure 
1.4). Primary cilia are expressed by the majority of mammalian cells, including the kidney.  
They project from the apical surface of tubular cells into the lumen and have a 9+0 microtubules 
arrangement (non-motile).  Primary cilia are thought to play a mechanosensory role through 
sensing fluid flow. The Polycystin complex in primary cilia is believed to mediate this process 
by regulating Ca2+influx in response to mechanical stimulation (Yoder, Hou et al. 2002, Nauli, 
Alenghat et al. 2003). Cilia bending results in Ca2+ entry and the further release of intracellular 
Ca2+from intracellular stores (Chebib, Sussman et al. 2015). Mutation of either Polycystin 
protein leads to a disruption in Ca2+ homeostasis with a resultant dysregulation of cAMP 
signalling and other downstream pathways. This in turn could lead to a cellular switch from 
inhibition to stimulation of proliferation, increased fluid secretion and interstitial inflammation 
of ADPKD (Deane and Ricardo 2007, Chebib, Sussman et al. 2015).  
Based on this evidence, ADPKD has been classified as a ciliopathy, a group of diseases 
resulting from mutations in genes encoding proteins that regulate cilia structure or function. 
Most of these rare syndromic disorders are characterised by renal and hepatic cysts but also 
other features lacking in ADPKD such as the presence of neural tube defects, polydactyly, brain 
tumours and retinal abnormalities (Badano, Mitsuma et al. 2006).  
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Forman, Qamar et al. 2005. 
Figure 1.4: Model of how cilia mediate flow sensing and calcium signaling in the kidney. 
The renal cilium is important in the maintenance of renal structure and ability of this organelle to sense 
fluid flow through collecting ducts and nephrons.  Polycystin-1 and 2 are both membrane proteins that 
co-localize to the renal cilium and both are required for cilium mediated flow sensing in cultured renal 
epithelial cells (Pazour 2004). Polycystin-1 acts as a mechano-sensor that detects the fluid flow through 
its extracellular N-terminal domain (Forman, Qamar et al. 2005). The influx of Ca2+is augmented by 
the release of intracellular Ca+2 stores. Increased levels of Ca+2 into the cell activate a series of events 
that maintain the epithelial phenotype (Puri, Magenheimer et al. 2004).   
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1.6. Pathophysiology of cystogenesis. 
ADPKD is a disease with a highly variable phenotype, expressed in the interfamilial and intra 
familial age of onset of ESRD (Qian and Germino 1997, Koptides, Hadjimichael et al. 1999). 
Cysts develop focally and less than 5% of all nephrons develop cysts, although all cells carry 
the germline mutation (Koptides, Hadjimichael et al. 1999). A possible explanation for the focal 
nature of cytogenesis is the somatic mutation ‘two hit’ model, or haploinsufficiency of PKD1 
(Lantinga-van Leeuwen, Dauwerse et al. 2004). 
Cysts in ADPKD can originate from all segments of the nephron and therefore are distributed 
between the cortex and medulla.  Increased tubular epithelial proliferation, fluid secretion, loss 
of differentiation leads to cyst expansion and disconnection from its tubular origin (Mochizuki, 
Tsuchiya et al. 2013). Tubular epithelial hyperplasia is the most prominent morphological 
change in human polycystic kidneys.  Analysis of cystic kidneys has revealed an increased 
proliferative index in cysts and non-cystic tubules (Nadasdy, Laszik et al. 1995). Another 
prominent factor for cyst formation is increased fluid secretion into cyst lumen. The increased 
fluid secretion is due to presences of chloride channel (CFTR) cystic fibrosis transmembrane 
conductance regulator (Hanaoka, Devuyst et al. 1996). The increased fluid secretion and cell 
proliferation is due to inappropriate elevation of cAMP level (Belibi, Reif et al. 2004).   
 Increases in apoptosis or programmed cell death are seen in kidneys from PKD patients (Savill 
1994). High levels of two key genes, c-myc and bcl-2 suggests dysregulation of both 
proliferative and apoptosis pathways in ADPKD (Lanoix, D'Agati et al. 1996). Furthermore, 
over expression of growth factors like TGF-α and EGF in PKD epithelial cells are believed to 
stimulate cellular proliferation and cyst growth (Lowden, Lindemann et al. 1994).  
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1.7. Treatment of ADPKD. 
Tolvaptan is an orally administered V2 receptor antagonist which was proven to be effective in 
treatment of hyponatremia in hypervolemia and euvolemia condition like liver cirrhosis, 
congestive heart failure and SIADHs (syndrome of inappropriate antidiuretic hormone 
secretion) (Costello-Boerrigter, Boerrigter et al. 2009). OP-31260 the nonpeptide vasopressin 
antagonist was applied in preclinical trials in four animal models of PKD. Three of which were 
orthologues to human PKD (Gattone, Wang et al. 2003). In the pcy mouse adolescent 
nephronophthisis type3, PCK rat (ARPKD), and Pkd2ws25/- mouse ADPKD models treatment 
with OP-31260 demonstrated a significant decrease in cyst growth, reduced renal cAMP levels, 
and slower disease progression measured by decreased kidney volume, blood urea nitrogen, 
and cystic area (Torres 2004, Torres, Wang et al. 2004). 
 Tolvaptan was proven to be effective in reducing proliferation and chloride secretion of human 
ADPKD cell in vitro culture model (Reif, Yamaguchi et al. 2011). These effects were mainly 
through inhibition of cAMP and ERK signalling which induce proliferation and fluid secretion 
(Reif, Yamaguchi et al. 2011).  
The result of vasopressin antagonists in PKD cell culture and animal models provided a strong 
rational for testing V2 antagonists in ADPKD patients which translated into a clinical trial 
called Tolvaptan efficiency and safety in management of PKD and outcome (TEMPO) clinical 
trial (Torres, Meijer et al. 2011). The TEMPO phase 2 started in 63 ADPKD patients for three 
year of Tolvaptan treatment and demonstrated decreased cyst growth by annual increase of total 
kidney volume 1.7% for Tolvaptan group versus 5.8% for control group P <0.001, and 
improved the decline of kidney function (annual eGFR decline 0.07 Tolvaptan group versus 2.1 
ml/min/1.73m2 placebo group the  P= 0.01 (Higashihara, Torres et al. 2011). 
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Tolvaptan phase 3 (TEMPO 3/4): a three year multicentre randomized double blind trial 
collected 1445 ADPKD patients  treated with 60-120 mg/day twice day versus placebo control.. 
There was a significant decrease in the rate of TKV increase (2.8% in Tolvaptan group versus 
5.5%/year in placebo P > 0.001).  While the secondary endpoint of measurement of decreasing 
kidney function (decreased 2.7 in Tolvaptan group versus 3.7 ml/min/1.37m2 in placebo group), 
blood pressure control and renal pain (5 in Tolvaptan group versus 7 event /100 person/year P 
= 0.007)(Torres, Meijer et al. 2011). The common side effects seen were polyuria, thirst, 
hyperuricemia, and abnormal liver function lead to 8% of patients being unable to complete the 
trial (Blair and Keating 2015). 
Tolvaptan (Jinarc) has been approved in Europe, Canada and Japan as a potent selective oral 
V2 antagonist  for treatment of ADPKD and to delay the progression of the disease in adults 
with stage 1-3 of chronic renal failure (Blair and Keating 2015).  
Until the development of Tolvaptan the treatment of ADPKD was directed toward managing 
complications of the disease. Hypertension is a major cause of morbidity and mortality in 
ADPKD patients. Treatments with ACEI or angiotensin receptor blockers have a renoprotective 
effect, and reduce both the proteinuria and left ventricular hypertrophy (Osawa, Nakamura et 
al. 2006).  The HALT-PKD study was a prospective trial seeking to determine whether 
combined therapy with ACEI and an angiotensin II-receptor blocker was superior to ACEI 
alone in delaying the progression of PKD in patients with stage 1 or 2 of renal failure, or to 
slow decline of renal function in stage 3. A second aim of this study was to determine whether 
lower blood pressure (<110/75) control was better than standard blood pressure (130/80) in the 
group of patients with preserved renal function. The total kidney volume and left ventricular 
mass index (predictive disease progression of ADPKD) were significantly decreased in low 
blood pressure control compared to standard blood pressure group (Chapman, Torres et al. 
2010, Torres, Chapman et al. 2011, Schrier, Abebe et al. 2014)  
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Flank pain can be caused by cyst infection, bleeding, kidney stones or renal tumours. This may 
be avoided by reducing the use of nephrotoxic drugs, and surgical intervention like cyst 
aspiration under CT guidance may also be helpful in reducing flank pain. Cyst infection and 
haemorrhage can be treated with bed rest, analgesia, and hydration (Lee and Clayman 2004). 
Treatment with antibiotics may be difficult due to poor penetration into cysts. ADPKD patients 
do better on dialysis than other ESRD patients, and this may be due to lower co-morbidity. The 
treatment of choice of ESRD with ADPKD is transplantation (Abbott and Agodoa 2002). 
 
1.8. The role of cyclic AMP in a normal kidney. 
Cyclic AMP was first discovered by Earl Sutherland and a colleague in the 1950’s for which 
they won the Nobel Prize in Physiology and Medicine in 1971. Cyclic AMP is a small cyclized 
monophosphate that acts as a ubiquitous second messenger, and is involved in the regulation 
of several biological processes such as cell proliferation, differentiation, transcription, and fluid 
and electrolyte transport (Dumaz, Hayward et al. 2006).   
The cAMP-dependent signal transduction pathway involves different enzymatic reactions. The 
most important enzymes are the adenylyl cyclases, phosphodiesterases, protein kinase A (PKA) 
and protein phosphatases. The adenylyl cyclases are comprised of nine isoforms each of which 
is a product of a distinct gene (Borrelli, Montmayeur et al. 1992).  Adenylyl cyclase is dually 
regulated via G-protein Gs stimulatory activity and Gi inhibitory activity, and can also be 
stimulated by Forskolin. Certain subclasses are regulated by Ca2+/calmodulin or 
phosphorylation through various kinases (Taussig and Gilman 1995). Adenylyl cyclase 
catalyses the conversion of ATP to 3”, 5”- cyclic-AMP and pyrophosphate (Taussig and 
Gilman 1995). Increased cyclic AMP levels lead to activation of specific proteins including 
protein kinase A (PKA) (Figure 1.5). The PKA holoenzyme is a tetrameric complex consisting 
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of four subunits: two catalytic subunits (C), and two regulatory subunits (R), which bind with 
two cAMP molecules causing dissociation of holoenzyme and the release of the two active 
catalytic subunits (Yamaguchi, Pelling et al. 2000). PKA plays an important role in the 
phosphorylation of membrane receptors (Daniels, Hall et al. 1998) enzymes and transcription 
factors, leading to changes in gene expression and cell metabolism (Bourne, Tomkins et al. 
1973).   
Cyclic AMP levels are lowered via phosphodiesterase (PDE) enzymes. The phosphodiesterases 
are a group of enzymes that degrade the phosphodiesterase bond and hydrolyse cAMP to AMP 
thus inactivating this second messenger (Conti 2000). Based on their specificity, two of these 
families (PDE4 and PDE7) have a higher specificity to be activated by cAMP than cGMP.  In 
addition to the activation of existing PDE enzymes, cAMP can stimulate the synthesis of new 
PDE mRNA (Swinnen, Joseph et al. 1989, Daniels, Hall et al. 1998). The important features 
of cAMP signalling are the cellular specificity of the response (Houslay and Milligan 1997). 
Extracellular ligands bind to G protein-coupled receptors that can be either positively 
stimulated by Gs or negatively stimulated by Gi, both of which can then bind and regulate 
adenylyl cyclase (ACs). The biological effect of cAMP is mediated mainly by protein kinase 
A, which is targeted to specific cellular compartments by A kinase-anchoring proteins 
(AKAPs) (Faux and Scott 1996). The specificity of cAMP signalling is controlled not only 
through the variety of the enzymes, ACs, PDEs, PKAs and AKAP but also by cell type specific 
communication with other signalling pathways such as mitogen-activated protein kinase and 
extracellular regulated kinase (MAPK/ERK) cascades (Lewis, Shapiro et al. 1998). These 
cascades couple the Ras and growth factor receptors (Figure 1.5) which finally lead to cell 
proliferation (Torres 2004). 
 In normal renal epithelial cells, cAMP has been found to inhibit proliferation. This effect 
appears to be mediated by inhibition of the Raf-1/MEK/ERK pathway through PKA. B-Raf, 
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which is independently stimulated by MEK (Figure 1.6), is normally inhibited by Akt (protein 
kinase B) in the presence of normal intracellular Ca2+levels (Yamaguchi, Hempson et al. 2006). 
This is dependent on a normal PC1/PC2 complex (Figure 1.6) that regulates Ca2+ entry and 
normal intracellular Ca2+ levels, which in turn maintain the activity of PI3kinase and Akt 
pathways (Figure 1.5). Inhibition of B-Raf kinase activity is through the phosphorylation of 
S365 and T440 residues by Akt (Guan, Figueroa et al. 2000, Wellbrock, Karasarides et al. 
2004). 
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(Nagao, Yamaguchi et al. 2003) with permission. 
Figure 1. 5. The cAMP signalling pathway.   
cAMP stimulates proliferation through stimulation of a MAP kinase (mitogen activating 
kinase) pathway at MEK (mitogen extracellular kinase) through intermediate elements. On the 
other hand growth factors bind with the receptor tyrosine kinase leading to sequential activation 
of Ras, Raf-1, MEK, and ERK pathways that will stimulate cell proliferation. When a hormone 
binds with its receptor it blocks the Gi inhibition of adenylyl cyclase (AC) and stimulates Gs 
proteins that activate AC which catalyzes the conversion of ATP to cAMP, increasing cAMP 
levels that in turn stimulates PKA. In ADPKD this stimulates cyst formation through cells 
proliferation via cross talk with ERK (extracellular kinase) pathways. Fluid secretion into cysts 
occurs through cAMP regulated channels stimulating trans epithelial secretion of Cl- into the 
lumen of the cyst  mainly through a CFTR (cystic fibrosis  transmembrane conductance 
regulator ) chloride channel on an apical membrane of the cells (Yamaguchi, Pelling et al. 
2000). 
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  (Cowley 2008) with permission 
Figure 1.6: Signal transduction pathways in normal and polycystic kidney disease  
(A) Normal kidney cell: adenylyl cyclase is stimulated by extracellular ligands such as 
vasopressin, prostaglandins, parathyroid hormone; increasing intracellular cAMP leads to 
activation of protein kinase A; this result in inhibition of Raf-1/MAP kinase 
Kinase/extracellular signal-regulated kinase (Raf-1/MEK/ERK). B-Raf, which can 
independently stimulate MEK, is inhibited by Akt with normal intracellular Ca2+levels. Normal 
intracellular Ca2+and activation of tyrosine kinase receptors via EGF lead to activation of 
phosphatidylinositol -3-kinase to generate PIP3, a ligand for the serine/threonine kinase Akt. 
This is responsible for inhibition of B-Raf. Inhibitions of Akt by low intracellular Ca2+might 
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lead to B-Raf dependent ERK activation and hence increase the rate of proliferation and 
apoptosis in polycystic kidney disease (Yamaguchi, Hempson et al. 2006)   
(B)  Polycystic kidney cell:  when EGF binds to the receptor-tyrosine kinase, it activates Ras 
which phosphorylates Raf-1, followed by downstream activation of MEK and ERK.  Adenylyl 
cyclase is stimulated by extracellular ligands such as vasopressin, parathyroid hormone and 
prostaglandins, increasing cAMP results in activation of protein kinase (PKA). Protein kinase 
activates the B-Raf/MEK/ERK pathway; low Ca2+evels abolish Akt inhibition of B-Raf, with 
a pro-proliferate effect (Torres and Harris 2006). PC: Polycystin, PI3K: phosphatidylinositol -
3-kinase, PKA: protein kinase A, MAP kinase, ERK extracellular signal-regulated kinase, AC 
Adenylate cyclase (Cowley 2008). 
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1.9. The role of cyclic AMP in adult polycystic kidney disease. 
Cyst formation in ADPKD requires epithelial cell proliferation, and fluid secretion into closed 
cyst cavities. These effects are mediated mainly by intracellular cAMP through the activation 
of protein kinase A, MEK and ERK (Nagao, Yamaguchi et al. 2003). When EGF binds to a 
receptor-tyrosine kinase it activates Ras which phosphorylates Raf-1 and results in activation 
of MEK and ERK signalling pathways (Erhardt, Troppmair et al. 1995).  This in turn induces 
cell proliferation (Figure 1.5).  
 In ADPKD, there is a phenotypic switch in PKD cells in their response to cAMP such that this 
stimulates proliferation. In ADPKD cells, there is a decrease in intracellular Ca2+ levels, due to 
a loss of either polycystin-1 or polycystin-2 function (Hanaoka and Guggino 2000).  This 
relieves Akt inhibition of B-Raf leading to B-Raf activation, phosphorylation of MEK, which 
in turn phosphorylates and activates ERK. Activated ERK then translocated into the nucleus 
where it upregulates the transcriptional activity of several genes involved in cell proliferation 
(Chang, Steelman et al. 2003).  
 In addition to cell proliferation, cAMP has a recognised role in stimulating fluid secretion in 
ADPKD mediated through a Cl- dependent mechanism (Hanaoka and Guggino 2000). Fluid 
secretion in ADPKD cysts is dependent on ion channels and transporters within the basolateral 
and apical membranes. cAMP-dependent anion secretion is mediated by Cl-  transport through 
apical CFTR Cl channels (Hanaoka, Devuyst et al. 1996).  The Na+-K+- ATPase transporter is 
the important active transporter in the basolateral membrane that pumps sodium out of the cell 
in exchange with potassium. This is important in maintaining the chemical gradient for Na+ 
and K+ across the membrane (Hanaoka, Devuyst et al. 1996). The second transporter is Na+-
K+-2Cl- which utilizes the Na+ gradient to transport Na+, K+, and 2 Cl- into the cell. This 
increases the Cl- concentration above its electrochemical gradient. For example, when 
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vasopressin binds to the V2 receptor, a G-protein coupled receptor, this leads to an increase in 
the synthesis of cAMP via adenylyl cyclase. This increase in cAMP activates PKA which in 
turn activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride 
channel on the apical membrane of the cell, leading to Cl- efflux by cAMP dependent secretion 
(Figure 1.5) (Wallace, Grantham et al. 1996).  Subsequently, this activates the KCa3.1 channel 
which increases basolateral K+ conductance and both channels create a driving force for 
paracellular transport of Na+ and this addition of NaCl to the luminal fluid creates the osmotic 
movement of fluid into the cyst (Sullivan, Wallace et al. 1998).        
 
1.10. Targeting cAMP pathway in PKD. 
Animal models of polycystic kidney disease have helped to provide a significant new 
understanding of the molecular and cellular pathogenesis of ADPKD. In addition, they have 
enabled the testing of novel treatments for ADPKD. Furthermore, animal models have been 
used to identify genes which modify the severity of the disease (Saigusa and Bell 2015).  
Several trials targeting the cAMP pathway in PKD animal models and ADPKD patients have 
been completed. One trial used the vasopressin antagonist V2R antagonist OPC-31260 which 
was found to be very effective in reducing the disease progression in both ADPKD and ARPKD 
in animal models pkdws25/- mouse, pck rat respectively, by down regulation of cAMP 
signalling, cell proliferation and chloride driven fluid secretion (Wang, Gattone et al. 2005).  
 The second drug was Octreotide, a somatostatin analogue which is being used to antagonise 
the action of vasopressin in collecting ducts. In one study, octreotide binds with somatostatin 
G coupled receptors inhibiting AC activity and decreasing cAMP production. It has been 
shown to decrease kidney and liver cysts in a pck rat model of polycystic kidney disease 
(Masyuk, Masyuk et al. 2007). A trial was carried out in ADPKD patients using long acting 
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somatostatin analogue (multicentre randomised controlled trial), on kidney volume and cyst 
growth in ADPKD patients compared to control group over 3 years  There was decrease in 
total kidney volume in somatostatin group compared to placebo (Caroli, Perico et al. 2013).   
Furthermore, the SKI-606, a Src inhibitor, which is intermediate between receptor activation 
and the Ras/Raf/MEK/ERK pathway, caused a decrease in biliary and renal cysts in pck rat, 
and bpk mouse models (Sweeney, von Vigier et al. 2008).  It was entered into a phase II 
randomised clinical trial (Riella, Czarnecki et al. 2014). A c-src inhibitor (SKI606) and a 
tyrosine kinase inhibitor (KD019), both shown to be effective in other cancers e.g. non-small 
cell lung carcinoma (Pietanza, Gadgeel et al. 2012). Based on promising preclinical data in 
rodent models (Gile, Cowley et al. 1995),  In addition, the inhibition of fluid secretion through 
the use of CFTR inhibitors was found to decrease cyst expansion in an embryonic pkd1-/- 
mouse kidney (Yang, Sonawane et al. 2008). BPO-27 is CFTR inhibitor with great efficiency 
and potency and anti- secretory effects in culture model of PKD. It is potential candidate for 
further preclinical study (Snyder, Tradtrantip et al. 2011). Other studies have examined a role 
for the mammalian target of rapamycin (mTOR) pathway in the pathogenesis of ADPKD. In 
animal models, mTOR inhibition resulted in decreased cyst growth (Tao, Kim et al. 2005, 
Shillingford, Murcia et al. 2006). Two human trials have studied the effect of sirolimus 
compared to standard care for 18 months (SUISSE) or everolimus for 24 months in a second 
trial. However the results have been disappointing with non-significant decreases in kidney 
volume in the first trial and no improvement in GFR in both studies (Perico, Antiga et al. 2010, 
Walz, Budde et al. 2010).  
Finally, a RCT of pravastatin in paediatric and young adults with ADPKD revealed a positive 
effect in reducing TKV increase associated with an improvement in oxidative stress markers 
(Klawitter, McFann et al. 2015). 
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Many other new treatments for ADPKD have been identified in preclinical studies but have not 
been formally tested in man. It is likely that the clinical management of ADPKD will change 
from monitoring to active treatment with a combination of different drugs that targeting 
different disease pathways (Rathaus 2007). 
1.11. The prostaglandins and their receptor function in normal kidney. 
Prostaglandins are a group of biologically active lipids originating from the twenty carbon 
essential fatty acids (Antonucci, Cuzzolin et al. 2007). Prostaglandin production involves three 
important stages: the first step is the conversion of cell membrane phospholipids by the enzyme 
phospholipase A2 to arachidonic acid. The second step is catalysis of arachidonic acid by 
COXs enzymes (COX1-COX2) to an intermediate endoperoxide, prostaglandin H2. The final 
step consists of a change of PGH2 through enzyme PG synthase to PGs (PGE2, PGI2, PGD2 
and PGF2) and thromboxane (TXA2) (Figure 1.7) (Cha, Solnica-Krezel et al. 2006). 
Prostaglandins have a central ring called the cyclopentane ring, and two side chains called α 
and ω that are attached to the cyclopentane ring (Narumiya, Sugimoto et al. 1999) (Figure 1.7).  
PGE2 functions as an autocrine and paracrine factor to maintain local homeostasis (Tsuboi, 
Sugimoto et al. 2002). The action of prostaglandins is controlled by COX, prostaglandin 
synthase and its receptors. These prostaglandins have significant roles in body homoeostasis, 
platelets aggregation, inflammation and control of fever and pain. Furthermore, they play an 
essential role in renal, respiratory, reproduction and gastrointestinal functions. In addition, they 
play vital roles in the immune system, sleep control, apoptosis and tumorigenesis (Nasrallah, 
Clark et al. 2007). The function of PGs is mediated primarily via binding to a family of cell 
surface membrane proteins called G- protein coupled receptors (GPCRs). These are called EP 
receptors for PGE2, IP receptors for PGI2, DP receptors for PGD2, FP receptors for PGF2α 
and TP receptors for thromboxane 2 (Tsuboi, Sugimoto et al. 2002). The GPCRs consist of 
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seven transmembrane alpha-helices that move in and out of membrane and are involved in cell 
signalling transmission. PGE2 binds to a G-protein heterotrimer consisting of α, β, and γ 
subunits, that activates downstream signalling pathways important for regulating cell 
proliferation, inflammation, tissue repair and remodelling (Dorsam and Gutkind 2007).  
Prostaglandin E2 (PGE2) is the major prostanoid in the kidney, followed by PGI2, PGF2α and 
thromboxane A2 (Nasrallah, Clark et al. 2007). Prostaglandin E2 production occurs primarily 
in glomeruli and collecting ducts (Breyer and Breyer 2000). It plays a significant role in 
glomeruli and tubular function. For example, PGE2 maintains the glomeruli filtration rate and 
regulates renal blood flow through vasoconstrictors and the secretion of renin. In tubules it has 
an important role in water and electrolyte transport in a different tubular segments and 
collecting ducts (Breyer and Breyer 2000).  
The effect of prostaglandin E2 in the kidney is mediated mainly by four G-protein coupled 
receptors (PTGER1, PTGER2, PTGER3 and PTGER4) (Nasrallah, Hassouneh et al. 2014). 
Both receptors PTGER2 and PTGER4 coupled with Gs-activating adenylyl cyclase lead to 
increased cAMP and protein kinase A activation (Castellone, Teramoto et al. 2005) (Figure 
1.8).  
The PTGER1 and PTGER3 receptors contribute to the renal arterial vasoconstriction through 
effects on Ca2+ levels and the inhibition of cAMP levels respectively (Pena-Silva and Heistad 
2010).  PTGER1 is located mainly in the connecting segment, cortical collecting ducts, inner 
and outer medullary collecting ducts. It is coupled to Gq and activates phosphatidylinositol 
hydrolysis and protein kinase C leading to increases in intracellular Ca2+ and a decrease in Na+ 
and water reabsorption in collecting ducts (Morath, Klein et al. 1999) (Breyer and Breyer 2000) 
(Figure 1.8).  
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PTGER3 is mainly situated in the glomeruli, thick ascending limb, cortical and medullary 
collecting ducts and arterial endothelial cells. It has multiple splice variants coupled to either 
Gαi, Gαs, or Gαq and activates multiple signalling pathways. In humans, there are eight 
PTGER3 splice variants (Hata and Breyer 2004). PTGER3, couples primarily with Gαi and 
causes vasoconstriction by decreasing cAMP through stimulation of MAPK. It can also couple 
with Gαs or Gαq depending on the splice variant (Morath, Klein et al. 1999) (Breyer, Davis et 
al. 1996, Breyer, Jacobson et al. 1996) (Figure 1.8).  
PTGER2 has the lowest expression in the kidney compared to other PTGER receptors. It is 
present primarily in interstitial cells, media of arteries and glomerular arterioles and vascular 
smooth muscle, it has a significant role in salt excretion (Morath, Klein et al. 1999). 
PTGER4 is highly expressed in glomeruli, media of arteries and outer medullary collecting 
ducts. It has an important role in regulating the glomerular filtration and hemodynamic function 
(Breyer and Breyer 2000). PTGER2 and PTGER4 may cause vasodilatation of renal arteries 
through their effects on cAMP. They  also regulates sodium and electrolytes transport 
(Poschke, Kern et al. 2012) (Nasrallah, Hassouneh et al. 2014).  
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(Narumiya, Sugimoto et al. 1999). 
Figure 1.7. Biosynthesis of prostanoid. 
The first step is conversion of arachidonic acid to PGG2 and then to PGH2 by cyclooxygenase 
(COX1-COX2). Step 2 is the change of PGH2 to PGI2, PGD2, PGE2, PGF2α and TXA2 via 
the enzyme PG synthase (Narumiya, Sugimoto et al. 1999) 
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American Journal of Renal Society 2014 (Nasrallah, Hassouneh et al. 2014) 
Figure 1.8. The signalling pathway for PGE2, and its 4 receptors. 
PGE2 synthesised first from changing of phospholipid by PLA2 to arachidonic acid that 
changes to PGH2 by cyclooxygenase (COX1/COX2). The PGE2 is produced by changing of 
PGH2 to PGE2 by enzyme prostaglandin synthase. PGE2 works via its four receptors PTGER1, 
PTGER2, PTGER3 and PTGER4. The four receptors bind to G protein- coupled receptors; the 
PTGER1 binds with Gq and increases Ca2+ levels by activating PLC. The PTGER2, and 
PTGER4 couple with G stimulatory protein (Gs) that stimulate AC to increase the cAMP level. 
PTGER3 acts mainly by coupling with Gi to increase intracellular Ca2+levels through PLC and 
decreases the cAMP level through AC. 
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1.12. PTGER2 and PTGER4 receptor signalling. 
Although activation of both PTGER2 and PTGER4 receptors lead to increased intracellular 
cAMP, they differ in both their structure and subcellular localization. Both proteins have only 
30% identity in their transmembrane domains (Fujino and Regan 2003). PTGER2 contains 358  
amino acids whereas PTGER4 consists of 488 amino acids (Regan 2003). Unlike PTGER2 that 
has a short tail, PTGER4 has a long carboxyl tail enclosing several phosphorylation sites 
(Tsuboi, Sugimoto et al. 2002).  Furthermore, PTGER4 responds to an agonist by 
internalisation and desensitisation and no such effect is observed for PTGER2 (Nishigaki, 
Negishi et al. 1996, Desai, April et al. 2000). 
 PTGER2 and PTGER4 couple with Gαs proteins to activate adenylate cyclase thus increasing 
intracellular cAMP levels which activate PKA. The activation of PKA leads to phosphorylation 
of CREB at Serine-133 (cAMP response element protein) and its nuclear translocation.  This 
is important in promoting cell survival by increasing the gene expression of Bcl-2 which has 
an anti-apoptotic effect. It can also promote gene expression of COX-2 which leads to increased 
synthesis of PGE2 and cyclin D1 which is important in regulating cell cycle progression at mid 
and late G1 phases (Mayr and Montminy 2001). PTGER4  phosphorylates and stimulates 
CREB (cAMP response element protein) mainly through PI3K/Akt pathway and the PKA 
pathway (Fujino, Salvi et al. 2005) (Figure 1.9).  
On other hand, PTGER2 through PKA can also phosphorylate and inactivate glycogen synthase 
kinase (GSK-3α) which leads to activation of the β-catenin pathway. β-catenin translocate to 
the nucleus and forms a complex with transcription factor T-cell factor (TCF) (Castellone, 
Teramoto et al. 2005, Shao, Jung et al. 2005, Elberg, Turman et al. 2012). The TCF complex 
activates gene expression important in promoting cell growth, decreasing apoptosis, and 
increasing cell motility (cyclin D1, VEGF or vascular endothelial growth factor, c-myc and 
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matrilysin) (Shao, Jung et al. 2005) (Figure 1.9). The anti-apoptotic effect is mediated through 
PI3K and phosphorylated Akt that blocks the translocation of BAX from cytoplasm to the 
mitochondria, this in turn prevents caspase activation and apoptosis (Stenson 2007).  
The PTGER4 receptor induces phosphorylation of GSK-3α and subsequent activation of the β-
catenin pathway primarily through PI3K pathway rather than through the activation of the 
cAMP/PKA Pathway (Fujino, West et al. 2002). Additional differences between the two 
receptors are that PTGER2 principally induces the PKA (protein kinase A) pathway (Figure 
1.9) which activates the -catenin pathway and finally stimulates T-cell factor whereas 
PTGER4, in addition, to stimulating the PKA pathway also activates Gαi protein and 
downstream signalling through PI3K activating -catenin and T-cell factor. Furthermore, 
PTGER4 can increase expression of early growth factor-1 (EGF-1) through the Ras/ 
MAPK/ERK pathway which is important for the transcription of PGE2 synthase leading to 
increased production of PGE2. This results in a positive feedback loop that increases cell 
proliferation (Figure 1.9) (Fujino, Xu et al. 2003).  
 
 
 
1.13. Prostaglandin and its receptors in ADPKD. 
Several previous studies had indicated a role for PGE2 in the pathogenesis of ADPKD, For 
example, elevated levels of PGE2 were shown to be present in the cystic fluid of human 
ADPKD patients by radioimmunoassay compared to normal blood levels (Gardner, Burnside 
et al. 1991). A rodent polycystic kidney model had a higher level of PGE2 compared to control 
animals (Sankaran, Bankovic-Calic et al. 2007). One study found that an elevated level of 
PGE2 was present throughout progression of ADPKD (Sorensen, Glud et al. 1990). PGE2 acts 
to increase cAMP production in cystic epithelial cells of ADPKD, mainly through its 
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interaction with the receptors PTGER2 and PTGER4. Together they act by coupling the G-
stimulatory protein Gs activating adenylyl cyclase to produce cyclic AMP (Sankaran, 
Bankovic-Calic et al. 2007). Another study was able to demonstrate that cyst formation was 
increased following stimulation of cystic cells with PGE2. This effect was mediated mainly 
through increased expression of PTGER2 receptors in these cells (Elberg, Elberg et al. 2007).  
Gene analysis to investigate the molecular mechanism of cystogenesis using cDNA microarray 
analysis of the ADPKD cysts found an upregulation of PTGS2 (8.2 fold) and  of PTGER2 (>3-
fold) (Song, Di Giovanni et al. 2009). The  upregulation of PTGER2 may stimulates adenylyl 
cyclase and increase cAMP production (Belibi, Reif et al. 2004, Song, Di Giovanni et al. 2009). 
On the other hand, the PTGER3 receptor is downregulated (-3.5 fold) which decreases the 
cAMP production in ADPKD. 
PGE2 secretion in cyst fluid stimulates PTGER2 receptor mRNA expression by three- to 
fourfold in cystic epithelial cell (CEC) primary cultures (Elberg, Elberg et al. 2007).  The 
PTGER2 receptor antagonist (AH-6809) has been shown to inhibit PGE2 stimulation of cAMP 
production in CEC (Elberg, Elberg et al. 2007). Another study highlighted the role of PTGER4 
in IMCD-3 cyst expansion (Elberg, Turman et al. 2012). Another study on mouse IMCD-3 
cells showed that PGE2 increased proliferation and fluid secretion through a PTGER4 but not 
PTGER2-dependent pathway (Liu, Rajagopal et al. 2012). Therefore, blocking both PTGER2 
and/or PTGER4 receptors using selective antagonists may have a therapeutic role in ADPKD.  
These results are consistent with data from studies of PGE2 in cancer. PGE2 is a potent 
stimulus for the growth of certain tumours such as colorectal carcinoma. PGE2 acting via 
PTGER4 receptor can enhance the growth and invasiveness of colorectal carcinoma through 
the Wnt pathway (Sheng, Shao et al. 2001). PTGER4 knockout mice had a decrease in 
abnormal crypt formation in colon cancer (Regan 2003). While PTGER2 knockout in an APC 
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mouse model cell decreased the number and size of intestinal polyp in adenomatous polyposis 
coli (Sonoshita, Takaku et al. 2001). 
Although nonsteroidal anti-inflammatory drugs (NSAIDs) have been used for the prevention 
and treatment of colon cancer through inhibition of cycloxgenase-2 (COX-2), long-term 
treatment with NSAIDs has been associated however with increased risk of cardiovascular 
death (Myung and Kim 2008). Similarly, NSAIDs have also been shown to inhibit PKD in 
rodent models (Aukema, Adolphe et al. 2003). Antagonism of PTGER4 or and PTGER2 
receptors could potentially be used for the treatment of ADPKD (Liu, Rajagopal et al. 2012), 
avoiding cardiovascular side effects (Takahashi, Uehara et al. 2014).  
 
 
  
 
. 
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(De Keijzer, Meddens et al. 2013). 
Figure 1.9: PTGER2 and PTGER4 regulate different signalling pathways activated by 
PGE2. 
Activation of PKA and PI3K signalling pathways leads to activation of TCF and CREB 
transcription factors that increase the gene expression which involved in proliferation and cell 
survival. Activation of PI3K/ERK induce expression of early growth response-1 that increase 
PGE2 synthase. PI3K and PKA pathway inhibits the GSK-3α leading to stabilization of -
catenin that translocates to the nucleus and regulates TCF dependent genes (De Keijzer, 
Meddens et al. 2013).  
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Hypothesis 
Increased levels of PTGER2 contribute to the pathogenesis of APDKD. Therefore, blocking 
PTGER2 using specific receptor antagonists may have a therapeutic role in reducing cyst 
growth in ADPKD. 
Objectives: 
1. Optimization of 3D culture method for cell lines derived from patients with ADPKD. 
2. Determination of the expression levels of PTGER receptors 2 and 4 by Western 
blotting, IHC from human ADPKD tissue sections. 
3. Determination of expression levels of PTGER receptors 2 and 4 by qPCR and IHC from 
two independent orthologous mouse models of ADPKD. 
4. Test the effect of PGE2, PTGER2, and PTGER4 receptor antagonists on cyst growth, 
cell proliferation and apoptosis in control and ADPKD kidney epithelial cell lines. 
5. Compare cAMP levels in control and ADPKD kidney epithelial cell lines incubated 
with PTGER2, and PTGER4 receptor antagonists. 
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Chapter 2 
Materials and Methods 
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2.1. Cell lines and culture conditions: 
 
The primary epithelial cell lines used in this study are tabulated below (Table 2.1.1): 
Cell Lines Description Origin 
OX161 Human kidney epithelial cell 
line originated from ADPKD 
kidney 
Prof. Albert Ong. UK 
OX161/C1 Human kidney epithelial cell 
line originated from ADPKD 
kidney 
Prof. Albert Ong. UK 
SKI-001 Human kidney epithelial cell 
line originated from ADPKD 
kidney 
Prof. Albert Ong. UK 
OX938 Human kidney epithelial cell 
line originated from ADPKD 
kidney 
Prof. Albert Ong. UK 
SKI002 Human kidney epithelial cell 
line originated from ADPKD 
kidney 
Prof. Albert Ong. UK 
UCL93 Human kidney epithelial cell 
line originated from normal 
adult human kidney 
Prof. Albert Ong. UK 
RFH Human kidney epithelial cell 
line originated from normal 
paediatric human kidney 
Prof. Albert Ong. UK 
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MDCK  II Canine kidney epithelial cell 
line originated a cocker 
spaniel  kidney  
Prof Nick Simmons, 
Newcastle 
 
2.1.2. Cell culture material that used in the experiments are tabulated in (Table 2.1.2). 
 
Culture media and reagent in tissue 
culture 
Supplier Address 
Dulbeccoʼs Modified Eagle Medium 
(DMEM). 500ml 
Life technology 
 
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF, UK 
Phone: 0141 814 6100 
Fax: 0141 814 6260 
Email: ukorders@lifetech.com 
 
Dulbeccoʼs Modified Eagle Medium: 
Nutrient Mixture F-12(DMEM/F-12) 
500Ml. 
Life technology 
FCS (Foetal Calf Serum) Bio sera 1 Acorn House, The Broyle, 
Lewes BN8 5NN 
+44 1273 814466 
NU Serum Fisher scientific Fisher Scientific UK Ltd  
Bishop Meadow Road  
Loughborough  
LE11 5RG 
Antibiotic-Antimycotic). 100x  
 
Life technology 3 Fountain Drive 
Inchinnan Business Park 
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L-Glutamine 1% 200mM  Life technology. Paisley PA4 9RF, UK 
Phone: 0141 814 6100 
Fax: 0141 814 6260 
Email: ukorders@lifetech.com 
Phosphate buffer saline (PBS) (1X).  Bio Whittaker. 875 Brockelman Road 
Lancaster, MA 01523  
Phone: (978) 368-3124 
.05% trypsin-EDTA (1x)  Life technology. 3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF, UK 
Phone: 0141 814 6100 
Fax: 0141 814 6260 
Email: ukorders@lifetech.com 
EGF (epidermal growth factor) 10ng/ml 
5ul 
Sigma Technical Services 
PO Box 14508 
St. Louis, MO 63178 
UNITED STATES 
Hydrocortisone 5ug/ml  Sigma 
Prostaglandin E2 Sigma 
100X Insulin-Transferrin-Selenium 
(ITS -G) 
Life technology 3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF, UK 
Phone: 0141 814 6100 
 db-cAMP Calbiochem 165 New Boston Street 
 Woburn, MA 01801 
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 Phone:  +1-781-937-0777 
Forskolin Sigma Technical Services 
PO Box 14508 
St. Louis, MO 63178 
United states 
10x MEM Sigma 
EGF Sigma 
 
 
2.2. Three Dimensional gel cell cultures 
 
Gels Amount 
Collagen I  Rat tail (Invitrogen) 5mg/ml  
Collagen 2009 Rat tail  Prepared in house 
Geltrex (Invitrogen cell culture) 5ml 
BD Matrigel  BD Biosciences 
BD matrigel matrix high concentration 
 
BD Biosciences 
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2.3. Western Blotting 
2.3.1 List of primary antibodies used in Western Blotting and immunohistochemistry. 
Raised in Name Directed 
against 
Dilutions Source Catalogues 
number 
Rabbit Calnexin Control  WB1/2000 Sigma C4731 
Mouse 7e12 PC1 WB1/2500 Albert Ong  
Goat G-20 PC-2 W.B 1/1000 SantaCruz 
biotechnology 
Sc10376 
Mouse 
 
Rabbit 
PTGER2 
 
PTGER2 
PGER2 
 
PTGER2 
WB 2ug/ml 
IH 8-25ug/ml 
WB 100µg 
0.6mg/ml 
Rand D System 
 
Abcam 
MAB6656 
 
Ab73191 
Rabbit PP-30 PC-2 WB 1/2000 Albert Ong  
Mouse IAII PC2 WB 1/2500 Guangqing Wu, 
Vanderbilt 
 
Rabbit -actin  -actin 
protein 
WB 1/2000 Cell signaling 4970P 
Rabbit 
 
PTGER4 PTGER4 WB1/1000 Sigma  HPA012756 
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2.4. Lists of primary antibodies used in Immunofluorescence and 
immunohistochemistry. 
Raised in Name Directed 
against 
Dilution
s 
Source Catalogues 
number 
Rabbit Cleaved-
Caspase-
3(Asp175) 
(D3E9) 
Caspase-3 1/200 Cell signaling 
technology 
9579S 
Rat Zo-1 R26-4C Zo 1/200 David 
Goodenough 
 
Mouse Gp135 GP135 1/200 George 
Ojakian 
 
Mouse PTGER2 PGER2 IH 8-
25ug/ml 
R and D 
Systems 
MAB6656 
Rabbit PTGER4 PTGER4 IHC 1/25 Sigma  HPA011226 
Alexa Phalloidin Actin IF 1/40 Life 
technology 
A12381 
 
 
 
 
2.5. Lists of kits used in ELISA.  
Kit Supplier Catalogues number 
In Situ Cell Death Detection 
Fluorescein 
Roche Version 17 11684795910 
Cell proliferation Elisa BrdU Roche Version 16 11647229001 
cAMP Assay  R& D KGE002B 
Cell Titer 96® AQueous One 
Solution Cell (MTS) 
Proliferation Assay  
 
Promega G3582 
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2.6. mRNA assay (qPCR): 
2.6.1 Samples: 
N0 Cell Line Normal/Cystic 
1 CL5 Normal 
2 CL8 Normal 
3 CL11 Normal  
4 RFH Normal 
5 UCL93 Normal 
6 OX161 Cystic 
7 OX938 Cystic 
8 SKI-001 Cystic 
9 SKI-002 Cystic 
 
2. 6.2 RNA isolation: 
Chloroform    (sigma) 
Isopropyl alcohol (sigma) 
75% ethanol (in DEPC-Treated water) VWR 
RNase-free water  
 
Polypropylene micro centrifuge tubes 
DNA ladder  life technology 
Water bath (55-600C) 
Ethidium bromide (sigma) 
Centrifuge and rotor capable of reaching up to 12,000xg 
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2.6.3. qPCR primers: 
N0 qPCR Reference/Experimental Source 
1 GADPH Human control RNA 
A&B applied biosystems 
2 PTGER-1 Human Hs00909194 g1 
3 PTGER-2 Human Hs04183523 m1  
4 PTGER-3 Human Hs00168755 m1 
5 PTGER-4 Human Hs00168761 m1 
 
2.6.4 Reverse Transcription: high capacity RNA-to-cDNA Kit. 
Component Component volume/ Reaction(ul) 
 + RT reaction -RT reaction 
2X RT Buffer 10.00 10.00 
20X Enzyme Mix 1.0 - 
RNA Sample Up to 9ul up to 9 ul 
Nuclease- free H2O To final volume 20ul To final volume 20ul 
Total per Reaction 20.0 20.0 
 
2.6.5 qPCR: TaqMan Gene Expression Assay 
component Volume(ul)/20ul Reaction 
20X TaqMan Gene Expression Assay 1.0 µl 
2X TaqMan Gene Expression Master Mix 10µl 
cDNA template(1-100 ng) x µl 
RNase-free Water Up to 9µl 
Total 19ul 
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2.6.6. Reverse Transcription: TaqMan qPCR  
Thermal cycle conditions 
Time (Minutes) Temperature (°C) 
60 37 
5 95 
∞ 4 
 
2.1. Mammalian cell culture. 
The kidney epithelial cells that were used throughout the project were of two types: non cystic 
cells (UCL93, RFH), and cystic cells (OX161, OX161/C1, OX938, SKI-001, SK002). All cell 
lines, other than the MDCK II, were immortalised from primary cultures of tubular cells taken 
from ADPKD and the normal human kidneys which were removed for clinical proposes. The 
cells were transduced with replication-defective retroviral vector containing the temperature 
sensitive LT antigen and the catalytic subunit of human telomerase (hTERT) or sequentially 
with vectors containing either gene. All clones were generated from pooled cultures of cystic 
cells at early passage except for OX938 where cells were isolated from three individual cysts 
(C6-8) and propagated. 
The cells were grown in the DMEM-F12 media (Invitrogen) with 1% L-Glutamine 5ml 
supplement and1% antibiotic/anti-mycotic (penicillin/streptomycin) (Invitrogen) 5ml to 
prevent bacterial and fungal infections, and 5% (25ml) NuSerum (Becton Dickinson). In 
preliminary experiments a number of different kidney cell lines were tested for their ability to 
form cysts in 3D cultures including, IMCD3 (Inner medullary collecting duct), MEK wildtype 
and null (PC1) cells and PTEC (proximal tubular epithelial) cell. Unfortunately, none of these 
cells form cystic structures in 3D culture media.  That is why I decided to use the MDCKII cell 
line which forms cysts in 3D culture and has been used in many studies as a model of cystic 
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cells (Buchholz, Teschemacher et al. 2011, Engelberg, Datta et al. 2011) The MDCKII cell 
kidney epithelial cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (life 
technology) supplemented with 1% L-Glutamine (Invitrogen), 10% FCS and 1% 
antibiotic/antimycotic solution (Invitrogen). 
T75 flasks were used for the cell growth at 330C and 5% CO2. The cells were passaged when 
they reached 75-95% confluence.  The passaging was carried out by applying aseptic technique 
in hood with gloves; media was aspirated from the flask by suction and the cell monolayer was 
washed with 10ml sterile PBS. 1X trypsin 2ml (Invitrogen) solution was added to the cell and 
flask was incubated for 5min in an incubator 33ºC or until the cells were detached from the 
flask.  Trypsin was then neutralised by adding 10ml of the culture media. The cells were by 
pipetted into a universal tube and centrifuged for 5 minutes. The media was removed and the 
cell pallet was dissolved in 5ml media; the cell was then seeded into a new flask. The process 
was followed up by microscope for confluency. The media was usually changed every 2 days. 
Cell cryopreservation: after trypsinisation and centrifugation, the cells pellets were 
resuspended using freeze media containing 10 %( v/v) Nu serum, 10% DMSO.  The cell were 
placed into a cryovial, and frozen in a -80ºC freezer in an isopropanol container for 24 hours, 
before transferring them into liquid nitrogen reservoir at -190 ºC for long term storage. 
2.2. Rat tail collagen preparation. 
Rat tail tendons were dissected from 70% ethanol washed rat tails and extensively washed in 
sterile distilled water. Type I collagen was extracted by incubation in 0.1M acetic acid for 72 
hours at 4°C with stirring.  The solution was transferred to ultra-centrifuge tubes and insoluble 
material spun down at 10000g for 30 min. The supernatant was transferred to sterile tubes and 
stored at 4°C until use.  
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2.3. Three-dimensional Cyst assays. 
2.3.1. Type I collagen gel cyst assay. 
Collagen gels were formed by mixing ice-cold type I Collagen gel (3.84 mg/ml 70% vol/vol), 
20% NaHCO3 solution (11.76 mg/ml), and 10% 10X MEM (Invitrogen). A mixture 
(100µl/well) of Collagen and cells at a density of 2x104 cells/well were plated in triplicate into 
96 well plates. The gel was allowed to polymerise at 370C for 20 minutes prior to adding 100 
µl of the growth media on top of the polymerised cell-containing Collagen gel. This was then 
incubated at 370C in a humidified atmosphere of 5% CO2 for 10-15 days. The media was 
changed every 2 days. The cells were observed and phase-contrast images of cells were taken 
by inverted microscope (Olympus IX71) from day 2 and observed every two days for eight 
days. The cAMP and Forskolin experiment first the dibutyryl cAMP 100µM (Calbiochem) and 
Forskolin (Calbiochem) 10µM were added to MDCK II cells at day 2 in triplicate, and the 
control cells were added just media in triplicate. The treatment and control were changed every 
two days as well. The cells were observed, phase contrast image of the cells were taken every 
two days and measurement of cyst area were taken for treatment and control cells every two 
days. 
To test the effects of prostaglandin E2, different concentrations of PGE2 (Sigma) were first 
prepared by diluting with the media (12.5nM, 25nM, 50nMand 100nM, 250nM, 500nM, 1µM) 
and every concentration were adding in triplicate into the seeding MDCK II cells.  The control 
cells were maintained in normal media in triplicate from day 2 and media changed every two 
days. Cells were observed daily and phase contrast images taken every two days for the 
measurement of cyst area. 
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2.3.2. Cyst assay with collagen and Matrigel 
Collagen gels were formed as described in section 2.4.1 and mixed with an equal volume of 
Matrigel. Cell density and cyst growth were as described in section 2.4.1. 
2.3.3. Matrigel cyst assay. 
To culture cells on top of a Matrigel layer, Matrigel was first thawed on tice for 1-2 hours 
before 100 µl of Matrigel was added to each well of a 96 well plate. The plate was incubated 
at 37°C for 30 minutes to promote polymerisation of the Matrigel. Cells were plated directly 
onto the surface of the gel at a density of 4x104 cells/well in culture media containing 100 µl 
matrigel/5ml media.  
To culture cells embedded inside Matrigel 4 x104 cells were mixed with 100µl of matrigel and 
seeded in triplicate into the wells of a 96 well plate. The plate was incubated at 37°C for 30 
minutes to promote polymerisation of the Matrigel.  Culture media was added to the top of the 
Matrigel.  
This was then incubated at 330C (human cells) or 370C (MDCK II) in a humidified atmosphere 
of 5% CO2 for 10-15 days. The media was changed every 2 days. The cells were observed, 
and phase-contrast images of cells were taken by inverted microscope (Olympus IX71) from 
day 2. After 48 h, the dibutyryl cAMP 100µM (Calbiochem) and Forskolin (Calbiochem) 
10µM were added to OX161/C1cells in triplicate, and the control cells were added just media 
in triplicate. The cells were observed every two days and measurement of cyst area were taken 
for treatment and control cells every two days.   Next, the prostaglandin experiment was carried 
out. First different concentrations of PGE2 (Sigma) were prepared by diluting with the media 
(12.5nM, 25nM, 50nM, 100nMm, 500nM, and 1µM) and every concentration were adding in 
triplicate into seeding OX161/C1 cells.  The control was treating with just media in triplicate 
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as well at day 2. The cells were observed and phase-contrast images of cells were taken by 
inverted microscope (Olympus IX71) and measurement of cyst area were taken for treatment 
and control cells every two days.  
2.3.4. Measurement of average cyst area and statistical analysis. 
To measure the growth rate cysts from 3 independent wells were counted with at least 8 cysts/ 
well, 20 cysts for total 3 wells for MDCK II and 15 cysts/ well, 45 cysts / total 3 wells for 
OX161/C1. Cysts were defined according to the following criteria: transverse diameter of the 
cysts >100µm and cyst area >50µm2 (Elberg, Turman et al. 2012).  We measured at least 8 
randomly selected fields for each well measuring all the observable cysts which met our criteria 
for a definition of a cysts in each field. For statistical interpretation unpaired t test was used for 
two groups(two sets of measurement) and ANOVA test for more than two groups (mean± 
SEM). P value was significant if <0.05 .  
The average cyst area was measured using SimplePCI software (x20 magnification) and 
average cyst area in triplicate wells calculated. Three independent experiments were performed 
for each condition, and one experiment was chosen to represent the result of the experiment. 
The statistical analysis were carried out using Prism software (Graph Pad) with P-values 
reported as >0.05 (Non-significant) or <0.05 (significant). An unpaired t- test was performed 
to compare two groups, and one way ANOVA test was carried out to compare three or more 
groups. 
 
2.3.5. Testing the effect of PTGER2 and PTGER4 receptor antagonists in cyst assays. 
MDCK II and OX161/C1 cells were cultured in Collagen or Matrigel cyst assays as described 
previously. After 48h cells were treated in triplicate with PTGER2 antagonist (PF-04418948) 
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or PTGER4 antagonist (CJ-042794) with concentration ranging from 100 nM to 10 µM. 
Control cells were treated with 0.1% DMSO. In some experiments 50 nM PGE2 was added 
following pre-incubation for 2 hrs with PTGER2 or PTGER4 or a combination of PTGER2 
and PTGER4 receptor antagonists (500 nM or 1µM). Media was changed every 2 days and 
phase-contrast images of cysts were taken by inverted microscope (Olympus IX71) from day 
2.  
2.4. Immunofluorescence. 
2.4.1. Staining the cells in Collagen and Matrigel. 
The cell suspension of MDCK II and OX161/C1 was counted in heamocytometer to desired 
concentration of 2x104, and then plated in Collagen gel and OX161/C1 in Matrigel in 96well 
plates. Next day, the media was removed from the gel and replaced by media containing PGE2 
with three different concentrations (12.5nM, 25nM, 50nM, and100nM) in triplicate. The cAMP 
(50µm) and Forskolin (5µm) were prepared and added to gel in triplicate. The cell in the gel 
was followed in the microscope and media changed every two days for 10 days. On day eleven, 
the media was removed and washed three times with PBS. First, the cells were fixed with 4% 
paraformaldehyde for one hour at room temperature. Then, the gel was washed again three 
times with PBS with shaking for 10minutes. Next, the 4% paraformaldehyde was quenched 
with 0.15M glycine in PBS for 10min. After the gel had been washed with PBS three times for 
five minutes the gel permeabilized in 0.1% triton x-100 in PBS followed by washed three time 
with PBS for 10 min. Next, the cells were blocked with BSA for 30 minutes at room 
temperature. Subsequently, the cells were incubated with Phalloidin red 1/40 or ZO-1 or gp-
135 1/200 overnight at 40C. Next day, the gel was washed 1x15 minutes, then twice for 
30minutes, and lastly once for 15 min with PBS. For gp-135 and ZO-1 goat anti-mouse and 
anti-rat Alexa FITC secondary Ab 1/500(Abcam) was added to the cells for 1 hour at room 
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temperature. Then, the gel scoop out from the plate with spoon and placed in microscopic 
slides, followed by adding one drop of Vecta Shield mounting media and DAPI. Finally, the 
slid was sealed with DPX resin. The slides were investigated under fluorescent microscope and 
image taken for best represented image. 
 
2.5.1. Cell Lysate preparation 
Confluent cells in 10cm dishes were washed two times with PBS; then 1ml of PBS was added 
to the dish and the cells were then detached using a cell scraper. The cells were pipetted into 
1.5ml Eppendorf tube and kept on ice 40C. They were then centrifuged for 1minute at 40C 12. 
054g. The supernatant was discarded and the pellets containing the cells was dissolved by 
gentle pipetting with 100 µl IP Lysis buffer and protease inhibitor (0.5%Nonidet-P40, 1% 
Triton X-100, 25Mm NaPO4 PH7.0, and150 Mm NaCl) and incubated for 30 minutes on ice 
at 40C. The cell lysates were centrifuged at 17, 000g for 5 minutes at 40C. 10µl of the 
supernatant was used determine protein concentration using a colorimetric Bio-Rad DC protein 
assay.  
 
2.5.2. Protein concentration assay. 
A colorimetric Bio-Rad DC protein assay Kit (Bio-Rad) was used for the measurement of the 
protein concentration. The cell lysate was diluted 1:2, 1:4 and 1:8 in IP Lysis buffer. BSA was 
used as a known concentration to obtain a standard curve. The unknown protein samples and 
the BSA standard dilution (5µl) were pipetted in triplicate into a 96 well plate. 3ml of reagent 
A mixed with 60ul of reagent S to make a reagent Ȃ. 25ul of reagent Ȃ is added to each sample 
followed by 200ul of reagent B. It was incubated at room temperature for 15mints; then the 
absorbance was measured at 750nm.  
 
- 51 - 
 
 
2.5.3. Western blotting. 
10% Separating gel 6.3 ml H2O 
4.0 ml 1.5 M Tris-HCl pH8.8 
5.4 ml  acrylamide 30% 
160ul SDS 10% 
160ul APS 10% 
 16ulTEMED 
6% Separating gel 8.5 ml H2O 
4.0 ml 1.5 M Tris pH8.8 
3.2 ml acrylamide 30% 
160ul SDS 10% 
160ul APS 10% 
16ulTEMED 
4% Stacking gel 3.05 ml H2O 
1.25 ml 0.5M Tris-HCl pH6.8 
0.67 ml acrylamide 30% 
50 ul SDS 10% 
50 ul APS 10% 
12 ul TEMED  
SDS- PAGE Running Buffer 1.5g Tris 
7.2g Glycine 
0.5g SDS 
H2O to 500ml 
SDS-PAGE sample Buffer (2x) 10% 2-mercaptoethanol 
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0.1% Bromophenol Blue 
4% SDS 
100 Mm Tris pH8.8 
20% Glycerol 
SDS-PAGE Transfer Buffer 3g Tris  
14.4g Glycine 
200 ml methanol 
800 ml H2O 
IP Lysis Buffer  0.5 % Nonidet-P40 
1% Triton X-100 
25 Mm NaPO4 PH7.0 
150 Mm NaCl 
TBST 8g NaCl 
2 ml Tween 20 
10ml Tris 2M pH 7.6 
1L H2O 
Blocking Buffer 10% Non-fat milk in 1x TBST 
 
 
2.5.4. SDS-PAGE. 
Start with preparing a separating gel 6% and 10% as described in section 2.6.3. The separating 
gel was overlaid with 100% ethanol and gel allowed to set incubator at 370C. The gel was set, 
drained and washed with water. After preparing a 4% stacking gel, it was poured above the 
separating gel and the wells were made using a comb; they were kept in an incubator at 370C 
until they were set. Prepare the protein samples by mixing them with 20µl of 2x sample buffer.  
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The protein samples were then denatured at 370C for 30mins; then centrifuged at 12,054g for 
1 min. afterwards, the samples filled the wells alongside a molecular weight marker (standard 
protein dual colour, Bio-Rad). The gels ran in SDS-PAGE; the running buffer was at 100 V 
until the dye in the sample buffer had run to the lower part of the gel.  
2.5.5. Protein Transfer. 
The protein was transferred from the gels to the PVDF membranes in the presence of transfer 
buffer. The PVDF membranes were cut into a size similar to that of the gel and it was activated 
with methanol for 2mins; it was then washed with distilled water and kept shaking in distilled 
water for 30mints. Finally, the PVDF was soaked into the transfer buffer. For each gel, 
sandwich was prepared in the transfer buffer with two fibre pad, two filter papers, gel, PVDF 
membrane, one filter paper, and one fibre pad facing the black side of the cassette. The cassettes 
were inserted into the electrode module with the direction of the black side of the cassette next 
to the black side of the electrode module. A stirring magnet was placed with an ice cooling unit 
(-200C) in the butter tank. The tank was filled with transfer buffer to the top, the electrodes 
were attached to the power pack and electrophoresis was carried out at 100 V for 1 hr.  
 
2.5.6. Detection of antigen on membranes. 
 
After the transfer took place, the membranes were blocked in 10% milk- TBST (0.2% Tween 
20) at 40C for 1-3 hr. While shaking, the membranes were probed with primary antibodies 
diluted in 5% blocking buffer and kept in overnight at 40C. The membranes were washed 4 
times for 20mins with TBST at room temperature. The secondary antibodies were diluted in 
5% blocking buffer that was added to the membranes and incubated at room temperature for 1 
hr. Next, the membranes were washed 4 times for 20 minutes with TBST at room temperature. 
The membranes were developed by adding BM chemiluminescence blotting substances (Bio-
Rad, ClarityTM Western ECL substance). 1.5ml of bottle one was mixed with 1.5 ml of bottle 
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2 in a universal tube. The membranes were drained from the access of TBST; the membrane 
was put in the exposure cassette with the protein side facing up. It was then incubated with a 
substrate for 1-3 minutes. The membrane was then exposed to molecular imager, Bio-Rad 
Chemi DocTMXRST. Or to Super RX Fu medical X-ray films. 
 
2.6.1. RNA extraction from human ADPKD cell lines. 
The cells were plated into a 10 cm dishes. The aim was to achieve 60-70% confluence. The 
cells were incubated overnight. Next, the cells were washed with serum free media and they 
were incubated in the media with no serum for 24hr to synchronise the cells. After this time, 
the media was replaced with media containing serum; and incubated for a further 24 hrs. This 
will allow the cells to re-enter the cell cycle. Culture media was removed from the dish and 1 
ml of TRIzol (Ambion) was added directly to the cells. The cells were then lysed by pipetting 
up and down several times. Subsequently, the sample was incubated for 5 minutes at room 
temperature to permit complete dissociation of the nucleoprotein complex. 
 In addition, 0.2ml of chloroform per 1 ml of TRIzol Reagent was used for homogenization. 
The cap was closed securely, and the tube was shaken vigorously for 15 seconds and incubated 
for 2-3 minutes at room temperature. The samples were then centrifuged at 12,000xg for 15 
minutes at 4oC. The upper phase (aqueous phase) was removed into a new tube. Isopropanol 
was added to the aqueous phase (0.5ml per 1ml of TRIzol reagent used for homogenization). 
The complex was incubated at room temperature for 10 minutes.  
After that, the complex was centrifuged 12,000 x g for 10 minutes at 4oC. The supernatant was 
removed from the tube, leaving only the RNA pellet. The pellet was washed with 1 ml of 75% 
ethanol per 1 ml TRIzol reagent used in the initial homogenization process. The sample was 
vortexed briefly; it was then centrifuged at 7500 x g for 5 minutes at 4oC. The wash was 
discarded and the RNA pellet was air dried for 5-10 minutes. The RNA pellet was suspended 
in 50µl RNase-free water by passing the solution up and down several times through the pipette 
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tip. The dissolved RNA was then incubated in a water bath 600C for 15 minutes. The 
concentration of RNA was read using a Nano drop machine, quality was assessed by 
confirming the 260/280 ratio was between 1.8 and 2.0 and RNA was normalised to 1 µg/ml. 
The isolated RNA was stored at -800C. 
 
2.6.2. Agarose gel electrophoresis. 
A 1% agarose gel was prepared by dissolving 1 g of agarose powder in 100ml 1x TAE buffer 
(diluted from 50x stock containing 5% (v/v) glacial acetic acid, 2M Tris, 0.05 M EDTA at 
PH8.0). The dissolved gel was heated in a microwave for and the melted agarose was allowed 
to cool for few minutes before pouring the solution into the cast tray. Then 2µl ethidium 
bromide (10mg/ml, Sigma-Aldrich, UK) was added to the gel. The comb was placed in the tray 
to create wells for loading the samples. After the gel had set, the comb was removed, and the 
gel covered by TAE buffer. The RNA samples were mixed with 1:1 with loading dye 
(Promega) before being loaded into wells, and a 1kb DNA ladder was loaded for estimation of 
molecular weight of RNA fragment. The gel was run at 100V for 1 hour or until the loading 
dye had run half of length of the gel. The RNA was then visualised on a UV trans-illuminator. 
 
2.6.3. Reverse Transcription. 
Before starting the experiment, the work area was cleaned with 70% ethanol and then with 
RNase Away (Life Technologies, UK). In addition, all equipment was exposed to UV light for 
10 min.  The RT Master Mix was prepared by allowing the kit component to thaw on ice. A 
total of 2µg of RNA was used per 20µl reaction (see the Table below).  
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Reverse Transcription master Mix.  
Component Component volume/ Reaction(µl) 
 + RT reaction -RT reaction 
2X RT Buffer 10.00 10.00 
20X Enzyme Mix 1.0 - 
RNA Sample up to 9µl up to 9 µl 
Nuclease- free H2O To final volume 20µl To final volume 20µl 
Total per Reaction 20.0 20.0 
 
The tubes were caped and inverted several times to mix the reaction components. The tubes 
were then placed on ice until the start of the reverse transcription reaction.  
 
Time (Minutes) Temperature (0C) 
60 37 
5 95 
∞ 4 
 
2.6.4. TaqMan qPCR gene expression assay. 
The following Taqman primers were used for human and mouse cDNA samples. 
 
N0 qPCR primers Reference source 
1 GADPH control RNA 
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2 PTGER-1 Human Hs00909194 m1 Applied Biosystems/Life 
Technologies 3 PTGER-2 Human Hs04183523 m1  
4 PTGER-3 Human Hs00168755 m1 
5 PTGER-4 Human Hs00168761 m1 
 
A master mix was generated according to the kit instructions. 
Component Volume(ul)/20ul Reaction 
20X TaqMan Gene Expression Assay 1.0 µl 
2X TaqMan Gene Expression Master Mix 10µl 
cDNA template(1-100 ng) x µl 
RNase-free Water Up to 9µl 
Total 19ul 
 
The Master Mix was vortexed and 18µl was added to each well of the 384-well plate via reverse 
pipetting. 2ul of the 20 X TaqMan Gene Expression Assay primers was added to the designated 
wells. The plate was then sealed with the appropriate cover and centrifuged briefly. Later, the 
plate was loaded into the instrument and ABI7900 thermal cycler conditions were set. 
Time Temperature Cycle 
10 min 95C 0 
15 sec 95C  
40 60 sec 60C 
 
qPCR data was displayed as delta Ct (Ct value of PTGER expression minus Ct value of 
GAPDH control expression for each sample). Fold changes between control and disease groups 
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was analysed using the delta delta Ct method with Data Assist v3.1 software (Applied 
Biosystems). 
2.7 Immunohistochemistry. 
The human tissue sections from normal and ADPKD and tissue sections of two orthologous 
mice models of ADPKD used in this study were a gift from Dr. Dorien Peters (Leiden 
University, Netherlands). The first mouse model is a tamoxifen-inducible, kidney-specific 
Pkd1 deletion model (Lantinga-van Leeuwen, Leonhard et al. 2006). The second model was 
developed by decreasing the expression of the Pkd1 gene transcription (Happe, van der Wal et 
al. 2013).  
First, each slide was dewaxed with xylene twice for 5 minutes, followed by absolute alcohol 
for twice for 5 minutes, followed by 95% alcohol for 5minutes and then with 3% H2O2 for 20 
minutes. The slides were then rinsed under running tap water for 2 minutes. Next, the slides 
were exposed to the heat- induced epitope retrieval using a 0.1 M tri-sodium citrate buffer for 
10 minutes. The slides were then exposed to a high heat microwave for 10 minutes and then 
washed with cold tap water for 5 minutes. Next, the slides were blocked with peroxide reagent 
for 5-15 minutes and drained. The slides were then treated with a mixture of 10 ml PBS and 3 
drops of goat serum for 30 minutes. Subsequently, the primary antibody against PTGER2 in a 
concentration of 1:100 (anti mouse AB from R& D cat. No. MA6656) or PTGER4 anti rabbit 
antibody in a concentration of 1:200 (Sigma Cat. No PK6102) was added to the slides. Two 
slides were used for the purpose of control: one with a negative control that was treated with 
mouse IgG in a concentration of 1:100. The slides were incubated with primary antibody for 
1hr or at 4oC overnight and then washed with PBS and drained. The secondary antibody 
biotinylated anti-mouse or anti-rabbit IgG secondary antibody (1:200 dilution) (Vector Elite 
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mouse kit Cat. Number PK6102) was applied to incubate the slides for 30 minutes at room 
temperature.  
After that, each section was washed three times with PBS for 5 minutes and incubated with 
ABC (Avidin-biotin complex) (Vector Elite mouse kit) for 30 minutes at room temperature.  
The polymer HRP secondary detection Ab (MaxVisionbio) 100µl per slide for the mouse, or 
rabbit primary Ab incubated for 15 minutes were utilised as a secondary Ab to decrease the 
background from biotin activity. Next, the slides were washed three times with PBS and 
incubated with the DAB chromogen solution for 5 minutes and counterstained with Gills 
haematoxylin for 30 seconds to stain the nuclei (blue). Then, the slides were blued with Scott’s 
tap water and then mounted and covered with a coverslip. Finally, the images were taken using 
F-Cell software by Leica DMI 4000B inverted microscope at a different magnification (20X-
60X). 
 
2.8.1. Apoptosis assay (TUNEL staining). 
Labelling of DNA strand breaks was done using terminal deoxynucleotidyl transferase TdT 
labelling, which catalyzes the polymerization of labelled nucleotides to free 3´-OH DNA in a 
template-independent manner (TUNEL-reaction). Fluorescein labels incorporated in 
nucleotide polymers are detected and quantified by fluorescence microscopy (Roche).  
Cells were plated in triplicate (2x104 cells/ml; 100µl /well). When the cells had become 70% 
confluent they were treated with PGE2, PTGER2 and PTGER4 receptor antagonists as 
described for 72 hrs. As a positive control 100 µm of 3% H2O2 was added to control wells in 
triplicate and incubated for four hours. The staining assay was carried out according to the 
manufacturer’s instructions. Cells were washed three times with PBS, followed by fixation 
with 4% paraformaldehyde for 60 min. Next, the cells were washed three times with PBS. 
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Subsequently, the cells were permeabilized with 0.1% Triton-X-100 in 0.1% sodium citrate 
solution for two min on ice. Next, a TUNEL reaction mixture was prepared by mixing the total 
volume (50 µl) of enzyme solution (bottle 1) with 450 µl label solution in (bottle 2) to obtain 
500 µl TUNEL reaction mixture.  Cells were rinsed twice with PBS to dry the area around the 
samples. Then, 50 µl of TUNEL reaction mixture was added to the samples. At that point, label 
solution 50 µl was added in duplicate to the negative control. The slides were incubated in a 
humidified atmosphere for 60 minutes at 370C in the dark. Later, the cells were rinsed three 
times with PBS. Finally, the samples were analysed under a fluorescence microscope to detect 
the apoptotic cells. 
 
2.8.2. Caspase-3 staining. 
Cells were cultured in 96 well plates until they reached 70% confluence. The cells were fixed 
with 4% PFA for 20 minutes. Next, the cells were permeabilized with 0.25% TritonX-100 for 
15 minutes and blocked with 5% BSA in PBS for one hour at room temperature. Cells were 
stained with a caspase-3 (Asp175) rabbit monoclonal antibody at a dilution of 1:200(Cell 
signaling) in 1% BSA in PBS and incubated at room temperature for 1 hour. Next the secondary 
antibody goat anti rabbit FITC antibody at a dilution of 1:500 was added to the cells for 1 hour 
at room temperature. A DAPI counterstain was used top stain cell nuclei. Images were captured 
using Olympus IX71 microscope at 20X magnification. 
 
2.9.1. BrdU cell proliferation assay. 
The cells were cultured in flat-bottomed 96-well microplates at a seeding density of 2x103 
cells per well. When the cells had become 70% confluent they were treated with PGE2, 
PTGER2 and PTGER4 receptor antagonists as described for 72 hrs. The assay was carried 
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out according to the manufacturer’s instructions. BrdU labelling solution (10 µl/well) was 
added and cells incubated for two hours at 370C. Culture media was removed and cells were 
dried. The FixDenat solution was then added to the cells, and incubated for 30 min.  An anti-
BrdU-POD working solution was added to the cells, and incubated for 90 min. Cells were 
washed three times with PBS. A substrate solution was added to the cells and incubated for 5 
min. The absorbance was measured at 340 nm. 
2.9.2. Cell Titer 96® AQueous One Solution Cell (MTS) Proliferation Assay. 
The cells were cultured in flat-bottomed 96-well microplates at a seeding density of 2x103 cells 
per well. When the cells had become 70% confluent they were treated with PGE2, PTGER2 
and PTGER4 receptor antagonists as described for 72 hrs. The assay was carried out according 
to the manufacturer’s instructions. Labelling reagent was added into each well of the 96 well 
plate in 100µl of serum free culture media and incubated at 37°C for 2 hours. The absorbance 
was measured at 490nm wavelength using a 96-well plate reader (LabSystem Multiskan 
Ascent). 
2.10. cAMP assay. 
A cAMP ELISA kit (R&D Systems) was used to measure cAMP levels in the cells.  It based 
on a competitive binding technique, using cAMP specific monoclonal antibody to bind to goat 
anti-mouse antibody coated onto the microplate. The cAMP was present in the samples, to 
compete with a fixed amount of (HRP)-labeled cAMP for sites on the monoclonal antibody. 
This was followed by 3 washes to remove excess conjugate and unbound samples, and a 
substrate solution was added to the wells to determine the bound enzyme activity. Color 
development was stopped and absorbance was read at 450nm. The intensity of color was 
inversely proportional to the concentration of cAMP samples. 
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The cells were washed three times in cold PBS. Then the cells were re-suspended in cell lysis 
Buffers 5(1X) to a concentration of 1x 107 cells/ml. Next, the cells were frozen at <200C, then 
the cells were thawed with gentle mixing. This freeze and thaw cycle was repeated until the 
cells were completely Lysate. Subsequently, the cells were centrifuged at 600Xg for 10 minutes 
at 2-8˚C to remove cellular debris. The supernate was assayed immediately, or aliquots of the 
supernate, and stored at <-200C.  
The reagents and samples should be brought to room temperature before use, and the samples, 
control and standards should be assayed in duplicate. First, the primary antibody solution was 
added to all wells plates except the non-specific binding wells; then; the plate was covered with 
the adhesive strips provided, and incubated for one hour at room temperature on a horizontal 
micro plate shaker set at 500 rpm±50 rpm. After one hour, the primary antibody solution was 
aspirated from each well and washed, repeating the process three times for a total of four 
washes. Washing was done by filling each well with wash buffer (300 µl) using a squirt bottle, 
and after the last wash, the plate was inverted and blotted against clean paper towels. Next, 
cAMP conjugate 50µl was added to all wells. Then, the standard, control, and samples (100 
µl) were added to appropriate wells within 15 minutes of addition of the cAMP conjugate. The 
cell lysis buffer 5(1X) was added to NSB and zero standard (B0) wells. They were covered 
with a new adhesive strip, and incubated for two hours at room temperature on the shaker.  
Next, the aspiration and washing cycle was repeated three times with washing buffer. 
Subsequently, 200µl of the substrate solution was added to each well and incubated for 30 
minutes at room temperature on the bench top, protecting it from the light. After that, 100 µl 
of the stop solution was added to each well, which caused the color in the well to change from 
blue to yellow. The optical density was determined of each well within 30 minutes, using a 
microplate reader set at 450 nm. Then, the calculations of the results were done by averaging 
the duplication for each standard, control, and the sample and then subtracting to obtain the 
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average NSB optical density. Finally, a standard curve was created using computer software 
that can generate four parameter logistic (4-PL) curves- fit. 
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Chapter 3 
Establishment of a 3D culture assay to investigate cyst formation 
in human ADPKD cell lines 
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3.1. Introduction. 
Cells cultured in 3 D environments allow in vitro modelling in order to study cell behaviours 
such as differentiation, apoptosis, cell signalling, and drug metabolism (Benton, George et al. 
2009). It has the advantage over traditional monolayer cultures by creating environmental 
conditions similar to cells growing in vivo. Many different types of extracellular matrices have 
been used to grow cells in 3D cultures. The most commonly used include collagen, 
proteoglycoproteins, and glycoproteins such as laminin and fibronectin (Kleinman, McGarvey 
et al. 1986). 
3D cultures provide a controlled in vitro setting more closely resembling the in vivo 
environment, enabling the effects of drugs and reagents (either inhibitory or stimulatory) to be 
tested on cell differentiation and growth (Benelli and Albini 1999).  However, 3D cultures have 
the disadvantage that not all cells respond as expected and the response may be partial due to 
the absence of required growth factors in the matrix. Furthermore, there are several 
preconditions for optimising the 3D basement membrane, depending on the cell type, passage 
number, type of growth factors needed for the cells, type and amount of serum, time in 3D 
culture, and finally, the amount of protein concentration of the basement membrane (Yamada 
and Cukierman 2007).  
The most commonly used extracellular matrix is type I collagen.  It has successfully been used 
as a 3D matrix for culturing bone, hepatocytes, prostate and respiratory cells amongst others 
(Morath, Klein et al. 1999, Chen, Revoltella et al. 2003, Zhang, Xu et al. 2010). Cells cultured 
in Type I collagen often exhibit enhanced growth and differentiation compared to other 
extracellular matrices (Elsdale and Bard 1972). Collagen I, which is abundant in bone, skin, 
and other connective tissues, is, therefore, the well-characterised gel used in 3D cultures. It is 
mainly isolated from rat tail tendons (Ehrmann and Gey 1956, Elsdale and Bard 1972). Cells 
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can typically be grown either on top of, inside or under a preformed collagen gel (Ball, Scoggin 
et al. 2013) depending on the experimental conditions being tested. The gel induces polarity of 
the cells generating a three-dimensional situation representative of the in vivo environment  
(Elsdale and Bard 1972). In the 1980s, a second basement membrane began to be used for 
three-dimensional gel cultures (Kleinman, McGarvey et al. 1986). EHS (Engelbreth-Holm-
Swarm) matrix was purified from a mouse sarcoma line that produces a significant amount of 
basement membrane and extracellular matrix proteins (Benton, George et al. 2009). It is 
composed mainly of laminin, collagen IV, nidogen, entactin, and heparin sulphate proteoglycan 
(Kleinman, McGarvey et al. 1986). It also contains TGF-beta, EGF, insulin-like growth factor, 
fibroblast growth factors, and other growth factors which occur naturally in EHS tumours. 
These growth factors play important roles in cell differentiation and morphology (Vukicevic, 
Luyten et al. 1990) and are essential for the growth of cells in 3D cultures.  
EHS matrix (or Matrigel) was found to be effective for cell differentiation, morpholgy, and cell 
attachment of both normal and transformed epithelial cells, including hepatocytes, Sertoli cells, 
and vascular endothelial cells (Yu, Sidhu et al. 2005, Zhang, Xu et al. 2010, Dal Vechio, 
Giudice et al. 2011). Matrigel alone as 3 D culture media has been used in a large number of 
studies, for example breast cancer cells were cultured in Matrigel to study the effect of BMP4 
on cells proliferation in 3 D matrix using Matrigel gel and glycol gel {Ampuja, 2013 #377}. 
Renal carcinoma cells have been successfully cultured in growth factor reduced Matrigel 
coated filter as 3 D environmental media {Koochekpour, 1999 #380}. To specifically study the 
PKD orpk mutant cells cultured on top of growth factor reduced Matrigel to study the laminin-
332 expression on cell proliferation and cyst growth (Vijayakumar, Dang et al. 2014). 
Epithelial cells cultured in 3 D cultures normally respond by ceasing proliferation and start to 
develop a polarised morphology; for example, breast cells (Becker and Blanchard 2007). The 
extracellular matrix collagen I and Matrigel induce “capillary-like” structures in endothelial 
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cells. These are important in growing endothelial cells, which produce capillary-like structures 
in angiogenesis and vasculogenesis (Kleinman, Philp et al. 2003). Prostate, pancreas and 
salivary glands cells form acinar structures when cultured in basement membrane matrix 
{Yonemura, 2014 #385}. On other hand, some cells such as bone cells form interconnecting 
cell processes in a 3 D matrix (Fridman, Giaccone et al. 1990). Each epithelial cell responds 
with discrete phenotypes. For example, when Madin-Darby canine kidney (MDCK) cells are 
seeded in Collagen I gels, they form luminal cystic structures with the apical surface facing the 
lumen and a basolateral surface that makes contact with adjacent cells and ECM (O'Brien, Jou 
et al. 2001) However, if MDCK cells are stimulated by hepatocyte growth factor (HGF), they 
start to develop branching tubular structures (Pollack, Apodaca et al. 2004).  
A number of studies have utilised 3 D cyst cultures using patient-derived cells. Renal tubular 
epithelial cells originating from ADPKD and normal kidneys were cultured in 3D collagen gels 
to study cadherin eight expression in cystic cells (Kher, Sha et al. 2011). ADPKD and normal 
cells have been used to investigate the effect of cAMP on cystic cell proliferation and cyst 
formation in 3 D collagen gels. In this study, the cell treated with 50uM sp-cAMP and Forskolin 
showed a significant increase in cyst diameter compared to control cells. Furthermore, cysts 
formation were maintained in presence of growth factors and FCS. cAMP activates cell 
proliferation, fluid secretion and cysts expansion in ADPKD but not normal cells  (Hanaoka 
and Guggino 2000). Additional studies were performed to study the effect of arginine 
vasopressin (AVP) and its antagonist Tolvaptan on cyst growth and proliferation. Tolvaptan 
inhibited the total surface area of cysts stimulated with AVP (Reif, Yamaguchi et al. 2011). 
Mouse embryonic kidney cells were seeded on mixed Matrigel and Collagen scaffolds matrix 
and the cells formed cystic structures in cells derived from PKD1 mice and tubular structures 
in cells from control cells (Subramanian, Rudym et al. 2010). In this study, a mixed 
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collagen/Matrigel matrix was better than collagen alone for forming cystic structures 
(Subramanian, Rudym et al. 2010).  
In this chapter, a range of 3D culture methods were optimised for the formation of cysts using 
human kidney epithelial cells as well as the well-established MDCKII model of cystogenesis. 
Following optimisation of 3D cyst assays the effects of dbcAMP, Forskolin, and PGE2 
stimulation on cyst expansion was determined. 
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3.2. Aim and objectives. 
Aims: 
1. To establish a 3 D cell culture model system using cells derived from patients with 
ADPKD, a control renal epithelial cell line and MDCK II.  
2. To test the effect of cAMP and PGE2 on cyst growth using these two model systems.  
Objectives: 
1. Develop a 3D cyst culture model for cell lines derived from patients with ADPKD. 
2. Optimisation of cell culture conditions such as growth factors, media, and type of 
matrix and protein concentration. 
3. Test the ability of epithelial cell lines to develop a polarized morphology i.e. to form 
cysts in cystic cell lines and branching tubules in normal cell lines. 
4. Test the effect of cAMP and PGE2 on cyst morphology and growth. 
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3.3. Results. 
3.3.1. Mutation analysis of human cell lines derived from patients with ADPKD.          
In this chapter, non-cystic (UCL93, RFH) and cystic (OX161, OX161/C1, OX938, SKI-001, 
SKI002) epithelial cells were used, These lines had been immortalised from primary cultures 
of tubular cells isolated from normal and ADPKD human kidneys removed for clinical 
indications (Parker, Newby et al. 2007). Germline PKD1 mutations were identified in all 4 
patients studied. In addition, distinct somatic PKD1 mutations or LOH were detected in 
different cell lines. This data is summarised with the predicted sizes of all potential truncated 
proteins (Table 3.1) and the likely sites of truncation (Figure 3.1).        
All OX161 clones carried the germline mutation in exon 15 (E1537X). However, two cell 
lineages with distinct somatic mutations were found: c.402delG (exon 5) and 
12335_12350delCCTTGCGTGGAGAGCT (exon 45).  The germline mutation in exon 16 
(7000_7001insGCTGGCG) was confirmed in all three OX938 clones. The presence of 
homozygosity for the germline mutation indicated additional LOH of the normal allele (Figure 
3.1).  In one clone (C7), weak heterozygosity was noted at an earlier passage after transduction 
with T antigen. However, later passage cells transduced with hTERT were hemizygous for the 
germline mutation. 
For SKI-001, two distinct somatic mutations were found suggestive of at least two different 
original lineages whereas a single somatic change was detected in SKI-002 (Figure 3.1). No 
PKD2 mutations were detected in any of the cystic lines examined. 
The cystic cell lines (OX161, OX161/C1, OX938 (C7), and SKI-001), and two normal 
control kidney cell lines (RFH, UCL93) were grown in a 75cm2 flask. The cells were 
confluent, attached as a single monolayer sheet to the bottom of the plastic flask. The cells 
appeared healthy, with the characteristic polygonal shape seen in epithelial cell culture with 
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clear cell- cell contacts. Some elongated shaped cells were seen under an inverted phase 
contrast microscope. (Figure 3.2 A, B, C, D, E, and F). 
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Table 3.1. Identification of germline and somatic PKD1 mutations detected in human cystic 
cell lines with predicted size of mutant proteins. 
 
  
  
  
Patient   Germline  
or  
Somatic   
Mutation designation   Consequence at the  
ORF level   
Predicted truncated  
Protein (aa)   
SKI-001   Germline   IVS43 - 2A>G   Skip - Include ex43   3904 - 4001aa   
SKI-001   Somatic  
(S1)   
3364delG   ORF ends at nt3397  
(TGA)   
1132aa   
SKI-001   Somatic  
(S2)   
6549_6550insT   ORF ends at nt6548  
(TGA)   
2183aa   
SKI - 002   Germline   IVS25 - 3C>G   Skip - Include ex25   2983 - 3067aa   
SKI - 002   Somatic  
(S1)   
2312_2324delTGCTTGCAGCCAC   ORF ends at nt2350  
(TGA)   
783aa   
OX161   Germline   4609G>T   E1537X (TAG)   1536aa   
OX161/C1   Somatic  
(S1)   
12335_12350delCCTTGCGTGGAGAGC 
T   
ORF ends at nt12589  
(TGA)   
4197aa   
OX938   Germline   7000_7001insGCTGGCG   ORF ends at nt7253  
(TGA)   
2418aa   
OX938 C7   Somatic   LOH   Early heterozygosity    Likely null allele   
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Figure 3.1. Domain structure of polycystin-1 with sites of germline and somatic mutations  
DNA was analysed for PKD1 mutations from cystic cell lines derived from four patients 
(OX161, OX938, SKI-001, and SKI-002). The germline mutations are marked by black 
arrowheads and somatic mutations by white arrowheads. Refer to Table 3.1 for details of 
mutations.  
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Figure 3.2. Human cell lines cultured in monolayer. 
The following cell lines were cultured as a monolayer culture and images captured at x10 
magnification (A). OX161, (B). OX161 C1, (C). SKI-001, (D). RFH, (E). UCL93 and (F) 
OX938 C7. Scale Bar = 100µm. 
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3.3.2 MDCKII cells form cysts in Type I collagen gels.  
The MDCK II cell line is a well-established kidney epithelial model which forms polarised 
cysts in collagen gels and has been used extensively in 3 D assays. MDCKII cells have 
previously been used in our lab and others used to study cystogenesis and to evaluate the effects 
of rosiglitazone and cAMP on cyst growth (Buchholz, Teschemacher et al. 2011, Engelberg, 
Datta et al. 2011, Mao, Streets et al. 2011).  
MDCK II were used to optimise 3D culture techniques prior to using the less well characterised 
human ADPKD cells. MDCK II cells were cultured in collagen gels composed of two different 
concentrations (3 or 3.8 mg/ml collagen) and observed over 8 days. The average cyst area was 
measured every two days for 8 days as described in section 2.4.1 (Figure 3.3 A, B).  We 
observed that cells grown in the higher concentration collagen (3.8 mg/ml) formed well 
polarised cysts with apical lumen which were statistically larger when compared to cells 
cultured in the lower concentration collagen (3mg/ml) by two way ANOVA test P value 0.0004 
(Figure 3.3 A, B). Taken together, what was observed under a microscope, and statistical 
analysis of the cyst area, the high concentration collagen (3.8 mg/ml) was superior to the low 
concentration collagen (3mg/ml). Therefore, the higher concentration collagen (3.8 mg/ml) 
was chosen for subsequent experiments in MDCKII.  
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3.3.3. Comparison of MDCK II cell cystogenesis when cultured in Collagen or Matrigel. 
In order to determine the optimal extracellular matrix for culturing MDCK II cells, I tried three 
types of gels (Collagen I, mixture of Collagen and Matrigel, Matrigel alone). I observed that 
cells cultured in Collagen exhibited superior growth and well defined formation of cyst lumen 
at day eight (Figure 3.4 A) compared to cells grown in a 1:1 mixture of Collagen and Matrigel 
or Matrigel alone. Cells grown in 1:1 Collagen and Matrigel exhibited less clear lumen 
formation and less expansion when compared with cells grown in collagen alone (Figure 3.4 
B). In the cells cultured in Matrigel alone, MDCKII cells started to cluster together from day 
4, and by day 8, the cells had clumped together to form large structures with no clear lumen 
(Figure 3.4 C). From the observation of images of cysts and experimental data, I concluded 
that MDCK II cells cultured in collagen developed cysts optimally compared to Matrigel or a 
combination of Collagen and Matrigel. 
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Figure 3.3. MDCKII cells form cysts in type I collagen gels  
 (A). The inverted light microscope images show MDCK II cultured in Collagen (3 mg/ml) and 
followed over days 2, 4, 6, and 8. (B). MDCKII was grown in Collagen (3.8mg/ml) and 
developed over days, 2, 4, 6, and 8. The cells grown in Collagen with a higher protein 
concentration exhibited clearer and well defined lumen and more expansion in cyst size when 
compared with those grown in Collagen with lower protein concentrations. All scale bars were 
represented as 50µm. (C). The graph illustrates that the average cyst area from 3 wells of 
MDCK II cells was higher in cells grown in the higher concentration Collagen by two way 
ANOVA test  ***p<0.0004. 
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Figure 3.4. Comparison between MDCK II cultured in 3 types of the extracellular matrix: 
Collagen, Collagen and Matrigel and Matrigel alone.  
(A). The inverted light microscope images show MDCKII cultured in Collagen I (3.8 g/ml), 
followed over days 2, 4, 6, and 8. (B). MDCK II cultured in 1:1 Collagen and Matrigel, 
followed over days, 2, 4, 6, and 8. (C)  MDCK II colonies inside Matrigel alone. All scale bars 
were represented as 50µm. (D). The graph illustrates that the average cyst area from 3 wells of 
MDCK II cells was higher in cells grown in Collagen compared to Matrigel ***p<0.001 or 
Matrigel/Collagen to Matrigel ***p <0.001. Two way ANOVA test was used. Data represented 
as mean± SEM. 
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3.3.4. Human cells form tubules in Collagen gels. 
The first aim of this project was to create three- dimension gel conditions suitable for culturing 
the ADPKD and normal cell lines. Kidney epithelial cells derived from patients with ADPKD 
(OX161, OX161/C1, SKI-001, and OX938) and normal control cell lines (UCL93, RFH) were 
cultured in collagen gels for 8 days to determine the ability of these cells to form cysts or 
tubules in 3D cultures. 
The first cystic cell line OX161/C1 formed two distinct structures; the first was a luminal cystic 
structure in which  20% of the total cells formed developed a well-defined lumen from day 2 
to day 4. From day 6, the cells stopped proliferating and by day 8, most of the cystic cells had 
growth arrested. Around 35% of cells started to develop simple tubules from day 2, which 
continued to proliferate up to day 8.  The remaining 45% of the cell were non-proliferative 
(non-cystic often single cellular structures which were defined as structures with an area less 
than 50µm2 and which do not form a clear lumen) (Figures 3.5 A and B). The second cystic 
cell line OX161 formed mainly tubular structures by day 8 (Figure 3.5 A and B). In SKI-001 
cells, most of the cells formed a definite lumen and cysts by day 2, but from  day 4 to day 8, 
two-thirds of the cells developed simple branching tubules and only 10% of cells had cysts and 
15% were dying (Figure 3.5 A and B). In OX938, most of the cells started to form branching 
tubules from day 2 and on day 8, two-thirds of cells formed tubular structures and only 10% 
formed cystic changes (Figure 3.5 A and B). In UCL93, a non-PKD cell line, 85% of cells 
formed branching complicated tubules with more than two branches by day 8. There were no 
cystic changes in the normal cell lines (Figure 3.5 A and B). The second non-PKD cell line, 
RFH, formed simple branching tubules from day 2, but two-thirds of cells were starting to die 
by day 8 (Figure 3.5 A and B.). A range of different serum concentrations (0%-2.5%-5%) 
were tested, but all cells only proliferated in 5% serum conditions. 
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The graph show the mean of 10 random fields from each cell line in triplicate wells. Each 
structure within individual fields was assigned as cystic, tubular or non-proliferative and 
quantified as a percentage of total number of structures. The only cystic cell lines that formed 
cysts were OX161/C1 and OX161 although these comprised a small percentage of total 
structures and most had stopped growing by day 8. The other cystic and normal cell lines 
formed simple tubules or like the normal cell line UCL93, formed complicated tubules with 
multiple branching structures (Figure 3.5 A and B).  
In conclusion, our results indicate that the human cystic cells failed to form well-polarised cysts 
in Collagen gels. Most cystic cells did not proliferate or formed tubular structures in contrast 
to MDCK II cells that formed well-polarised cysts. 
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Figure 3.5. Human cells cultured in Collagen gels.  
(A). Human cells mainly form tubules when cultured in collagen gels. (B). The graph represents 
the % of structures on day 8; 10 slides were analysed to quantify the percentages of tubules and 
cysts, and the percentage of cells that were non-proliferative All scale bars represented are 
50µm.  
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3.3.5. Comparison of human cell cystogenesis when cultured in Collagen and Matrigel.  
I next cultured cells in a matrix composed of a mixture of 1:1 (vol/vol) Collagen I: Matrigel 
gels. Previous work had shown that a mixture of Collagen and Matrigel was successfully used 
in a study of PGE2 on cystogenesis using primary cultures of cystic epithelial cells derived 
from ADPKD patients compared to normal cells (Elberg, Elberg et al. 2007).  
The clone OX161/C1 cultured in 1:1 mixture of Collagen and Matrigel started to form lumen 
from day 2. However, by day 4, 50% of the cells began to elongate and developed simple 
tubular structures. On day eight, 30% had definite lumen. The other 20% either died or failed 
to grow, and remaining cells formed tubular structures (Figure 3.6. A and B). 
In the parental cell line OX161, simple tubules were observed from day 2. These tubules then 
became elongated and branching (two branches maximum) in 70% of the cells by day 8. 
Around 25% of the cells formed lumen with clear cysts, 5% were non-cystic, non-proliferative 
cysts (Figure 3.6 A and B). 
SKI-001, the third cystic cell line, developed small notches from the cells from day 2, which 
elongated and formed simple branching tubules in 60% of cells. 25% showed no proliferation 
or cystic changes, and only 15% of cells formed cysts with polarized lumen (Figure 3.6 A and 
B). 
60% of OX938, the fourth cystic line, formed small tubules from day 2 onward to day 8. Only 
10% of cells developed cystic changes. 30% of cells formed non-proliferative cells (Figure 3.6 
A and B). 
 90% of the normal cell line UCL93 formed tubular structures from day 2 onward. These 
tubules developed more than two branching tubules. Only a small percentage (5%) underwent 
simple cystic change, and 5% of cells formed non-proliferative cells (Figure 3.6 A and B). 
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The second normal cell line, RFH, formed simple tubules from day 2, and these tubules grew 
to more than two branches by day 8; no cystic changes were followed, and 20% of cells died 
by day 8 (Figure 3.6 A and B).  
In summary, our results showed that using a mixture of Collagen and Matrigel did not facilitate 
the formation of cysts. Most cells derived from patients with ADPKD formed simple tubules 
or were non-proliferative. The next step was to test the ability of ADPKD cells to form cysts 
in Matrigel alone. 
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Figure 3.6. Human cell lines, cystic (OX161/C1, SKI-001, OX161, OX938) and normal 
(UCL93, RFH), cultured in Collagen and Matrigel. 
(A). Human cells mainly form tubules at day 8 when cultured in collagen and Matrigel gels. 
(B). The graph represents the % of structures on day 8; 10 slides were analysed to discover the 
percentages of tubules and cysts, and the percentage of cells that were non-proliferative. All 
scale bars represented are 50µm.  
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3.3.6. Comparison of human cell cystogenesis when cultured in Matrigel. 
The human ADPKD cell lines (OX161/C1, SKI-001, OX161, and OX938) and normal cells 
were grown in Matrigel gels for 8 days. When OX161/C1 was cultured inside Matrigel, cells 
began to create small luminal structures on day 2. This progressively expanded over day 4 such 
that by day 6, it formed clear cysts with a cell monolayer surrounding a single lumen. By day 
8, some cells even developed multiple lumens in a number of cysts. Only a negligible number 
of cells produced simple tubular structures, and only 5% exhibited non-proliferative non-lumen 
formation (Figure 3.7 A and C).  SKI-001, the second cystic cell line, developed small notches 
from the cells from day 2, which elongated and formed cystic changes in 25% of cells, while 
30% of cells formed tubular changes on day 8 (Figure 3.7 A and C). However, more than 45% 
of the cells appeared non-proliferative with no lumen formation. 
In OX161, the third cystic line, cultured in Matrigel, cells began to a cluster of cells and 
developed small lumens on day 2. Then, the cells started to expand and clump together to form 
larger structures with around 60% developing luminal structures. There were no tubular 
structures observed (Figure 3.7 A and B). 
OX938, the fourth cystic cell line, developed small luminal structures. However, most of the 
cells did not grow well in Matrigel and were non-proliferative by day 8 (Figure 3.7 A and C). 
The first normal cell line, UCL93, formed clustered structures on day 2, and grew into tubules 
showing more than two branches on day 4 expanding in size until day 8 (Figure 3.7 A and C). 
The second normal cell line, RFH, progressed to simple tubular structures from day 2 to day 4 
and expanded to form branching tubular structures on day 6 and day 8. However, one- quarter 
of the cells were non-proliferative by day 8 (Figure 3.7 A and C). 
The total cystic area of 20-25 structures per well was measured at day 2, day 4, day 6, and day 
8 in triplicate and the mean and SEM values compared between OX161/C1, SKI-001 and 
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OX161. Significant differences were found between OX161/C1, SKI-001 and OX161 with 
OX161/C1 forming the largest cysts. (P value <0.0001 for row, column and interaction factors, 
two-way ANOVA) (Figure 3.7 B). From the results of the 3 D culture optimisation 
experiments, we decided to use the OX161/C1 cell line cultured in Matrigel 3 D gels and 
MDCK II cells grown in Collagen gels as models of cystogenesis in further experiments. 
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Figure 3.7. Human cell lines, cystic (OX161/C1, SKI-001, OX161, OX938) and normal 
(UCL93, RFH), cultured in Matrigel for 8 days.  
(A). Inverted light microscope images show that the majority of OX161/C1 cells formed a clear 
polarized lumen at day 6, and even multiple lumens in occasional cells at day 8. For SKI-001, 
most of the cells formed small cysts but there were some simple branching tubules at day 8. 
For OX161, most of the cells formed large clumps with few visible lumen but no tubules were 
observed at day 8. For OX938, most cells were non proliferative and dying at day 8. The normal 
cell lines, UCL93 and RFH, formed branching complex tubules by day 8. All scale bars were 
represented as 50µm. 
(B). Average cyst area of three cystic cell lines (OX161/C1, OX161, and SKI-001) measured 
over 8 days. OX161/C1 were the most efficient cells in terms of forming cysts in Matrigel 
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compared with OX161 and SKI-001. The data are presented as two way ANOVA test with 
significant differences between OX161/C1 and both OX161 and SKI-001 ****p<0.0001. 
(C). Graph representing the % of cellular structures present on day 8. Ten slides were analysed 
to discover the percentages of tubules, cysts, and the percentage of non-proliferative cells. 
OX161/C1 had the highest percentage of cells forming cysts compared with the other cystic 
cell lines. While, UCL93 had a higher rate of cell forming tubules compared to RFH. 
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3.3.7. Morphology of ADPKD and MDCK II cysts. 
Immunofluorescence staining was used to confirm the polarity of MDCK II cells cultured in 
Collagen gels and OX161/C1 cultured in Matrigel. Characteristically epithelial cells grown in 
3D extracellular matrix cultures will organise as a single polarised layer of cells containing 
definite cell-cell attachments and the presence of tight junctions surrounding a fluid filled 
lumen. Cells will organise themselves with the apical surface facing the lumen and the 
basolateral surface contacting the extracellular matrix (Ashley, Yeung et al. 2013, Frickmann, 
Schropfer et al. 2013, Chen, Guo et al. 2014). 
MDCK cells formed clear well defined cystic structures, and we were able to delineate a single 
central lumen clearly by staining the cells with apical protein glycoprotein gp-135/ podocalyxin 
or by staining F-actin with phalloidin. Cell nuclei were counterstained with DAPI (Figure 3.8 
B, D).  
OX161/C1 ADPKD cells formed less well defined cystic structures by day 8. However, a 
lumen was identified following immunofluorescence staining of the core-tight junction protein 
Zonula-occludes (ZO-1) which stains the border between the apical and baso-lateral membrane 
(Figure 3.9 D). Cells were also stained with phalloidin which stains F-actin and delineates the 
luminal surface. The nuclei stain blue with DAPI (Figure 3.9 B). Taken together these 
experiments confirmed that both ADPKD and MDCK cells formed polarised cysts with a 
clearly defined central lumen in Matrigel and Collagen gels respectively.  
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Figure 3.8. Immunofluorescence images of MDCKII staining with phalloidin and GP-
135. 
(A). The inverted microscope of MDCKII cultured in collagen I at day 8 exhibited clear and 
well- defined lumen (B). MDCKII lumen defined by staining with Alexa fluor® Phalloidin 
stain F-actin (red), and nuclei were counterstained with DAPI by immunofluorescence.  Scale 
bar was 50µM (C). Inverted microscope of MDCKII cultured in collagen I at day 8 exhibited 
clear and well- defined lumen. (D). Apical staining of gp-135 (green) in MDCKII cells in 3 D 
cultures, nuclei were counterstained with DAPI Image magnification for immunofluorescence 
20X, scale bar was 50µM. 
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Figure 3.9: Immunofluorescence images of OX161/C1staining with phalloidin and ZO-
1. 
(A, C). The inverted microscope of OX161/C1 cultured in Matrigel at day 8, exhibited 
irregular, multi-lumen cell.  
(B). OX161/C1stain outlined the lumen with ZO-1 (green) small lumen in the middle (white 
arrow). Two small lumens in peripheral and nuclei were counterstained with DAPI.  
(D). OX161/C1 we delineated the lumen by staining with Alexa fluor® Phalloidin stain F-
actin irregular middle lumen (white arrow) (red) and nuclei were counterstained with DAPI.  
Image magnification for immunofluorescence 20X, scale bar was 50µM. 
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3.3.8. Effect of cAMP and Forskolin on MDCK cysts. 
Levels of the secondary messenger cyclic AMP are elevated in ADPKD cells and tissues. 
cAMP promotes cell proliferation through the ERK pathway and through phosphorylation of  
nuclear transcription factor CREB (cAMP response element binding protein) at serine residue 
133. The CREB is activating various target genes that is important in cell proliferation and 
survival like proto-oncogene c-fos and cell cycle regulating gene like cyclin D1 and cyclin A1 
(Siu and Jin 2007). 
 cAMP increases chloride secretion into the lumen of the cysts through stimulation of cystic 
fibrosis transmembrane conductance regulator (CFTR) channel (Belibi, Reif et al. 2004) 
(Hanaoka and Guggino 2000). Previous studies have shown that cAMP stimulates proliferation 
of ADPKD cells both in monolayer culture, 3D gel cultures and organ cultures when compared 
to normal control cells (Hanaoka and Guggino 2000, Belibi, Wallace et al. 2002, Belibi, Reif 
et al. 2004). 
The aim of this experiment was to examine the effect of exogenous dibutyryl-cAMP (dbcAMP) 
and Forskolin on the growth of MDCK II cysts.  Combining dbcAMP and Forskolin as an 
adenylyl cyclase agonist has been used previously to study the effect of cAMP signalling in 
kidney cells (Mangoo-Karim, Uchic et al. 1989, Ye, Grant et al. 1992, Yamaguchi, Pelling et 
al. 2000, Parker, Newby et al. 2007) so this approach was utilised in my experiments.  MDCK 
II cells cultured in collagen gels were stimulated with dbcAMP (100µM) and Forskolin (10µM) 
for 8 days. The average cyst area was calculated by measuring cysts from at least 10 random 
fields in triplicate wells. The experiment was repeated 3 times. 
MDCK II cells cultured in Collagen gels for 8 days showed a significant increase in average 
cyst area when stimulated with dbcAMP and Forskolin. Interestingly, cells stimulated with 
dbcAMP and Forskolin often contained multiple lumen when compared to control cells 
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indicating an additional effects on cell polarity and apical lumen formation (Figure 3.10) 
(Jaffe, Kaji et al. 2008, Mao, Streets et al. 2011). 
 
3.3.9. Effect of prostaglandin E2 on MDCK II cysts. 
Previous studies have shown that prostaglandin E2 (PGE2) signalling is increased in ADPKD. 
PGE2 has been shown to increase cyst formation, cell proliferation and fluid secretion in mouse 
and human kidney cells (Elberg, Elberg et al. 2007) (Sauvant, Holzinger et al. 2003) (Elberg, 
Turman et al. 2012) (Matlhagela and Taub 2006, Buchholz, Teschemacher et al. 2011). 
MDCK II cells cultured in Collagen gels for 8 days showed a significant increase in average 
cyst area when stimulated with PGE2 (Figure 3.11 and 3.12). The minimum concentration of 
PGE2 required to increase average cyst area was 12.5nM and maximum effect was observed 
at 25nM (Figure 3.12 A, B). No significant effect was seen at the highest dose of 1 µM which 
may be due to a toxic effect of high dose treatment or saturation of the receptor with PGE2. 
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Figure 3.10: MDCKII cells cultured in Collagen I and treated with dbcAMP 100µM and 
Forskolin10µM.  
(A). MDCK II cultured in Collagen I treated with DMEM and 5% FCS alone (control) and 
MDCK II treated with dbcAMP and Forskolin with media over 8 days. Cyst formation in 
MDCK II in collagen gel treated with both dbcAMP and Forskolin appeared greater in size and 
larger in number than the control. All scale bar represent in 50µM. (B). Quantification of 
number of lumen per cyst showed a significant increase of number lumens/ cyst in cells treated 
with dbcAMP and Forskolin compared to control (Control= 1.200 ± 0.1069, n=15 vs 100µM 
dbcAMP+10µM Forskolin = 2.200 ± 0.3266, n=15**p value = 0.007.  Unpaired t-test was 
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used. (C). MDCK II treated with dbcAMP and Forskolin showed a significant increase in cyst 
area (Control= 3452 ± 198.9, n=24 vs 100µM dbcAMP+10µM Forskolin = 6773 ± 802.4, 
n=24) ⃰  ⃰⃰  ⃰P value = 0.0007compared to the control. Unpaired t-test was used. Data represented 
as mean± SEM.  
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Figure 3.11: MDCK II cells cultured in Collagen I and treated with 4 different 
concentration of PGE2. 
(A). MDCKII cultured in Collagen I treated with DMEM and 5%FCS media alone exhibited 
an increase in size and lumen formation over 8 days. MDCKII treated with PGE2 100nM, 
revealed more expansion in the size and apparent lumen formation compared with the control. 
MDCKII grew in Collagen I treated with 250nM PGE2, developed better growth and lumen 
formation than the control. MDCKII cultured in Collagen I treated with 500nM PGE2, 
produced superior growth and lumen formation than the control.  MDCK II grown in Collagen 
I treated with 1µM PGE2, produced better lumen formation and clearer cysts than the control.  
All scale bar represents in 50µM.  
(B). Graph represents the average cyst area of MDCKII treated with PGE2 relative to the 
control on day 8. There was a significant dose-dependent increase in MDCKII treated with 
100-500nM PGE2. However there was no significant difference between cells treated with 
1µM PGE2 and controls (n=24).  One-way ANOVA test was used. Data represented as mean± 
SEM. 
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Figure 3.12. Effect of lower doses of PGE2 on MDCKII in 3 D culture media over 8 days. 
(A). MDCKII cultured in collagen I treated with DMEM and 5% FCS alone (control) and 
different concentration of PGE2. The cyst formation in MDCKII in collagen gel treated with 
the smaller dose of PGE2 appeared more expanded, and the cysts formed by MDCKII were 
greater in size and larger in number than the control. Scale bar was 50µM. 
 (B). MDCKII treated with PGE2 (12.5-100nM) showed a significant dose-dependent increase 
in cyst area compared to controls (n= 20). *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA 
test was used. Data represented as mean± SEM. 
 
 
 
 
 
 
 
 
 
- 103 - 
 
3.3.10. Effect of cAMP and Forskolin on OX161/C1 cystogenesis. 
OX161/C1 cells cultured in Matrigel gels were stimulated with dbcAMP (100µM) and 
Forskolin (10µM) for 8 days. The average cyst area was calculated by measuring cysts from at 
least 10 random fields in triplicate wells and the experiment repeated 3 times. 
OX161/C1 cells cultured in Matrigel gels for 8 days showed a small but significant increase in 
average cyst area when stimulated with dbcAMP and Forskolin (Figure 3.13 A-C). Comparing 
the two results of dbcAMP effects on MDCK II and OX161/C1. MDCK II showed a larger 
response to dbcAMP than OX161/C1. 
 
3.3.11. Effect of prostaglandin E2 on OX161/C1 cystogenesis 
OX161/C1 cells cultured in Matrigel gels were stimulated with PGE2 at concentrations from 
12.5 nM to 1 µM for 8 days. The average cyst area was calculated by measuring cysts from at 
least 10 random fields in triplicate wells and the experiment repeated 3 times. 
OX161/C1 cells cultured in Matrigel gels for 8 days showed a significant increase in average 
cyst area when stimulated with PGE2 (Figure 3.14). The minimum concentration required to 
increase average cyst area was 25 nM and a maximum response observed at 50nM. Thus, in 
both MDCK and OX161/C1 cyst assays, cAMP and PGE2 caused a significant increase in 
average cyst area. 
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Figure 3.13. OX161/C1 cells cultured in Matrigel and treated with dbcAMP and 
Forskolin. 
 
(A). Phase contrast microscopy of OX161/C1 cells cultured in Matrigel treated with 
supplemented media (control) (B). OX161/C1 treated with dbcAMP and Forskolin with media 
over 8 days. Cyst formation in OX161/C1 treated with both dbcAMP 100µM and Forskolin 
10µM appeared no different in term of the size and number of cysts compared to the control. 
(C). Average cyst area between the control group and one treated with dbcAMP and Forskolin 
(Control= 1383 ± 48.86, n=59. vs 100µM dbcAMP +10µM Forskolin = 1545 ± 65.18, n=58) 
*P value = 0.047compared to the control.  The scale bar represents 50µM.  Unpaired t-test 
was used.. Data represented as mean± SEM.  
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Figure 3.14. The effect of PGE2 on cyst formation in matrigel using human epithelial 
ADPKD cell line clone OX161/C1.  
(A). OX161/C1 treated with supplemented media and 5% Nu serum only (control), and 
OX161/C1 treated with supplemented media and 5% Nu serum and different concentrations of 
PGE2. Cysts formed under control conditions but developed well-defined lumen and expanded 
more in size and the number after treatment with different concentrations of PGE2 (12.5nM, 
25nM, 50nM, 100nM, 500nM, 1µM). All scale bars represented 50µM.  
(B). There was no significant increase in cyst area when cell treated with 12.5nM PGE2 
compared to control (Control= 2186 ± 104.7, n=29 vs 25nM PGE2 = 2548 ± 217.5, n=29, p = 
0.13). However, there were significant increases in cyst area at higher concentrations of PGE2 
(25nM and above). A maximal increase in cyst area was observed at 50 nM. One-way ANOVA 
test was used. *p<0.05; **p<0.01. Data represented as mean± SEM. 
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3.4. Discussion. 
The main aim of this chapter was to optimise the growth of epithelial cell lines derived from 
patients with ADPKD in 3 D cyst assays. Cells growing in 3D culture are more representative 
of the in vivo situation compared to monolayer cultures and are considered more physiological 
assays to screen potential compounds prior to testing in animal models. A cellular response to 
an in vitro 3D environment however depends on a number of different factors including cell 
type, cell density, passage number and protein concentration of the basement membrane 
(Cukierman, Pankov et al. 2001).  Collagen has been used since the 1970s as 3D in vitro method 
for studying cell biology and morphogenesis (Elsdale and Bard 1972, Benton, George et al. 
2009). Matrigel is also commonly used in 3 D cultures although it is more expensive and 
difficult to manipulate compared to collagen (Debnath, Muthuswamy et al. 2003, Yu, Sidhu et 
al. 2005).  Cells will typically polarise in 3 D Collagen or Matrigel cultures to form either cysts 
or branching tubular structures with an apical side facing the lumen and a basolateral side that 
is in contact with ECM and adjacent cells (Pampaloni, Reynaud et al. 2007).  
In this chapter, the first experiments were designed to develop a suitable 3D culture model that 
could be utilized to investigate the effects of PGE2 and cAMP on cyst expansion. I first utilised 
Collagen I as a 3 D matrix. ADPKD cells however failed to differentiate or polarize to form 
cysts in Collagen I gel despite optimal growth conditions. The reasons for this are unclear. One 
possible explanation is that the Collagen I is too simple a matrix and lacks growth factors and 
other essential proteins for promoting differentiation and polarisation. Matrigel has a different 
composition of basement membrane proteins (laminin, collagen IV and heparin sulphate) and 
growth factors like EGF that provide natural environmental media for cell differentiation and 
polarity. However, only OX161/C1 cells reliably formed cysts in matrigel 3 D cultures. SKI-
001 and SKI-002 cells formed small cysts and unexpectedly OX938 cells mainly formed 
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tubules. In addition, these lines did not proliferate well in 3 D cultures compared to OX161/C1 
cells.  
To complement the OX161/C1 assays, I utilised the well-established MDCK II model of 
cystogenesis. OX161/C1 and MDCK II cells were cultured in Matrigel and Collagen 
respectively, and the effect of exogenous cAMP and PGE2 on cyst expansion were tested. Both 
PGE2 and cAMP have been reported to increase proliferation of ADPKD cells in culture and 
this was also seen in our 3 D cyst assays. cAMP and PGE2 caused a significant increase in 
average cyst area after 8 days. The result are consisted with previous studies (Hanaoka and 
Guggino 2000, Belibi, Reif et al. 2004). The response of OX161/C1 to cAMP was less than 
that in MDCKII cells. One possible explanation is that the cystic cells could already be 
maximally stimulated by high levels of cAMP; in this case, a reduction in endogenous cAMP 
levels could be effective. Elberg et al. (2007) demonstrated that the growth of human ADPKD 
cysts was increased by PGE2 (Elberg, Elberg et al. 2007) and that these effects were mainly 
mediated through PTGER2. In contrast, a later study by the same group demonstrated that the 
effects of PGE2 was primarily through PTGER4 in murine Pkd1 knockdown cells (Elberg, 
Turman et al. 2012). In contrast to the experiments conducted in this study, Elberg et al used 
PKD cells with unknown mutations, whereas I used ADPKD cells with a known mutation 
(PKD1). In addition, Elberg et al used a compound (AH-689) as a PTGER2 antagonist which 
is both weakly potent and a non-selective PTGER2 antagonist (blocks PTGER2, PTGER2, TP, 
P3 and DP1) and has agonist activity and was shown to be unsuitable for in vivo study 
(Abramovitz, Adam et al. 2000). This project used a new compound (PF-04418948) which is 
the first potent and highly selective competitive inhibitor of human PTGER2 showing 2000 
fold potency to PTGER2, and is suitable for in vivo study (af Forselles, Root et al. 2011). 
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The aim of the next chapter was to determine the expression of PTGER receptors in our human 
ADPKD cell lines with the aim of testing the effect of specific PTGER 2 and 4 receptor 
antagonists on cystogenesis in these two model assays.  
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Chapter 4 
Prostaglandin receptor expression in ADPKD 
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4.1 Introduction 
In this chapter the expression of both PTGER2 and PTGER4 receptors in a variety of ADPKD 
models was analysed by microarray, qPCR, western blotting and immunohistochemistry 
(IHC). Human cell lines described in the previous chapter were studied, as well as human 
ADPKD tissue and two independent orthologous mouse models of ADPKD. 
 
4.2 Aims and objectives: 
1. Determination of expression levels of PTGER receptors 1, 2, 3 and 4 by microarray, qPCR 
and western blotting from human ADPKD cell lines and normal controls. 
2. Determination of expression levels of PTGER receptors 2 and 4 by IHC from human 
ADPKD tissue sections. 
3. Determination of expression levels of PTGER receptors 2 and 4 by qPCR and IHC from 
two independent orthologous mouse models of ADPKD. 
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4.3 Results 
4.3.1. PTGER 1, 2, 3 and 4 gene expression in human cell lines. 
A pilot experiment in our lab using an Agilent mRNA expression microarray was performed 
to identify changes in gene expression levels in the ADPKD cell lines described in chapter 3. 
This information was used to identify novel genes and pathways which may contribute to the 
pathogenesis of ADPKD. The expression of 1515 genes was significantly altered by more than 
2 fold between control and ADPKD cell lines. Of those, 447 genes were significantly up-
regulated and 1068 genes significantly down-regulated in ADPKD cells. Relevant to this 
project was a significant increase in PTGER2 expression in ADPKD cell lines (6 fold increase), 
with no significant increase in PTGER 1, 3 or 4 (Figure 4.1). 
Data generated by microarray was validated in this study. TaqMan qPCR was carried out to 
determine the mRNA expression levels of PTGER 1, 2, 3 and 4. Expression levels were 
normalised using GAPDH mRNA expression level as a housekeeping gene. (Figure 4.2 A, B). 
Expression of PTGER2 mRNA was higher in ADPKD cell lines by comparing average ΔCT 
values (9.18 for ADPKD samples vs 12.745 for controls). The fold change in PTGER2 
expression between ADPKD and controls was calculated using the comparative ΔΔCT method 
of relative quantification. A 6.21 fold increase in PTGER2 was seen in the ADPKD samples 
compared to normal controls. No significant difference was seen for PTGER1, 3 and 4 mRNA 
levels validating the results seen in the Agilent microarray. 
 
4.3.2. PTGER 1, 2, 3 and 4 gene expression in orthologous mouse models of ADPKD. 
mRNA expression levels of PTGER 1, 2, 3 and 4 was then determined in two orthologous mice 
models of ADPKD. Samples of cDNA and tissue sections used in this study were a gift from 
Prof. Dorien Peters (Leiden University, Leiden, Netherlands). 
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The first mouse model used in this study was the Pkdnl,nl hypomorphic mouse which was 
developed used a neomycin selection cassette (Figure 4.3 B). The second mouse model used 
in this study was the CreLox model (Lantinga-van Leeuwen, Leonhard et al. 2007).  The 
CreLox model is characterised by a specific deletion of Pkd1 created using a site-specific 
recombination mechanism and induced by tamoxifen (Cre-loxP) (Branda and Dymecki 2004). 
(Lantinga-van Leeuwen, Leonhard et al. 2006) (Figure 4.3 A). 
The cystic changes following treatment with tamoxifen were mainly in collecting ducts and 
distal tubules (Lantinga-van Leeuwen, Leonhard et al. 2007). When tamoxifen was 
administered to the mice, it induced deletion of the Pkd1 gene at exons 2 -11 leading to cyst 
formation. The timing of introduction of tamoxifen to the mice can affect the severity of 
disease. For example, administration of tamoxifen at one month in adult mice gave few cysts 
compared to severe cystic disease when tamoxifen was given to new born mice (Lantinga-van 
Leeuwen, Leonhard et al. 2007). cDNA samples were available from control mice and CreLox 
mice at 4 months following tamoxifen treatment.  
TaqMan qPCR analysis was carried out on cDNA samples from these two independent mice 
models of ADPKD. In both models, a significant increase in PTGER2 mRNA expression was 
seen when analysed by comparative ΔCT using Data Assist v3.1 software (Figure 4.5 A, B 
and C). Fold change increases in PTGER2 were 2.68 in the Pkd1nl,nl model and 2.77 in the 
CreLox model. In contrast to the human ADPKD cells, a significant increase in PTGER4 was 
also observed in both models. Fold change increases in PTGER4 were 4.61 in the Pkd1nl,nl 
model and 5.42 in the CreLox model (Figure 4.4 A , B). The other two receptors PTGER1 and 
PTGER3 showed no significant increases by fold change compared to control mice.  
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Figure 4.1. Agilent mRNA microarray expression of PTGER 1, 2, 3 and, 4 in human 
ADPKD cell lines. 
mRNA microarray was carried out on 6 cell lines and analysis using Agilent Gene Spring 
software showed that only PTGER2 mRNA expression levels were significantly increased by 
6 fold in the cystic lines (n=4) *P = 0.014 (B). No significant increase in PTGER1 (n=4) P= 
0.88, PTGER3 (n=2) P= 0.33, or (n=4). P= 0.88 (A, B, D) was seen.. Unpaired t-test was used. 
Data represented as mean± SEM.  
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Figure 4.2. TaqMan qPCR expression of PTGER1, 2, 3 and 4 in human ADPKD cell 
lines. 
Taqman qPCR carried out on the same human samples used for microarray. (A). an increase 
in PTGER2 was seen when relative changes in expression were analysed by delta CT values 
(n=4). P value= 0.09.  Unpaired t-test was used. (B). Fold changes relative to normal controls 
(6 fold increase). 
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Figure 4.3. ADPKD orthologous mouse models used in this study 
A. Transgenic mice containing Cre-recombinase expressed only in the kidneys were crossed 
with mice containing floxed gene (lox P 2-11). In the presence of tamoxifen the Cre becomes 
active and deletes the floxed gene resulting in a specific deletion of PKD1 (CreLox model) 
(Lantinga-van Leeuwen, Leonhard et al. 2007).  
B. Transgenic mice with a neomycin cassette flanked in two LoxP position in intron one and 
third LoxP in intron 11 of the PKD1 gene (Neolox model) (Happe, van der Wal et al. 2013).  
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Figure 4.4. TaqMan qPCR expression of PTGER1, 2, 3 and 4 in two mouse models of 
ADPKD. 
A. A significant fold change increase in PTGER4 but not PTGER1, 2 or 3 was seen in the 
Neolox mouse Pkd1 model.  
B. A significant fold change increase in PTGER2 and 4 was seen in the CreLox mouse Pkd1 
model (CreLoxLox+tam = 11.66± 0.359, n=5. CrLoxwt+tam=13.45± 0.349, n=5) P<0.0007. 
(CreLoxLox+tam = 11.33± 0.160, n=3. CrLoxwt+tam=12.87± 0.49, n=3) P<0.03. Unpaired t-
test was used 
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Figure 4.5. TaqMan qPCR expression of PTGER2 in two mouse models of ADPKD. 
A. There was a significant increase in PTGER2 as measured by changes in delta CT and fold 
change in a CreLox Pkd1 model following tamoxifen treatment.  
B. There was a significant increase in PTGER2 as measured by changes in delta CT and fold 
change in a CreLox Pkd1 model following tamoxifen treatment compared to wt mice treated 
with tamoxifen. One- way ANOVA test was used. 
C. There was a significant increase in PTGER2 as measured by changes in delta CT in a Neolox 
Pkd1 model. Unpaired t-test was used. Data represented as mean± SEM.*p<0.05. 
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4.3.3. Western Blotting with PTGER2 and PTGER4 specific antibodies in human cell 
lines. 
To demonstrate that the increases in PTGER2 and PTGER4 mRNA levels translated into 
increases in protein receptor expression in human ADPKD cell lines (described in chapter 3), 
western blotting with specific antibodies was carried out. PTGER2 expression was tested using 
two separate antibodies. The first experiment used a rabbit polyclonal antibody to PTGER2 
(Abcam, UK). This antibody recognised multiple non-specific bands in a preliminary western 
blot (Figure 4.6 A) and was therefore not used in subsequent experiments. A mouse 
monoclonal antibody to PTGER2 (R+D Systems, UK) recognised a specific protein at the 
correct MW for PTGER2 (49 kDa). Expression of PTGER2 was significantly increased in 3 
ADPKD cell lines and undetectable in two control cell lines confirming the increase in mRNA 
expression levels seen in the human microarray and qPCR assays (Figure 4.6 B).  
The expression of PTGER2 in OX161/C1 ADPKD cells was significantly increased in serum-
stimulated cells compared to serum-starved cells (Figure 4.7 B, E). The increased expression 
following serum stimulation may be due to the increased proliferation rate in ADPKD cells 
following serum stimulation. No detectable PTGER2 expression was seen in control UCL93 
cells following serum stimulation (Figure 4.7 B, C and D)  
PTGER4 expression was tested using a rabbit polyclonal antibody to PTGER4 (Sigma, UK). 
This antibody recognised a specific protein at the correct MW for PTGER4 (50 kDa). 
Expression of PTGER4 was similar in ADPKD and control cell lines confirming the similar 
mRNA expression levels seen in the human microarray and qPCR assays (Figure 4.8 A).  
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Figure 4.6. Western blotting of PTGER2 in human kidney cell lines 
A. Specific detection of PTGER2 was not seen with a rabbit polyclonal antibody against 
PTGER2. Equal loading was confirmed by probing the same membrane with a specific 
antibody to Calnexin. 
B. Specific detection of PTGER2 was seen with a mouse mAb against PTGER2. Increased 
expression of PTGER2 was seen in cell lines derived from patients with ADPKD with strongest 
expression seen in OX161/C1 and SKI-001 cell lines with weaker expression in OX938 cells. 
No expression was seen in control cell lines. Equal loading was confirmed by probing the 
membrane with an antibody to polycystin-2.  
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Figure 4.7. PTGER2 expression is increased following serum stimulation in ADPKD cell 
lines. 
A. Increased expression of PTGER2 was seen in the OX161/C1 ADPKD cell line following 
serum stimulation with no expression detectable in the UCL93 control cell line (n=3) serum 
free (OXC1= 591±12 n=4, UCL93=243±5, n=4)*P value= 0.04. Serum stimulated (OXC1= 
1813±422 n=4, UCL93= 309.5±74) *P value= 0.012. (Serum free=591±1230, n=4, serum 
stimulated= 1813±422, n=4) *P value=0.03. Equal loading was confirmed by probing the 
membrane with an antibody to Calnexin. (SF = 24 h serum free, SS = 24 h serum free followed 
by 24 h serum stimulation). Unpaired t-test was used. Data represented as mean± SEM. 
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B, C, D, E. Quantification of PTGER2 band intensity relative to calnexin demonstrated a 
significant increase in PTGER2 expression in OX161/C1 cells following serum stimulation as 
well as compared to UCL93. Unpaired t-test was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 123 - 
 
 
A. 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Western blotting of PTGER4 in human kidney cell lines 
A. No significant change in expression of PTGER4 was seen in cell lines derived from patients 
with ADPKD compared to control cell lines. Equal loading was confirmed by probing the 
membrane with an antibody to Calnexin. 
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4.3.4. Immunohistochemistry of human kidney tissue sections with PTGER2 and 
PTGER4 specific antibodies. 
Next, I studied the expression of PTGER2 and its localisation in human ADPKD kidney tissue 
sections. Expression was then compared to normal control sections taken from non-ADPKD 
kidneys removed for clinical indications. In addition, the same tissue samples were used to 
determine PTGER4 expression. 
Firstly, the average cyst area was measured in both the ADPKD and control tissue sections.  A 
cyst was defined a structure with an area greater than five times that of a normal tubule or more 
than 6000 µm2 (Chang, Parker et al. 2006). Not surprisingly, there was a significant difference 
in average cyst area between ADPKD and control tissue sections (Figure 4.9).  
Immunohistochemistry with a specific antibody revealed weak PTGER2 staining in renal 
tubules of control tissue sections (Figure 4.11 A). In ADPKD tissue sections, prominent 
tubular cell staining was seen especially in the apical membrane (Figure 4.11 B).  There was 
no glomerular staining in control tissues. To analyse the difference in staining intensity, the 
ImageJ plugin ImmunoRatio which calculates the percentage DAB positive staining relative to 
total nuclear area to account for cell density was used (Figure 4.10 B, D) (Tuominen, 
Ruotoistenmaki et al. 2010). A total of six ADPKD tissue sections and six normal tissue 
sections were analysed using ImmunoRatio. There was a significant increase PTGER2 
expression in ADPKD tissue compared to control tissue (Control 10.20± 0.948 vs PKD=23.72± 
3.705 n=6) **P value= 0.005 (Figure 4.11 B, D).  
Immunohistochemistry with a specific rabbit PTGER4 antibody in control sections revealed 
staining primarily in a subset of tubules (Figure 4.12 A). In ADPKD tissue, strong PTGER4 
staining of non-cystic tissue was mainly localised to tubules and glomeruli (Figure 4.12 A). 
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There was no significant difference in PTGER4 expression in ADPKD tissue compared to 
control tissue (Control= 35.69 ± 1.039, n=7 vs PKD=43.89 ± 4.689, n=7. P value 0.11 (Figure 
4.12 C). 
The immunohistochemistry data confirmed the increase in PTGER2 expression in human 
ADPKD samples seen at the mRNA and protein level in human cell lines, but not of PTGER4. 
 
To confirm these findings in other disease models, the expression of PTGER2 and PTGER4 
was next studied by immunohistochemistry in the two orthologous mouse Pkd1 models  
(Lantinga-van Leeuwen, Leonhard et al. 2006) (Happe, van der Wal et al. 2013). 
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Figure 4.9. Average cyst area in human ADPKD tissue sections compared controls. 
A significant increase in average cyst area was observed in human ADPKD tissue sections 
compared to controls. (Control= 2348 ± 155.8, n=45. PKD= 14462 ± 2570, n=45). Unpaired t-
test was used. ****P value <0.0001. Data represented as mean± SEM.  
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Figure 4.10. Semi-quantitative analysis of DAB staining intensity using ImmunoRatio 
ImageJ plugin. 
A, C. The top panel shows PTGER2 staining of human tissue sections. B, D. The bottom panel 
shows the pseudo coloured image based on threshold DAB staining comapared to a negative 
control. Nuclear area is coloured blue and DAB staining is coloured orange. The Immunoratio 
ImageJ plugin uses this to calculate the DAB/nuclear area average % for each image. 
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Figure 4.11. Immunohistochemistry of human kidney tissue sections with an antibody to 
PTGER2. 
(A).Control kidney sections showed weak staining at the apical surface in normal tubules  
(B).Strong staining for PTGER2 was seen in tubular lining epithelium in human ADPKD tissue 
sections. 
(C). No specific staining was seen in sections incubated with non-immune serum. 
(D). ImmunoRatio analysis showed a significant increase in PTGER2 staining in ADPKD 
sections compared to controls. Unpaired t-test was used.  (n= 6) ⃰⃰⃰ ⃰ P value= 0.0054.  
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Figure 4.12. Immunohistochemistry of human kidney tissue sections with an antibody to 
PTGER4. 
(A).Control kidney sections showed strong PTGER4 staining at the apical surface and 
cytoplasm in normal tubules.  
(B).Strong staining for PTGER4 was seen in the tubular epithelium in human ADPKD tissue 
sections. 
(C). ImmunoRatio analysis showed no significant increase in PTGER4 staining in ADPKD 
sections compared to controls. Unpaired t-test was used. (n=7) P value 0.11. 
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4.3.5. PTGER2 expression in a tamoxifen-inducible, kidney epithelium-specific Pkd1-
deletion mouse model. 
A significant increase in cyst area was seen after 1 month treatment with tamoxifen and this 
increase in cyst area become more pronounced following each additional month of treatment 
(Figure 4.13 A, B) . No significant increase in cyst/tubule area was seen in untreated animals 
highlighting the kidney specific induction of Pkd1 deletion and cystogenesis in this model by 
tamoxifen. Immunohistochemistry of tamoxifen treated and untreated tissue sections with a 
specific mouse PTGER2 antibody revelaed staining in all sections localised mainly to the apical 
surface within tubules with some cytoplasmic but no nuclear staining (Figure 4.14). 
Quantification of staining by ImageJ immunoRatio plugin showed background staining and no 
significant difference after 1, 2, 3 or 4 months of non- tamoxifen treatment. While in tomoxifen 
treatment there is significant difference after 4months of tamoxifen treament ( Figur 4.15 A, 
B and C). A significant difference between DAP/nuclear area between between treated and 
untreated mouse tissue was only observed after 4 months of tamoxifen treatment P value 0.002 
(Control= 7.119±.0.381%, PKD=22.03± 0.525 n=12, n=12)  (Figure 4.15 D). 
One problem with quantifying PTGER2 expression by immunohistochemistry was the variable 
and patchy staining of PTGER2 in tamoxifen- treated mouse tissue. Therefore a grading system 
was used to classify the intensity of staining of PTGER2 into four classes. These were defined 
as 0 or no staining; grade 1 or weak staining in apical area; grade 2 or moderate staining and 
grade 3 or very intense dark staining (Figure 4.16 A, B, C, and D). Analysis was carried out 
by defining the percentage of positively stained cysts showing each grade of staining per 
section. Grade 1 was most commonly seen in tamoxifen untreated mouse tissue after one, two, 
three, and four months. Grade 1 staining was most common in tamoxifen treated mouse tissue 
after the first, second and less frequently in the third, and fourth month (Figure 4.16 E, F, G 
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and H). Grade 2 staining was seen commonly in three month and in four month treated mouse 
tissue (Figure 4.16 G, H).  Grade 3 staining was present only in four month tamoxifen treated 
mouse tissue (Figure 4.16 H). In summary, the third and fourth month tamoxifen treated mouse 
tissue contained more cysts with increased PTGER2 expression (Grade 2, and 3) compared to 
untreated tamoxifen tissue. 
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Figure 4.13. Average cyst area in a CreLox mouse ADPKD model  
(A). A significant increase in average cyst area was observed in mouse CreLox tissue sections 
treated with tamoxifen compared to untreated controls at 1, 2, 3 and 4 months after treatment. 
At 1 month (n=12) *P<0.0203. At 2 months (n=12) *P<0.0145. At 3 months (n=12) 
***P<0.0003. At 4 months (n=12) **P<0.003. Unpaired t-test was used. (B). Two-way 
ANOVA test showed a significant differences between –ve tamoxifen and +ve tamoxifen tissue 
with ****p value<0.0001. 
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Figure 4.14. Expression of PTGER2 in a tamoxifen treated CreLox mouse model of 
ADPKD 
A. No PTGER2 staining was seen in tissue sections incubated with non-immune serum.  
B, C, F, G, J, K, N and O. CreLox control mice tissue sections showed weak PTGER2 staining 
at 1, 2, 3 and 4 months (black arrow).  
D, E, H, I, L, M, P and Q CreLox tamoxifen treated mice showed weak PTGER2 staining 
mainly localised in the tubular epithelial apical surface after 1 month. After 2, 3 and 4 months 
staining intensity progressively increased at the apical surface of tubular epithelial cells and 
within the cytoplasm (black arrow).  
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Figure 4.15. Quantification of PTGER2 expression in a tamoxifen treated CreLox mouse 
model of ADPKD 
ImmunoRatio analysis was carried out on tamoxifen treated and untreated CreLox mouse tissue 
sections.  
A.  No significant difference in PTGER2 expression was seen after 1 month (n=6). P= 0. 73.  
B. No significant difference in PTGER2 expression was seen after 2 month ( n=6) P= 0. 219.  
C. No significant difference in PTGER2 expression was seen after 3 months ( n =6) P= 0. 113.  
D. A signifcant increase in PTGER2 expression was seen in tamoxifen treated mice after 4 
months(n=6). Unpaired t-test was used. ** P value= 0.002.  
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Figure 4.16.  Grading PTGER2 staining intensity of tamoxifen treated CreLox mouse 
tissue sections.  
A. PTGER2 staining intensity was graded by intensity level from 0: no staining. B. +1: weak 
staining. C. +2: moderate staining D. +3: intense staining.  
E, F. After 1 and 2 month tamoxifen treatment the majority of positively staining cysts were 
grades 0 or +1. 
G. After 3 months tamoxifen treatment the majority of positively staining cysts were grades 
+1 or +2. 
H. After 4 months tamoxifen treatment the majority of positively staining cysts were grades 
+1 or +2 with some showing the strongest grade of staining intensity at +3.(n=7). One-way 
ANOVA test was used. ****p<0.0001, **p<0.01, *p<0.05 
  
- 138 - 
 
4.3.6. PTGER4 expression in a tamoxifen-inducible, kidney epithelium-specific Pkd1-
deletion mouse model. 
Immunohistochemistry of tamoxifen treated and untreated tissue sections with a specific rabbit 
PTGER4 antibody staining was carried out. As with PTGER2 expression, PTGER4 staining 
was localised mainly to the apical surface with weak cytoplasmic and no nuclear staining. 
PTGER4 staining was similar in both treated and untreated mouse tissue sections at 1, 2, 3 and 
4 months (Figure 4.17). Staining intensity was graded as previously described due to the 
variable and patchy staining in tubules and cysts (Figure 4.18). Grade 1 weak apical staining 
was commonly seen in the treated and untreated mouse tissue at each time point (Figure 4.18 
E, F, G and H). Grade 2 staining was seen mainly in third, and fourth months treated mice 
tissue (Figure 4.18 G,  H). Grade 3 staining was seen in the fourth month of both the treated 
and untreated mice tissue, and less frequently in second, and third month treated mice tissue.  
(Figure 4.18 F, G and H).  
In conclusion, PTGER2 staining in a tamoxifen-inducible, kidney epithelium-specific Pkd1-
deletion mouse model was significantly increased over treated animals. This was also the case 
when intensity of PTGER2 staining was considered. The highest intensity (grades 2 and 3) 
were seen exclusively in treated animals. PTGER4 staining however was seen in both treated 
and untreated animals and no significant difference was demonstrated. 
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Figure 4.17. Expression of PTGER4 in a tamoxifen treated CreLox mouse model of 
ADPKD 
A. No PTGER4 staining was seen in tissue sections incubated with non-immune serum.  
B, D, F and H. CreLox control mice tissue sections showed weak PTGER4 staining at 1 and 
2 months which increased in intensity at 3 and 4 months mainly localised to the apical tubular 
surface with some cytoplasmic staining.  
C, E, G and I. CreLox tamoxifen treated mice showed strong PTGER4 staining mainly 
localised in the tubular epithelial apical surface with some cytoplasmic staining after 1, 2, 3 
and 4 months. 
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Figure 4.18.  Grading PTGER4 staining intensity of tamoxifen treated CreLox mouse 
tissue sections.  
A. PTGER4 staining intensity was graded by intensity level from 0: no staining. B. +1: weak 
staining. C. +2: moderate staining D. +3: intense staining.  
E, F, G. After 1, 2 and 3 months tamoxifen treatment the majority of positively staining cysts 
were grade +1 or +2 with a small number of cyst staining grade 3 after 2 and 3 months.(n=7). 
H. After 4 months tamoxifen treatment the majority of positively staining cysts were grade +1 
or +2 with a larger proportion at grade +3. One way ANOVA test was used. A significant 
differences between 0 grade and each grade of staining ****p<0.0001. ***p<0.001. *p<0.05. 
Data presented as mean± SEM. 
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4.3.7. PTGER2 expression in a orthologous Pkd1 (nl,nl) mouse model. 
There was a significant increase in cyst area in tamoxifen-treated mice compared with untreated 
animals. The Pkd1 (nl,nl) sections showed a significant increase in cyst area compared to wild- 
type as represented by average percent of cyst area (wild=4504± 817 vs. PKD=17072±1001%, 
n=6) ***P<0.0006 (Figure 4.19). 
Immunohistochemistry of tissue sections with a specific mouse PTGER2 antibody was carried 
out. Staining with PTGER2 was seen  in all sections localised mainly to the apical surface 
within tubules with some cytoplasmic but no nuclear staining (Figure 4.20 A, B). A significant 
increase in PTGER2 expression was seen in Pkd1 (nl,nl) tissue sections compared to wild type, 
as represented by the average percentage of DAB/nuclear area (wild=3.730±787, n=10 vs. 
PKD= 8.525± 2.878%, n=10)*P<0.0263 (Figure 4.20 C). In contrast to the tamoxifen-
inducible, kidney epithelium-specific Pkd1-deletion mouse model, PTGER2 staining was 
observed in the majority of cysts and was uniform in intensity. 
 
4.3.8. PTGER4 expression in a orthologous Pkd1(nl,nl) mouse model. 
Immunohistochemistry of tissue sections with a specific rabbit PTGER4 antibody was carried 
out. Staining with PTGER4 was seen in all sections localised mainly to the apical surface 
within tubules with some cytoplasmic but no nuclear staining. (Figure 4.21 A, B). A significant 
increase in PTGER4 expression was seen in Pkd1(nl,nl) tissue sections compared to wild type, 
as represented by the average percentage of DAB/nuclear area, as represented by the average 
percentage of DAB/nuclear area (wild=1.9±0.137, n=10 vs. PKD=30.87±2% 
n=10)⃰⃰  ⃰⃰ ⃰ ⃰P<0.0001 (Figure 4.21 C). In contrast to the tamoxifen-inducible, kidney epithelium-
specific Pkd1-deletion mouse model, PTGER4 staining was observed in the majority of cysts 
and was uniform in intensity.  
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Figure 4.19. Average cyst area in a NeoLox mouse ADPKD model  
A significant increase in average cyst area was observed in mouse NeoLox tissue sections 
compared to controls (n=6). Unpaired t-test was used. Data presented as mean± SEM.  
***P<0.0006. 
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Figure 4.20. Immunohistochemistry of NeoLox mouse kidney tissue sections with an 
antibody to PTGER2 
(A).Control mouse kidney sections showed weak staining at the apical surface in normal 
tubules.  
(B).Strong staining for PTGER2 was seen in the cyst lining epithelium in PKD1 -/- NeoLox 
mouse tissue sections. Scale bar = 50 µm. 
 (C). ImmunoRatio analysis showed a significant increase in PTGER2 staining in PKD1 -/- 
sections (n=10). Unpaired t-test was used. *P<0.0263. Data presented as mean± SEM. 
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Figure 4.21. Immunohistochemistry of NeoLox mouse kidney tissue sections with an 
antibody to PTGER4. 
(A).Control mouse kidney sections showed weak staining at the apical surface in normal 
tubules.  
(B).Strong staining for PTGER4 was seen in the cyst lining epithelium in PKD1 -/- NeoLox 
mouse tissue sections. Scale bar = 50 µm 
(C). ImmunoRatio analysis showed a significant increase in PTGER4 staining in PKD1 -/- 
sections compared to controls (n=10). Unpaired t-test was used. ⃰⃰ ⃰ ⃰P<0.001. Data presented as 
mean± SEM.  
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4.4. Discussion 
The major aim of this chapter was to determine the expression levels of PTGER receptors 
especially PTGER2 and PTGER4 in human and mouse models of ADPKD. There is evidence 
in the literature that levels of PTGER receptors as well as the ligand PGE2 may be increased 
in ADPKD. As such, these receptors may represent a novel therapeutic target. 
A study of oxidative stress and endothelial dysfunction in ADPKD showed an increase in 
prostaglandins including prostaglandin PGF2, PGD2, and PGE2 in patients with ADPKD 
patients compared to healthy controls (Klawitter, Reed-Gitomer et al. 2014). Furthermore, 
there were an increased levels of PGE1, PGE2, vasopressin and cAMP in cystic fluid from 
ADPKD cells compared to normal kidney cells (Ye, Grant et al. 1992). Adenylyl cyclase 
agonists such as epinephrine, PGE2, AVP and adenosine increase intracellular cAMP which 
stimulates proliferation and fluid secretion in ADPKD and ARPKD (Belibi, Reif et al. 2004).  
Previous studies have shown that exogenous treatment with PGE2 increased proliferation and 
fluid secretion in PC1-deficient IMCD3 cells. This effect was mainly through stimulation of 
PTGER4 receptors which stimulate the -catenin pathway (Liu, Rajagopal et al. 2012). Other 
studies have revealed an increased level of PTGER2 and PTGER4 in ADPKD and liver tumour 
cells (Elberg, Elberg et al. 2007, Elberg, Turman et al. 2012, Xia, Ma et al. 2014). Elberg et al 
found that PGE2 stimulates cystogenesis in an ADPKD model through the PTGER2 receptor 
(Elberg, Elberg et al. 2007). Turman and Elberg, discovered that PGE2 stimulates cystogenesis 
through the PTGER4 receptor in mouse IMCD-3cells (Elberg, Elberg et al. 2007; Elberg, 
Turman et al. 2012). Increased PTGER4 receptors stimulate tumour growth in hepatocellular 
carcinoma (Xia, Ma et al. 2014). Another study established that PTGER2 and PTGER4 
receptors stimulate tumour growth in colorectal carcinoma (Hawcroft, Ko et al. 2007). 
PTGER2 receptors have been localised by in-situ hybridization in both rabbit and human 
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kidneys. It was revealed that PTGER2 mRNA expression was localised in glomeruli and 
medullary collecting ducts of rabbit kidneys (Breyer, Davis et al. 1996, Guan, Stillman et al. 
2002). It was also found that PTGER2 mRNA was increased more in the cystic epithelial cells 
than in normal tubular cells (Elberg, Elberg et al. 2007). 
A preliminary study in our laboratory (conducted by Dr Andrew Streets) isolated mRNA from 
a panel of human cell lines derived from patients with ADPKD and analysed gene expression 
by microarray. This study identified over 2300 genes which were significantly altered in 
ADPKD compared to controls. The PTGER2 receptor was shown to be significantly increased 
in human ADPKD cells (Figure 4.1). I was able to confirm this finding by qPCR on the same 
cells. In contrast, the other three receptors PTGER1, PTGER3, and PTGER4 were not 
significantly increased in either the microarray or qPCR assays (Figure 4.2).  
Furthermore, I was able to detect the PTGER2 receptors by western blotting using a mouse 
monoclonal antibody. There was a significant increase in PTGER2 receptors in the cystic cell 
line (OX161/C1) compared to the normal cells (UCL93). This result was quantified by 
densitometry (Figure 4.7 A, B).  These findings confirm the previous finding of increased 
PTGER2 in cystic epithelial cells (Elberg, Elberg et al. 2007).  In contrast to the human data I 
found that both PTGER2 and PTGER4 mRNA were increased in two orthologous mouse 
models of ADPKD. Immunohistochemistry of the cystic tissues of human and two mouse 
models showed a significant increase in PTGER2 receptor expression in cystic tissue compared 
to control tissue, PTGER2 expression was localised mainly on the apical side of tubules in 
human and mouse tissue (Figure. 4.11, 4.14, 4.15 and 4.20). 
By contrast, expression of PTGER4 was not significantly increased in human ADPKD cell 
lines as determined by microarray, qPCR or western blotting (Figure 4.1. 4.2 and 4.8). 
Immunohistochemistry also showed no significant difference in PTGER4 expression between 
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cystic and normal tissue (Figure 4.12). However in both mouse models of ADPKD a 
significant increase in PTGER4 mRNA was seen by qPCR. Increases in PTGER4 expression 
in mouse tissue were also clearly seen by immunohistochemistry analysis in contrast to human 
tissue sections (Figure 4.4 and 4.21).  
Both PTGER2 and PTGER4 receptors are G-protein coupled receptors that activate the G 
protein GS, leading to stimulation of Adenylyl cyclase and increasing the level of intracellular 
cAMP, and finally it the -catenin pathway (Liu, Rajagopal et al. 2012). These changes result 
in increased proliferation and fluid secretion (Fujino, Salvi et al. 2005). However, recent studies 
have shown functional differences between the PTGER2 and PTGER4 mediated signalling 
pathways. Firstly, PTGER4 is a larger protein than the PTGER2 (488 versus 358 amino acid). 
Secondly, PTGER4, but not the PTGER2, can stimulate the expression of early growth 
response-1 (EGR-1) through activation of the PI3K pathway and ERK signalling (Fujino, Xu 
et al. 2003). Unlike PTGER2 that acts only on the Gs protein (Fujino and Regan 2006), 
PTGER4 couples with both Gs and Gi (pertussis toxin-sensitive Gi) and stimulates the 
phosphatidylinositol 3 kinase, which inhibits cAMP signalling and stimulates ERK (Fujino and 
Regan 2006). Thirdly, PTGER4 has a longer intracellular carboxyl terminal than PTGER2 (155 
versus 34 amino acid) that can act as phosphorylation sites for PKA and GRK (G-protein 
receptor kinase) leading to -arrestin binding (Yokoyama, Iwatsubo et al. 2013). PTGER4 but 
not PTGER2 undergoes agonist-induced desensitization (Nishigaki, Negishi et al. 1996) and 
internalization (Desai, April et al. 2000).   
The magnitude of PGE2 induced activation of cAMP in PTGER2 expressing cells is greater 
than (80%) of that observed in PTGER4 expressing cells (Fujino, Xu et al. 2003). Another 
important point is that the distribution and function of EP receptors are not identical and can 
be species-dependent (Virgolini, Muller et al. 1988, Larsen, Hansen et al. 2005). A recent study 
suggested the main receptor of PGE2 that led to an increase in proliferation of mouse cells 
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(IMCD3) is the PTGER4 receptor, and when antagonised this receptor may have a therapeutic 
role in murine ADPKD (Elberg, Turman et al. 2012). This indicates that human cells may act 
differently from animal cells regarding the response to the PTGER2 and PTGER4 receptors. 
Since PTGER2 and PTGER4 antagonists have highly specific actions and potentially fewer 
side effects, it is possible that they could be of therapeutic benefit in ADPKD (Zimecki 2012). 
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Chapter 5 
Effect of PTGER 2 and 4 receptor antagonists in cell culture 
models of ADPKD 
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5.1. Introduction 
The aim of this chapter was twofold. Firstly to investigate the role of cAMP and PGE2 on 
ADPKD cyst formation and secondly to explore the potential of PTGER2 and 4 antagonists as 
a novel therapeutic approach in cell models of ADPKD. 
Previously, a PTGER2 antagonist (AH-6809) has been used to block PTGER2 receptor 
function. However this antagonist has poor selectivity and affinity for the PTGER2 receptor 
(Abramovitz, Adam et al. 2000). Furthermore, it has unknown in vivo effects which makes the 
transition from in vitro to in vivo model experiments challenging (Abramovitz, Adam et al. 
2000). 
In this chapter, a new PTGER2 selective antagonist (PF-04418948) developed by Pfizer, was 
used to inhibit the effect of PGE2 in vitro. This compound exhibits a 2000-fold functional 
selectivity for human PTGER2 over other PTGER receptors (PTGER1, PTGER3 and PTGER4) 
and prostanoids (CRTH2, DP1, FP, TP and IP) receptors, The IC50 value is 16 nM for PTGER2, 
while for human PTGER1 and PTGER3 the IC50 is >10,000Nm The PTGER4 IC50 is >33,300 
nM. Additionally, it has little activity against a panel of other ion channels and GPCRs even at 
high concentrations. It acts via competitive inhibition for PGE2 binding (af Forselles, Root et 
al. 2011, Birrell and Nials 2011). In previous studies PF-04418948 was able to block the effect 
of PGE2 and the PTGER2 agonist butaprost in an in vitro study on human myometrium, animal 
smooth muscles (dog bronchi, mouse tracheas) and in vivo in rats after oral administration (af 
Forselles, Root et al. 2011). 
A second antagonist used in this study was the PTGER4 antagonist, CJ-042794 from Pfizer 
(Murase, Taniguchi et al. 2008). This compound exhibited a 200-fold functional selectivity for 
human PTGER4 compared to PTGER1, PTGER2, and PTGER3. Furthermore, it did not show 
any binding activity against a panel of 65 other proteins including ion channels, transporters 
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and GPCRs even at high concentration (10µM). CJ-042794 acts mainly through competitive 
inhibition of PTGER4.  It inhibited PGE2 mediated cAMP accumulation with an IC50 of 500nM 
(Murase, Taniguchi et al. 2008). The rodent PTGER4 receptor is highly homologous to the 
human PTGER4 receptor, therefore, CJ-042794 could serve as useful agent for investigating 
the physiological role in PTGER4 receptor in the rat (Murase, Taniguchi et al. 2008).  
I studied the effect of these two antagonists on cystic and normal human cells and MDCKII 
cytogenesis in cyst assays. In addition, their effect on proliferation and apoptosis was 
investigated. Finally, I measured cAMP levels in both cystic and normal human cells, and 
investigated the effect of PTGER2, and PTGER4 antagonists on cAMP levels. 
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5.2. Aims and objectives: 
1. Test the effect of PGE2, PTGER2, and PTGER4 receptor antagonists on proliferation 
and apoptosis in control and ADPKD kidney epithelial cell lines. 
2. Test the effect of PGE2, PTGER2, and PTGER4 receptor antagonists on cyst growth 
in control and ADPKD kidney epithelial cell lines. 
3. Compare cAMP levels in control and ADPKD kidney epithelial cell lines incubated 
with PTGER2, and PTGER4 receptor antagonists. 
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5.3. Results.  
 
5.3.1. The effect of PGE2 on the proliferation of ADPKD and control kidney epithelial 
cell lines. 
Using cell lines derived from ADPKD patients, we aimed to determine whether PGE2 
contributed to the hyper-proliferative phenotype of ADPKD renal epithelial cells, a consistent 
feature of cyst pathogenesis. Four ADPKD cell lines (OX161/C1, OX938, OX161 and SKI-
001) and two control cell lines (UCL93, and RFH) were used in these experiments.   
The effect of PGE2 on proliferation of ADPKD and control cell lines was determined using 
two separate assays, an MTS cell viability assay and a BrdU cell proliferation ELISA Assay.  
MTS is a widely used assay of cell number and viability. It measures cell metabolic activity by 
the reduction of yellow tetrazolium MTS (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) salt to purple formazan that can be quantified using a 
colorimetric method.  At the time of the assay, cells looked healthy and viable with no evidence 
of cell toxicity under the microscope. 
The second proliferation test used a BrdU proliferation assay kit. It measures DNA synthesis 
by detecting 5-bromo-deoxyuridine (BrdU) incorporated into newly synthesised cellular DNA 
using an anti-BrdU antibody. The BrdU-labeled DNA detected by BrdU mouse Ab does not 
cross-react with endogenous DNA.  
Cells were treated with PGE2 (25, 50, 100 nM) for 72 h prior to each assay. A significant 
increase in proliferation was seen in three ADPKD cell lines (OX161/C1, OX161 and SKI-
001) treated with PGE2 (Figure 5.1A). In contrast, PGE2 had no significant effect or inhibited 
proliferation in control cell lines and surprisingly, in one ADPKD cell line (OX938).  
After 72 hours of incubation with different PGE2 concentrations, ADPKD cells showed a 
significant increase in proliferation at a concentration of 50nM PGE2 in all four ADPKD cell 
- 155 - 
 
lines (OX161/C1, OX161, SKI-001 and OX938) (Figure 5.2 A). In control cell lines (UCL93, 
RFH), PGE2 inhibited proliferation at the same concentrations (Figure 5.2 B). These findings 
are comparable to those described by Yu Liu, and Yamaguchi et al (Yamaguchi, Pelling et al. 
2000) (Rajagopal, Thomas et al. 2014).  
These results demonstrated that PGE2 selectively increased proliferation of ADPKD cell lines 
compared to control cell lines presumably as a result of the increased levels of PTGER2 
receptors present in ADPKD cells described in chapter 4. 
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Figure 5.1. Effect of PGE2 on ADPKD cell proliferation (MTS assay) 
(A). There was a significant increase in viable cell number as measured by MTS assay after 72 
hours in OX161, OX 161/C1 and SKI-001 ADPKD cell lines (n=3) following stimulation with 
50 nM PGE2. PGE2 decrease proliferation of OX938 cells at higher doses (50-100nM). One-
way ANOVA was used.  *p<0.05; **p<0.01. Data presented as mean± SEM 
(B). PGE2 did not cause an increase in viable cell number as measured by MTS assay in control 
cells. Experiments are representative of 3 separate repeats. Control is DMSO treated cells. 
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Figure 5.2. Effect of PGE2 on ADPKD cell proliferation (BrdU Elisa). 
(A). There was a significant increase in viable cell number as measured by BrdU Elisa assay 
in OX161, OX161/C1, SKI-001 and OX938 ADPKD cell lines.( n=3), following stimulation 
with 50 nM PGE2 for 72 hours. Unpaired t-test was used.  *p<0.05; **p<0.01, ***p<0.001. 
Data presented as mean± SEM 
(B).PGE2 caused a significant decrease in viable cell number as measured by BrdU Elisa assay 
in control cells. Experiments are representative of 3 separate repeats. Control is DMSO treated 
cells. 
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5.3.2. The effect of a PTGER2 antagonist on the proliferation of ADPKD and control 
kidney epithelial cell lines. 
Following the observation that PGE2 selectively stimulates proliferation of ADPKD cell lines, 
we hypothesised that incubation with a selective PTGER2 receptor antagonist (blocking the 
action of endogenous PGE2) would have the opposite effect. Cells were treated with three 
different concentrations of PTGER2 antagonist (100 nM, 500 nM and 1 µM) and were 
incubated for 72 hours before analysis. PTGER2 antagonist treatment significantly inhibited 
the proliferation of ADPKD cell lines (OX16/1C1, OX938, OX161 and SKI-001) mainly at 
concentrations of 500 nM and 1µM (Figure 5.3 A). In control cell lines however there was no 
significant decrease in proliferation when treated with PTGER2 antagonist (500nM- 1µM) 
(Figure 5.3 B).  
A second proliferation assay was carried out using a BrdU proliferation ELISA. Incubation 
with PTGER2 antagonist (500 nM and 1 µM) significantly inhibited proliferation of three 
ADPKD cell lines (OX161/C1, OX161 and OX938) at a concentration of 500 nM or more 
(Figure 5.4 A). By contrast, in the normal cell lines (UCL93, RFH) there was a small but non-
significant decrease in proliferation when cells were treated with the PTGER2 antagonist at the 
same concentrations (Figure 5.4 B). In summary, these results indicate that the PTGER2 
antagonist selectively inhibits the proliferation of ADPKD cell lines compared to control cell 
lines, probably by blocking the action of endogenous PGE2. 
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Figure 5.3. Effect of PTGER2 antagonist on ADPKD cell proliferation (MTS assay) 
(A). There was a significant decrease in viable cell number as measured by MTS assay in 
OX161, OX 161/C1, SKI-001 and OX938 ADPKD cell lines( n=3) following incubation (72 
hours) with 500 nM -1 M PTGER2 antagonist compared to control. One-way ANOVA test 
used. *p<0.05; **p<0.01,***p<0.001. Data presented as mean± SEM.    
 (B). PTGER2 antagonist did not cause a significant decrease in viable cell number as measured 
by MTS assay in control cells. Experiments are representative of 3 separate repeats. Control is 
DMSO treated cells. 
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Figure 5.4. Effect of PTGER2 antagonist on ADPKD cell proliferation (BrdU Elisa 
assay) 
(A). There was a significant decrease in DNA synthesis as measured by BrdU Elisa assay in  
in OX161, OX 161/C1, SKI-001 and OX938 ADPKD cell lines ( n=3) following incubation 
(72 hours) with 500 nM -1 µM PTGER2 antagonist compared to control. Unpaired t-test was 
used.  *p<0.05; **p<0.01*** p<0.001. Data presented as mean± SEM 
(B). PTGER2 antagonist did not cause a significant decrease in viable cell number as measured 
by BrdU Elisa assay in the control cells (UCL93, RFH). Experiments are representative of 3 
separate repeats. Control is DMSO treated cells. 
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5.3.3. The effect of a PTGER4 antagonist on the proliferation of ADPKD and control 
kidney epithelial cell lines. 
The role of PTGER4 was next investigated using a PTGER4 selective antagonist. Cells were 
treated with three different concentrations of (100 nM, 200 nM and 500 nM) for 72 hours prior 
to analysis. PTGER4 antagonist treatment significantly inhibited proliferation of ADPKD cell 
lines (OX161/C1, OX938, OX161 and SKI-001) measured by an MTS assay mainly at 
concentrations of 200 nM and 500 nM (Figure 5.5 A). In both control cell lines there was a 
significant decrease in proliferation when cells were treated with PTGER4 antagonist at a 
concentration of 100 nM (Figure 5.5 B). Surprisingly, there was a significant increase in 
proliferation when UCL93 control cells were treated with higher doses (200 nM, 500 nM) of 
the PTGER4 antagonist (Figure 5.5 B). This was not observed in RFH cells. 
PTGER4 antagonist treatment also significantly reduced BrdU incorporation in three ADPKD 
cell lines (OX161/C1, OX938, and SKI-001) at concentrations of 200 nM and 500 nM (Figure 
5.6 A). In the control cell lines, there was no change in proliferation when UCL93 cells were 
treated with a PTGER4 antagonist (Figure 5.6 B). However, unlike the MTS assay, there was 
a significant increase in BrdU incorporation in RFH cells following incubation with a PTGER4 
antagonist. Together, these results suggest that a PTGER4 antagonist inhibits the proliferation 
of human cystic cells mainly at higher concentrations (500 nM).  
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Figure 5.5. Effect of PTGER4 antagonist on ADPKD cell proliferation (MTS assay) 
(A). There was a significant decrease in viable cell number as measured by MTS assay in 
OX161, OX 161/C1, SKI-001 and OX938 ADPKD cell lines (n=3) following incubation (72 
hours) with 200 and 500 nM PTGER4 antagonist. One-way ANOVA test was used. *p<0.05; 
**p<0.01, ***p<0.001, ****p<0.0001 Data presented as mean± SEM. 
 (B). PTGER4 antagonist caused a significant increase in viable cell number as measured by 
MTS assay in, UCL93 control cells following incubation with 200 and 500 nM PTGER4 
antagonist. (n=3). PTGER4 antagonist caused a significant decrease in viable cell number as 
measured by MTS assay in RFH control cells at 100, 200 and 500 nM. Experiments are 
representative of 3 separate repeats. Control is DMSO treated cells. 
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Figure 5.6. Effect of PTGER4 antagonist on ADPKD cell proliferation (BrdU Elisa 
assay). 
(A). There was a significant decrease in DNA synthesis as measured by BrdU Elisa assay in 
OX161, OX 161/C1, SKI-001 and OX938 ADPKD cell lines ( n=3) following incubation (72 
hours) with 2 different concentration of PTGRE4I (200nM, 500nM) compared to control.  
Unpaired t-test was used. *p<0.05; **p<0.01*** p<0.001. 
(B). PTGER4 antagonist did not cause a significant decrease in DNA synthesis as measured by 
BrdU Elisa assay in UCL93 control cells.  PTGER4 antagonist caused a significant increase in 
viable cell number as measured by BrdU Elisa assay in RFH control cells following incubation 
with 200 and 500 nM PTGER4 antagonist. Data presented as mean± SEM. Experiments are 
representative of 3 separate repeats. Control is DMSO treated cells. 
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5.3.4. The effect of PGE2, PTGER2 and PTGER4 antagonists on the proliferation of 
MDCK II kidney epithelial cells. 
In addition to using patient derived cell lines, I used the MDCK II kidney epithelial cell line as 
a model cell line in 3D cyst assays. Initial experiments were conducted to determine the effect 
of incubation with PGE2 or PTGER2 and 4 antagonists on proliferation. Incubation with PGE2 
had no significant effect on proliferation of MDCK cells at a concentration of 25 and 50 nM; 
it just failed to reach significance at 25 nM (p<0.051) (Figure 5.7A). In contrast, a PTGER2 
antagonist significantly decreased MDCK cell proliferation at 500 nM and 1 µM (Figure 5.7 
B). Surprisingly, incubation with a PTGER4 antagonist significantly increased proliferation at 
200 and 500 nM (Figure 5.7 C).  
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Figure 5.7. Effect of PGE2, PTGER2 and PTGER4 antagonists on MDCK II cell 
proliferation (BrdU Elisa assay) 
(A). There was no significant increase in proliferation of MDCKII cells ( n=3)  treated with 25 
and 50 nM PGE2 by unpaired t-test *p<0.05, **p<0.01, ***p<0.001 
 (B). There was a significant decrease in proliferation when MDCK II cells were treated with 
500 nM PTGER2 antagonist.  
(C). There was a significant increase in proliferation when MDCKII cells were incubated with 
200 and 500 nM PTGER4 antagonist compared to control. Unpaired t-test was used. 
Experiments are representative of 3 separate repeats. Control is DMSO treated cells. Data 
presented as mean± SEM. 
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5.3.5. Effect of pre-incubation with PTGER2 and PTGER4 antagonists on PGE2 
stimulation of cell proliferation. 
Since PGE2 was shown to selectively increase proliferation of ADPKD cell lines compared to 
control cell lines, I sought to confirm the roles of PTGER2 or PTGER4 in mediating this effect 
in both OX161/C1 and MDCK II cells by pre-incubating cells with antagonists for 2 h prior to 
adding PGE2. Cell proliferation was then determined using a BrdU ELISA. 
BrdU incorporation was significantly increased in OX161/C1 cells following incubation with 
PGE2 (50 nM). Pre-incubation with either PTGER2 or PTGER4 antagonists completely 
abolished the effect of PGE2 and further reduced proliferation below untreated controls 
(Figure 5.8 A). This indicates that PGE2 exerts its effect by binding to PTGER2 and or 
PTGER4 in OX161/C1 cells.  
MDCK II proliferation was also stimulated by PGE2 although the magnitude of change was 
much smaller. Unlike OX161/C1 cells however, only pre-incubation with the PTGER2 
antagonist but not the PTGER4 antagonist blocked PGE2 mediated proliferation in MDCK II 
cells (Figure 5.8 B). This suggests that in MDCKII cells, PGE2 exerts its effect primarily by 
binding to the PTGER2 receptor alone. 
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Figure 5.8. Effect of pre-incubation with PTGER2 and PTGER4 antagonists on PGE2 
stimulation of cell proliferation  
(A). OX161/C1 cells (n=3) showed a significant increase in proliferation when treated with 
50 nM PGE2. This was inhibited following pre-incubation with PTGER2 and 4 antagonists. 
***p<0.001, ****p<0.0001. One-way ANOVA test was used. 
(B). MDCK II cells (n=3) showed a significant increase in proliferation when treated with 50 
nM PGE2. This was inhibited following pre-incubation with a PTGER2 antagonist but not by 
pre-incubation with a PTGER4 antagonist. **p<0.01, ***p<0.001. Experiments are 
representative of 3 separate repeats. Control is DMSO only treated cells. One-way ANOVA 
test was used. Data presented as mean± SEM. 
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5.3.6. The effect of PGE2, PTGER2 and PTGER4 antagonists on apoptosis of ADPKD 
and control kidney epithelial cell lines. 
ADPKD is characterised by increased levels of proliferation as well as apoptosis (Chang, 
Steelman et al. 2003). The results so far in this chapter have shown that PGE2 selectively 
stimulates proliferation of ADPKD cell lines compared to control cell lines by binding to both 
PTGER2 and PTGER4 receptors.  
The effect of PGE2 as well as PTGER2 and PTGER4 antagonists on apoptosis was investigated 
next using two well established methods.  Firstly, a TUNEL assay was used to identify DNA 
strand breaks in apoptotic cells. Secondly, immunofluorescence staining was used to identify 
activated (cleaved) caspase 3 in apoptotic cells.  
For both assays, 100 mM H2O2 was used as a positive control to stimulate apoptosis and DMSO 
alone was used as a negative control. Based on the results of previous experiments, PGE2 was 
used at a concentration of 50 nM and PTGER2 and PTGER4 antagonists were used at a 
concentration of 500 nM for 72 h. 
Incubation of ADPKD and control cells with 100 mM H2O2 resulted in strong TUNEL staining 
as well as cleaved caspase-3 staining indicating the induction of apoptosis. Incubation with 
DMSO alone showed very few positively stained cells (Figure 5.9). The images shown are 
representative of the ADPKD and control cell lines used in this study.  
Incubation of ADPKD and control cell lines with 50 nM PGE2 had no effect on apoptosis 
although these cells displayed very low (<5%) levels of apoptosis in the absence of stimuli 
(Figure 5.10). Interestingly, all three ADPKD cell lines tested showed a significant increase in 
apoptosis by TUNEL assay following incubation with PTGER2 and PTGER4 receptor 
antagonists (Figure 5.10). This was not seen as consistently when apoptosis was assayed by 
staining for cleaved caspase-3 with only the OX161/C1 ADPKD line showing increased 
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apoptosis with both antagonists in this assay (Figure 5.11). The MDCKII cell line showed a 
consistent increase in apoptosis when treated with a PTGER2 receptor antagonist in both assays 
(Figure 5.10 and 11). 
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Figure 5.9. Identification of apoptotic cells by TUNEL and cleaved caspase-3 staining. 
(A). OX161/C1 cells treated with 100 mM H2O2 showed strong TUNEL staining whereas in 
cells treated with DMSO alone (B) staining was mostly absent. 
(C). OX161/C1 cells treated with 100 mM H2O2 showed strong cleaved caspase-3 staining 
whereas in cells treated with DMSO alone (B) staining was mostly absent. Staining was 
representative of the results from ADPKD cell lines as well as control cell lines. 
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Figure 5.10 Effect of PGE2, PTGER2 and PTGER4 receptor antagonists on apoptosis by 
TUNEL assay. 
(A). ADPKD cells (n=6) showed a significant increase  in apoptosis as seen by increased 
TUNEL staining following incubation with PTGER2 and 4 receptor antagonists. *P<0.05, 
**p<0.01, ***p<0.001. 
(B). Control cells (n=6) showed no significant increases in apoptosis with the exception of 
MDCKII cells treated with PTGER2 receptor antagonist. Experiments are representative of 3 
separate repeats. Control is DMSO only treated cells.  One-way ANOVA test was used. 
  
- 172 - 
 
 
 
Figure 5.11 Effect of PGE2, PTGER2 and PTGER4 receptor antagonists on apoptosis by 
cleaved caspase-3 staining. 
(A). OX161/C1 ADPKD cells (n=6) showed a significant increase in apoptosis as seen by 
increased cleaved caspase-3 staining following incubation with PTGER2 and 4 receptor 
antagonists. OX938 ADPKD cells showed a significant increase in apoptosis as seen by 
increased cleaved caspase-3 staining following incubation with PTGER4 receptor antagonist. 
PH1 ADPKD cells showed a significant reduction in apoptosis as seen by decreased cleaved 
caspase-3 staining following incubation with PGE2. 
(B). Control cells showed no significant increases in apoptosis with the exception of MDCKII 
cells treated with PTGER2 receptor antagonist. Experiments are representative of 3 separate 
repeats. Control is DMSO only treated cells. Data presented as mean± SEM. One-way Anova 
test was used. 
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5.3.7. The effect of a PTGER2 receptor antagonist on cystogenesis in 3D cyst assays. 
To assess the effect of a PTGER2 antagonist on cystogenesis, cyst assays were performed on 
OX161/C1 cells cultured in Matrigel and MDCKII cultured in Collagen gels respectively. The 
cells were treated in triplicate with different concentration of PTGER2 antagonist (100 nM-10 
µM) for 48 h and cells were observed every two days for eight days and average cyst area 
measured as described in the methods. I found that the PTGER2 receptor antagonist 
significantly inhibited the growth of cysts in OX161/C1 cells in a concentration dependent 
manner with a minimum concentration required of 500 nM (Figure 5.12). Similar results were 
observed in MDCKII cells (Figure 5.13). The results displayed are representative of 3 separate 
experiments. 
In conclusion, incubation with a PTGER2 antagonist inhibited cyst growth in both cell lines 
(OX161/C1 and MDCKII) tested. The reduction in average cyst area was seen at a 
concentration of 500nM and reached a maximum at 1µM. 
 
5.3.8. The effect of a PTGER4 receptor antagonist on cystogenesis in 3D cyst assays. 
Next, I assessed the effect of a PTGER4 receptor antagonist on cystogenesis in both OX161/C1 
cells and MDCKII cells in 3D culture. Cells were treated in triplicate with different 
concentrations of the PTGER4 antagonist (100 nM-10 µM) and photographed every two days 
for ten days.  
I found that the PTGER4 receptor antagonist significantly inhibited the growth of OX161/C1 
cysts in a concentration dependent manner.  The minimum concentration required was 200nM. 
The maximum effect was seen at concentrations 1 and 10 µM (Figure 5.14).  
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In contrast to OX161/C1 cells, MDCKII cells showed the unexpected finding that incubation 
with a PTGER4 receptor antagonist caused a significant increase in average cyst area especially 
at higher (10µM) concentrations (Figure 5. 15). There was no decrease in cyst growth at lower 
concentrations (Figure 5. 15). The mechanism why the PTGER4 antagonist increased average 
cyst area in MDCK II cells is not clear. At this dose, it may act on other receptors or other 
pathways in this cell line resulting in stimulation of proliferation. PTGER4 receptors can 
activate both Gi coupled receptors as well as Gs receptors (Fujino and Regan 2006). Therefore 
a PTGER4 receptor antagonist may activate alternative pathways which increase cystogenesis 
rather than inhibit cyst formation. 
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Figure 5.12. The effect of PTGER2 antagonist on OX161/C1 cysts in 3D culture  
 (A). Photographs of OX16 /C1 cysts cultured in matrigel treated with DMSO (control), or 
different concentrations of PTGER2 antagonist (100nM-10µM) monitored serially from day 2 
to day 8. Cyst formation was visibly reduced especially at concentrations (500nM -10µM) 
compared to the control. Scale bar 50µM. 
(B). Graph showing the change in average cyst area over time of OX161/C1cells treated with 
PTGER2 antagonist, or DMSO in 3D culture. The average cyst area OX16 /C1 cyst was not 
significant decreased by PTGER2 antagonist 100nM compared to the control. The values are 
however, significant suppression of cyst growth was seen by at higher concentrations. One-
way ANOVA test was used. *p<0.05; **p<0.01. 
 (C). The growth rate of OX16 /C1 cells measured over 8 d. Average cyst area was significantly 
decreased by the PTGER2 antagonist at concentrations between 500 nM-10 µM . Two way 
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ANOVA test was used. A total of 20 cysts were measured per well for a total of 3 wells (n=60). 
****p<0.0001. Experiments are representative of 3 separate repeats. Control is DMSO only 
treated cells. 
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5.3.9. Effect of pre-incubation with PTGER2 and PTGER4 antagonists on PGE2 
stimulation of cyst formation in 3D cyst assays. 
PGE2 was shown to selectively increase proliferation and cystogenesis of ADPKD cell lines. 
In order to determine whether PGE2 was binding to and mediating its proliferative effect 
through PTGER2 or PTGER4, OX161/C1 and MDCKII cells were pre-incubated with 
antagonists for 2 h prior to incubation with PGE2 for 72 h. MDCKII cells treated with 25 nM 
PGE2 alone showed a significant increase of cyst growth compared to the controls (Figure 
5.16). Conversely, when MDCKII cells were pre-incubated with a PTGER2 receptor antagonist 
(100nM -10µM), there was a significant reduction in cyst growth especially at concentrations 
1µM and 10µM compared to the control (Figure 5.16) indicating that PGE2 was exerting its 
effects through the PTGER2 receptor in MDCK II cells. 
OX161/C1 cells treated with 50nM PGE2 alone showed a significant increase in average cyst 
area (Figure 5.17). Conversely, when cell were pre-incubated with PTGER2, PTGER4 or both 
together prior to incubation with PGE2 there was a significant reduction in average cyst area 
(Figure 5.17).  In summary, cells treated with 50nM PGE2 showed a significant increase in 
average cyst area. This effect was inhibited by PTGER2 or PTGER4 antagonists singly or in 
combination. The results displayed are representative of 3 independent experiments. 
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Figure 5.13. The effect of PTGER2 antagonist on MDCKII cysts in 3D culture. 
(A). Photographs of MDCKII cyst cultured in Collagen I treated with DMSO (control);or 
different concentrations of PTGER2 antagonist (100nM-10µM) monitored  serially from day 
2-day to day 8.  Cysts were visibly smaller when treated with 500nM-10µM. All scale bar 
50µM. 
 (B). Graph representing the average cyst area of MDCKII cells treated with PTGER2 
antagonist or DMSO on day 8. The total cyst area of MDCKII cysts was not significantly 
decreased by PTGER2 antagonist 100nM compared to the control. The values are (mean± 
SEM) (n=20) Average cyst area was significantly reduced by higher concentrations of the 
antagonist. One-way ANOVA test was used. ***p<0.001; ****p<0.0001. 
 
 
 
 
. 
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Figure 5.14.  The effect of PTGER4 antagonist on OX161/C1 cysts in 3D culture  
(A). Photographs of OX161/C1 cyst cultured in Matrigel treated with DMSO (control) or 
different concentrations of a PTGER4 antagonist (100nM-10µM) monitored  serially from day 
2 to day 8. There was a clear decrease in size with 500-10µM of the PTGER4 antagonist 
compared to control. All scale bars - 50µM.  
 (B). Graph representing the average cyst area of OX161/C1 cells treated with PTGER4 
antagonist or DMSO. The average cyst area of OX161/C1 cysts was not significantly decreased 
by PTGER4 antagonist 100nM compared to the control. The significant value was analysed by 
one-way ANOVA test. A significant reduction in cyst area was observed at higher 
concentrations. *p<0.05 
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 (C). The growth rate of OX161/C1 cells, treated with DMSO or different concentrations of 
PTGER4 antagonist over time. Cyst area was decreased by the PTGER4 antagonist at higher 
concentrations i.e. 500nM-10µM. the significant was analysed by two- way-ANOVA test. A 
total of 20 cysts were measured per well in 3 wells (60 cysts). ****p<0.0001 
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Figure 5.15. Shows the effect of PTGER4 antagonist on MDCKII cysts in 3D culture. 
(A). Photographs of MDCKII cyst cultured in Collagen I treated with DMSO (control), and 
different concentrations of PTGER4 antagonist (100nM-10µM) monitored serially from day 2 
to day 8. Cysts increased significantly in size when treated with higher concentrations of 
PTGER4 antagonist (1µM, 10µM).  Scale bar - 50µM. 
 (B). Graph representing the average cyst area of MDCKII cells treated with different 
concentrations of PTGER4 antagonist or DMSO. **p<0.01; ****p<0.0001. One-way 
ANOVA test was used. 
(C). The growth rate of MDCKII cells treated with a PTGER4 antagonist (100nM-500nM). 
There was no significant decrease of the cyst area at these doses 100nM. Significant difference 
at 200nM* p<0.05 and 500nM**p<0.01 by two-way ANOVA test. A total of 10 cysts were 
measured per well for a total of 3 wells (n=30) which are monitored every two days for 8 days. 
Data presented as mean± SEM. 
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Figure 5.16. The effect of pre-incubation with PTGER2 antagonists on PGE2 stimulated 
MDCKII cysts. 
(A). Photographs of MDCKII cyst cultured in collagen I treated with DMSO (control), 50nM 
PGE2 and different concentrations of PTGER2 or PTGER4 antagonists monitored serially 
from day two. Treatment with 50nM PGE2 significantly increased cyst size and number 
compared to controls. The effect of PGE2 was inhibited by co-incubation with PTGER2 
antagonists. All scale bars - 50µM. 
(B). Graph representing the average cyst area at day 8 of MDCKII cysts treated with 50nM 
PGE2 in the presence or absence of a PTGER2 antagonist.  
MDCKII treated with PGE2 (50nM), showed a significant increase in cyst area (n=3) 
**p<0.01, *p<0.05, ****p<0.0001. A significant inhibition of this effect was observed at 
PTGER2I concentrations of 1 µM and above. Data presented as mean± SEM.  One-way 
ANOVA test was used.  
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Figure 5.17. The effect of pre-incubation with PTGER2 and PTGER4 antagonists on 
PGE2 stimulated OX161/C1 cysts. 
(A). Photographs of OX161/C1 cysts cultured in Matrigel monitored serially from day 2 to day 
8 following treatment with DMSO (control), 50nM PGE2, PTGER2 antagonist 500nM, 
PTGER4 antagonist 200nM or both.  All scale bars - 50 µM. 
(B). Average cyst area of OX161/C1 cells treated with PGE2 (50 nM) with PTGER2 and/or 
PTGER4 antagonists at day 8. ***p<0.001; ****p<0.0001. (n=3). There is additive effect 
when both PTGER2I and PTGER4I added to the cell.  Data presented as mean± SEM. One-
way ANOVA test was used. 
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5.3.10. The effect of PGE2 on cAMP levels in ADPKD and control kidney epithelial cell 
lines. 
The major effect of PGE2 binding to PTGER2 and PTGER4 receptors is to increase cAMP 
levels via activation of adenylate cyclase. We utilised a cAMP ELISA assay to determine the 
effect of PGE2 on baseline cAMP levels in ADPKD and control cell lines. There were 
significantly higher cAMP levels in OX161/C1 and OX161 ADPKD cells compared to UCL93 
control cells (Fig. 5.18 A). Levels in another ADPKD line, SKI-001 were raised though not 
significantly compared to UCL93. 
Incubation with PGE2 50nM caused a small but significant increase in cAMP levels in 
OX161/C1 cells though not in UCL93 cells (Fig. 5.18 B, C). Incubation with the PTGER2 
antagonist lead to the most striking reduction in cAMP concentrations in OX161/C1 cells, even 
below that of DMSO controls. No significant effect of either receptor antagonist was seen in 
normal cell line UCL93. These results suggest that PGE2 exerts its effects mainly through the 
PTGER2 receptor in human ADPKD cells and this is in agreement with the results seen in 
chapter 4 which shows that PTGER2 is over-expressed in ADPKD cells and tissue sections. 
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5.18. The effect of PGE2 on cAMP levels in cystic and normal cell lines. 
(A). A standard curve of cAMP level created using computer software that generate four 
parameter logistic (4-PL) curves- fit. 
(B). Basal cAMP levels in cystic (OX161/C1, OX161, SKI-001) and control (UCL93) cell 
lines. *p<0.05; **p<0.01. cAMP levels in SKI-001 were slightly higher than control but not 
significantly. (n=2). One-way ANOVA test was used. p= 0.22. 
- 192 - 
 
(C). PGE2 stimulated cAMP in OX161/C1 cells and this was blocked by the PTGER2 but not 
the PTGER4 antagonist. *p<0.05; ***p<0.001. (n=3). One-way ANOVA test was used. 
(D). PGE2 had no effect on cAMP in UCL93 cells and there were no effects of the PTGER2 
and PTGER4 antagonists. (n=3). One-way ANOVA test was used. Data represented as 
mean± SEM.
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5.4. Discussion.  
In this chapter, I have studied the possible role of PGE2 in cyst formation using established 
and unique cellular models. In chapter 3, I had demonstrated that PGE2, like cAMP, increases 
average cyst area in ADPKD cyst assays (Figure 3.13 and 3.14). In this chapter, I showed that 
PGE2 stimulated cellular proliferation in all ADPKD cell lines tested. PGE2 caused an increase 
in the proliferation of human renal epithelial cystic cells (OX161/C1, SKI-001, OX938 and 
OX161) by MTS and BrdU proliferation assays (Figure 5.1 and 5.2).  However, normal cell 
lines (UCL93, and RFH) showed a decrease in proliferation when treated with PGE2, 
especially at concentrations of 50nM (Figure 5.1 and 5.2). These results are in agreement with 
those obtained by Liu and Rajagopal 2012 (Liu, Rajagopal et al. 2012) in which PGE2 inhibited 
the proliferation of wild type renal cells. Using selective receptor antagonists, PTGER2 and 
PTGER4 were found to inhibit the proliferation and cyst formation in ADPKD cells. 
The effects of PGE2 on apoptosis (identified by TUNEL assay and cleaved caspase-3 staining) 
were more variable. In two human cystic epithelial cells (OX161/C1, and SKI-001) and 
MDCKII cells, exogenous PGE2 decreased apoptosis or there was a significant increase in 
apoptosis with PTGER2 or PTGER4 antagonists suggesting an anti-apoptotic effect of 
endogenous PGE2 (Figure 5.10 and 5.11). These effects were more variable in the other cells. 
The anti-apoptotic effect of PGE2 is consistent with a previous report in human cystic cells in 
which there was a significant decrease of apoptosis by 22% (TUNEL assay) with PGE2 
(Elberg, Elberg et al. 2007). Other studies have shown that there is decreased apoptosis in 
tumour cells treated with PGE2 (Nasrallah, Hassouneh et al. 2014, Xia, Ma et al. 2014). 
Overall, my results are consistent with primary effects of PGE2 on both proliferation and 
apoptosis, mediated through both PTGER2 and PTGER4.  
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I found that PTGER2 and PTGER4 receptor antagonists reduced the average cyst area in 3D 
gels (Figure 5.12, 5.13, 5.14, 5.16, and 5.17). There was a trend towards reduced proliferation 
when the cells were treated with PTGER2 and PTGER4 antagonists (Figure 5.3, 5.4 and 5.8).  
Although the PTGER4 antagonist inhibited proliferation and cyst formation in cystic cell lines 
(Figure 5.5, 5.6, 5.14 and 5.17), it paradoxically increased cyst formation and increased 
proliferation of MDCKII and normal cell lines especially in high dose 10µM (Figures 5.5, 5.6, 
5.7, 5.8 and 5.15). This finding was unexpected and suggests that the PTGER4 antagonist may 
at very high doses, produce nonspecific effects; or it act in a different manner in non-cystic 
cells. However, there were also differences between the different ADPKD cell lines in their 
response to PTGER2 and 4 receptor antagonists. The causes of these differences are unknown 
but could be due to genetic (mutations, background) or phenotypic (age, tubular origin) 
variability. 
In the study conducted by Elberg et al a PTGER2 antagonist (PF-04418948) was applied in a 
dose range of 0.01 - 10µM and a PTGER4 antagonist (CJ-42794) was applied in a dose range 
of 10nM - 10µM. These experiments were carried out in 3D cultures using a mouse model cell 
line (IMCD-3). The effective dose of CJ-42794 that inhibited cystogenesis was 100nM while 
no effect of a PTGER2 antagonist was seen even at high (10µM) concentrations (Elberg, 
Turman et al. 2012).  
In this study human and dog kidney cell lines were studied in 3D cyst assays. A PTGER2 
antagonist was used at a dose range of 100nM - 10µM to ensure high penetration of antagonist 
to the cells in the gel and media in 3D culture. The most effective dose was 500nM. A PTGER4 
antagonist was used at a dose range of 100nM - 10µM and the most effective dose was 200nM. 
These concentrations are similar to the IC50 values previously reported for these inhibitors. 
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A recent study of non-steroidal anti-inflammatory drug (NSAID) (celecoxib) in ADPKD has 
shown that COX2 acts through inhibition of PGE2 and decreases cell proliferation in ADPKD 
cells by targeting the apoptosis pathway and inducing cell cycle arrest (Xu, Wang et al. 2012). 
Several reports of NSAIDs have shown that they can decrease the growth of tumour cells. 
Indomethacin has been shown to have anti-tumour activity in colon cancer cells (Ikawa, Fujino 
et al. 2012). In addition, diclofenac treatment can lead to increased apoptosis of tumour cells 
in colon cancer by inhibiting the COX2 and PGE2 pathways (Kaur and Sanyal 2010). However, 
the long term use of NSAIDs is complicated by increased cardiovascular risks (van den Bemt, 
Tjwa et al. 2014).  
 
Targeting PTGER2 receptors through the use of highly selective antagonists could result in 
fewer side effects than NSAIDs (Eriksen, Richelsen et al. 1987).  A clinical trial conducted 
with PTGER4 selective antagonists in colon cancer reported inhibition of PGE2-induced cell 
proliferation mediated through ERK1/2 and CREB pathways (Cherukuri, Chen et al. 2007). In 
hepatic cellular carcinoma, a PTGER2 receptor antagonist was shown to induce apoptosis in 
tumour cells through the upregulation of caspase-3 (Xia, Ma et al. 2014).  
 
In summary, these results provide the first evidence that specific PTGER2 and PTGER4 
antagonists can inhibit cystic cell proliferation and cystogenesis suggesting they could be 
potential novel treatments for ADPKD through reducing cAMP.  
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Chapter 6 
General discussion and conclusions 
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6.1. General discussion. 
The major aim of this thesis was to investigate the role of prostaglandin E2 in the pathogenesis 
of ADPKD and to determine the receptor subtypes that could mediate its cellular responses in 
models of cystogenesis. 
One of the most important pathological mechanisms thought to regulate cyst expansion is 
increased levels of cyclic AMP. Activation of PKA by cAMP is responsible for activating a 
number of pro-proliferative pathways e.g. PTGER2, Wnt/-catenin pathways, EGF and IGF-1 
(Song, Di Giovanni et al. 2009). The basis for increased cAMP levels in ADPKD is not 
completely understood but could include changes in calcium-dependent synthesis (adenylate 
cyclases) and/or breakdown (phosphodiesterase). In addition, the upregulation of certain G-
protein coupled receptors such as vasopressin-2 (V2R) in mouse models of ADPKD has been 
shown to increase ligand-activated cAMP production (Torres, Wang et al. 2004). Treatments 
that modulate these signalling pathways may therefore be novel therapeutic targets for 
ADPKD. 
A preliminary microarray study in our laboratory was first carried out to investigate differential 
changes in gene expression between ADPKD and non-ADPKD human kidney cell lines. This 
demonstrated that PTGER2 expression was upregulated in ADPKD cystic cell lines compared 
to the normal cell lines (chapter 4). Previous studies have also reported an increase in 
expression of PTGER2 in ADPKD cell lines (Elberg, Elberg et al. 2007, Song, Di Giovanni et 
al. 2009). Based on this pilot data, two main objective of this thesis were proposed. Firstly, to 
investigate the role of PGE2 and expression of its receptors PTGER2 and PTGER4 in ADPKD 
cell lines. Secondly, to investigate whether specific PTGER2 and 4 receptor antagonists could 
inhibit cyst formation in in vitro using models of cystogenesis.  
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The first challenge was to optimise an in-vitro cyst assay which could be used to mimic 
cystogenesis of human ADPKD kidney epithelial cells (chapter 3). Different matrices 
(Collagen, Matrigel and combination of the two) were used to culture human cystic and normal 
cells in a 3D matrix. Four cystic cell lines (OX161, OX938, OX161/C1 and SKI-001) and one 
normal cell line (UCL93) were successfully grown in 3D cultures. One cystic line (SKI-002) 
and one normal cell line (RFH) did not grow in any of the 3D culture conditions used. However, 
most of the cystic cell lines formed either very small cysts or developed branching tubules 
similar to the normal cell line. Only the cystic cell line OX161/C1 reliably formed cysts which 
increased in size over time in a 3D Matrigel environment. This cell line was therefore chosen 
for further study. A second cellular model of cystogenesis, MDCKII, was used since it is a 
well-established model.  
The effects of PGE2, cAMP and Forskolin on cystogenesis in MDCK cells have been 
previously reported (Mangoo-Karim, Uchic et al. 1989). I confirmed these results and also 
showed that cAMP, Forskolin and PGE2 similarly increased cyst expansion in OX161/C1 cells 
(see in chapter 3). 
I initially validated the microarray results on PTGER2 by qPCR. No significant increases in 
the other PTGER receptors (PTGER1, PTGER3 and PTGER4) were seen in ADPKD cells 
(chapter 4). Immunoblotting of PTGER2 and PTGER4 receptors in human cystic cells and 
normal cells revealed increased expression of PTGER2 in the cystic cell lines. In agreement 
with our microarray data, the PTGER4 receptor was expressed equally in both normal and 
cystic cell lines (chapter 4). 
The renal expression of PTGER receptors by qPCR was then studied in two orthologous Pkd1 
mouse models of ADPKD, the Neolox model (Happe, van der Wal et al. 2013) and the CreLox 
mode l(Lantinga-van Leeuwen, Leonhard et al. 2007) . In contrast to the human cells, both 
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PTGER2 and PTGER4 receptor expression were found to be significantly higher in cystic 
kidneys compared to controls.  
Immunohistochemistry of human tissues taken from patients with defined mutations in PKD1 
illustrated that the PTGER2 receptor was highly expressed in the apical membrane of dilated 
tubules compared to control tissue. PTGER4 receptor expression was not significantly different 
in cystic tissue sections. Immunohistochemistry of the two mouse models of ADPKD revealed 
similar increased tubular expression of PTGER2 receptors compared to the controls. For 
PTGER4, staining intensity was significantly different compared to controls only in the 
NeoLox model.  
Differences in the findings between human and mouse tissues could reflect species differences 
in the expression of PTGER2 and PTGER4. Although PTGER2 has been reported in human 
epithelial ADPKD cells (Elberg, Elberg et al. 2007), it is absent in mouse IMCD-3 cells where 
PTGER4 is the functional receptor mediating the effects of PGE2 on proliferation and fluid 
secretion. Similarly, although all four PTGER receptors are expressed equally in MDCK cells, 
PTGER2 is the main receptor subtype mediating proliferation and sodium reabsorption 
(Wegmann and Nusing 2003) (Matlhagela and Taub 2006). Despite the lack of PTGER4 
upregulation in human cystic epithelia, my findings suggest that it is functional in mediating 
proliferation, apoptosis and cyst formation. Of note, the PTGER4 receptor has a higher binding 
affinity for PGE2 compared to PTGER2 (Fujino and Regan 2006). 
In summary, our data generated using microarray, qPCR, immunoblotting and immunostaining 
provide evidence of an increase expression of PTGER2 in human cystic cells and tissues 
compared to normal controls and provide a rational for testing the effectiveness of PTGER2 
and 4 receptor antagonists on reducing proliferation and inhibiting cyst growth in 3D cyst 
assays. 
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In the majority of our ADPKD cell lines, I observed a consistent increase in proliferation in 
response to PGE2 and a more variable decrease in apoptosis. These results are consistent with 
previous reports in PC-1 deficient cells (Yamaguchi, Pelling et al. 2000, Liu, Rajagopal et al. 
2012). Furthermore, I found a corresponding inhibition of proliferation and increase in 
apoptosis when these cells were treated with PTGER2 and PTGER4 antagonists. Therefore 
these responses appear to be mediated by both receptor subtypes.  
PTGER2 and PTGER4 antagonists both inhibited PGE2 stimulated cyst formation in 
OX161/C1 cells. However, the PTGER4 antagonist appeared to stimulate cyst formation in 
MDCKII cells, unlike the effect of PTGER2 blockade. The reason for this is unclear. 
Potentially, inhibition of PTGER4 might bypass or shift PGE2 action to an alternative 
proliferative pathway, similar to the bypass pathway that occurs after selective inhibition of 
oncogenic signalling in tumours (Niederst and Engelman 2013). 
Following the apparent success of these novel PTGER antagonists at inhibiting cystogenesis 
in in vitro cell culture models of ADPKD, the next step would be to test the effectiveness of 
these compounds in mouse models of ADPKD. However, prostanoid antagonists should be 
used with caution as PGE2 and PTGER2 and 4 receptor signalling play important roles in the 
regulation of many different functions in mammals. PTGER2 for example, acts to suppress 
premature labour and maintaining normal pregnancy. A PTGER2 antagonist was demonstrated 
to induce premature labour in female monkeys (Peluffo, Stanley et al. 2014). Furthermore, 
PTGER2 signalling promotes neuroprotection in excitotoxicity, and is important in neural 
plasticity and long term memory formation (Jiang and Dingledine 2013).  PTGER2 and 
PTGER4 receptor signalling has a bronchodilator effect in asthma in both a human and mouse 
model (Norel, Walch et al. 1999, Sheller, Mitchell et al. 2000). In addition, both receptors 
stimulate vasodilation in vascular afferent arterioles smooth muscle which is important in 
regulating blood pressure and salt water balance in the kidney. Furthermore, PTGER2 and 
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PTGER4 increase bone formation and protect from osteoporosis in animal study (Li, Okada et 
al. 2000, Ushikubi, Sugimoto et al. 2000). PTGER4 signalling plays an important role in 
embryonic development by increasing glomeruli size, PTGER4 knockout mice show a 
reduction in the size of glomeruli (Aoudjit, Potapov et al. 2006). Outside the kidney, PTGER4 
signalling plays an important role in the development of ductus arterioles in embryonic life. 
PTGER4 signalling also plays an important role in immunomodulation and inflammation by 
modulating T-cell and macrophage function (Tang, Libby et al. 2012). It also is important in 
colitis and gastric ulcer healing and acts to decrease inflammation during myocardial infarction 
(Woodward, Jones et al. 2011, Zimecki 2012). 
However therapeutic interventions targeting PTGER have been used successfully with minimal 
side effects in a number of clinical studies in humans as well as in mouse disease models. 
PTGER2 antagonist have produced promising results by decreasing the chronic inflammation 
associated with status epileptics, Alzheimer’s and Parkinson’s disease in animal model with 
few side effect (Jiang and Dingledine 2013). Furthermore, genetic ablation of EP-/- reduced 
skin tumour size in a mouse model by decreasing proliferation, angiogenesis and apoptosis 
(Sung, He et al. 2006). Interestingly genetically engineered or chemically mutant mice which 
lack PTGER2 and PTGER4 have been shown to have an obvious decrease in colon cancer 
incidence (Ushikubi, Sugimoto et al. 2000). From these studies it is clear that Prostanoid 
antagonist should be studied as a next generation of therapeutic agents in the treatment of 
cancer and inflammatory conditions rather than COX2 inhibitors which cause side effect in the 
cardiovascular and gastrointestinal system.  
Despite the promising result of the antagonists used in this study there use in human ADPKD 
must be viewed with caution as side effects could occur in other tissues in response to receptor 
antagonism. The similarities between receptor function in human and mouse means 
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investigation must be carried out first in mouse orthologues to human ADPKD and localised 
drug delivery may be safer to decrease systemic absorption and reduce side effects.  
6.2. Limitations. 
One of limitations of this study was the difficulty in inducing human cystic epithelial cells to 
form cysts in 3 D culture. OX161/C1 was the only cell line that form polarised cysts in 3 D 
culture. In addition, the proliferative and apoptotic responses to PGE2 were variable between 
different lines. The causes of variability might be due to the fact that cells were obtained from 
different ADPKD patients with different genetic and environmental backgrounds and types of 
PC-1 mutation (germline or somatic, complete or partial) or different PTGER receptor 
expression. In addition, different lines could have originated from different tubular segments 
or a mixture of cell types. 
 
6.3. Conclusions. 
Data presented in this thesis demonstrates that PGE2 and its receptors could play a key role in 
the pathogenesis of ADPKD. PTGER2 expression was significantly increased in ADPKD cell 
lines and human tissues and PTGER2 and 4 were significantly increased in orthologous mouse 
models of ADPKD. Stimulation of human ADPKD cell lines with PGE2 significantly increased 
proliferation which was blocked by selective PTGER2 and 4 receptor antagonists in monolayer 
cultures. More importantly in 3D cyst assays, PTGER2 and 4 receptor antagonists were able to 
significantly inhibit cyst growth of ADPKD cells. These experiments provide a proof of 
concept for the use of PTGER receptor antagonists as a novel therapy for the treatment of 
ADPKD. 
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6.4. Future work. 
These results will serve as the basis for future mechanistic studies on PTGER2 and PTGER4 
antagonists in ADPKD cells e.g. to examine the changes in cell signalling pathways that occur 
downstream of PTGER2 and PTGER4 stimulation. In addition, PTGER2 or PTGER4 
knockdown experiments by siRNA could be attempted in ADPKD cells. 
To further characterise the effect of PTGER2 and PTGER4 on ADPKD progression, we could 
compare the effect of crossing PTGER2 (EP2-/-) or PTGER4 knockout mice (EP4-/-) with 
ADPKD mice models, for example the  Neolox or tamoxifen induced model used in this study, 
as well as ADPKD models already utilised in previous studies of ADPKD such as pkd1fl 
(Shibazaki, Yu et al. 2008), pkd2fl (Nishio, Tian et al. 2010), and ksp-cre (Shao, Johnson et al. 
2002) with predominant C57B1/6 genetic background (Ma, Tian et al. 2013). If signalling 
through PTGER receptors contribute to ADPKD progression, then crossing receptor knockouts 
with ADPKD models should result in slower disease progression. Taking a similar approach, 
ADPKD researchers have demonstrated that combining conditional inactivation of polycystin 
genes with knockout of cilia genes supresses cyst growth highlighting the importance of 
primary cilia signalling in cyst progression (Ma, Tian et al. 2013).Disease progression would 
be evaluated following measurement of kidney weight to body weight ratio, serum urea, 
creatinine and percentage of cystic area. Finally, there is a need to validate the effects of 
PTGER2 and PTGER4 antagonists in animal models of ADPKD prior to clinical trials. 
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